2-heteroaryl carboxamides

ABSTRACT

The invention relates to novel 2-heteroaryl carboxamides and to the use thereof for producing medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning and/or memory.

The invention relates to novel 2-heteroaryl carboxamides, processes fortheir preparation, and their use for producing medicaments for thetreatment and/or prophylaxis of diseases and for improving perception,concentration, learning and/or memory.

Nicotinic acetylcholine receptors (nAChR) form a large family of ionchannels which are activated by the messenger acetylcholine which isproduced in the body (Galzi et al., Neuropharmacol. 1995, 34, 563-582).A functional nAChR consists of five subunits which may be different(certain combinations of α1-9 and β1-4,γ,δ,ε subunits) or identical(α7-9). This leads to the formation of a diversity of subtypes whichdiffer in the distribution in the muscles, the nervous system and otherorgans (McGehee et al., Annu. Rev. Physiol. 1995, 57, 521-546).Activation of nAChR leads to influx of cations into the cell and tostimulation of nerve cells or muscle cells. Selective activation ofindividual nAChR subtypes restricts this stimulation to the cell typeswhich have a corresponding subtype and is thus able to avoid unwantedside effects such as, for example, stimulation of nAChR in the muscles.Clinical experiments with nicotine and experiments in various animalmodels indicate that central nicotinic acetylchloline receptors areinvolved in learning and memory processes (e.g. Rezvani et al., Biol.Psychiatry 2001, 49, 258-267). Nicotinic acetylcholine receptors of thealpha7 subtype (α7 nAChR) have a particularly high concentration inregions of the brain which are important for learning and memory, suchas the hippocampus and the cerebral cortex (Seguela et al., J. Neurosci.1993, 13, 596-604). The α7 nAChR has a particularly high permeabilityfor calcium ions, increases glutamatergic neurotransmission, influencesthe growth of axons and, in this way, modulates neuronal plasticity(Broide et al., Mol. Neurobiol. 1999, 20, 1-16).

Certain N-(1-azabicyclo[2.2.2]oct-3-yl)heteroaryl carboxamides for thetreatment of, inter alia, psychoses are described in DE-A 37 24 059.

N-(Azabicycloalkyl)heteroaryl carboxamides, in particularN-(1-azabicyclo-[2.2.2]oct-4-yl)benzothiophene-3-carboxamides, aredisclosed in WO 93/15073 and in EP-A 485 962 as intermediates for thesynthesis of pharmaceutically active compounds.

U.S. Pat. No. 4,605,652 and EP-A 372 335 disclose, for example,N-(1-azabicyclo[2.2.2]oct-3-yl)thiophene-2-carboxamide and itsmemory-improving effect.

JP-A 14 030 084 describes 1-azabicycloalkanes for the treatment of,inter alia, dementia, attention deficit hyperactivity disorder andimpairments of learning and memory.

WO 02/44176, WO 02/085901, WO 01/60821, EP-A 1 231 212 and EP-A 1 219622 disclose further α7 nicotinic acetylcholine receptor agonists forthe treatment of central nervous system diseases.

The present invention relates to compounds of the formula

in which

-   R¹ is 1-azabicyclo[2.2.2]oct-3-yl, which is optionally substituted    via the nitrogen atom by a radical selected from the group of    C₁-C₄-alkyl, benzyl and oxy,-   R² is hydrogen or C₁-C₆-alkyl,-   R³ is hydrogen, halogen or C₁-C₆-alkyl,-   R⁴ is hydrogen, halogen, cyano, amino, trifluoromethyl,    trifluoromethoxy, C₁-C₆-alkyl, C₁-C₆-alkylcarbonyl,    C₁-C₆-alkylamino; formyl, hydroxycarbonyl, C₁-C₆-alkoxy,    C₁-C₆-alkoxycarbonyl, C₁-C₆-alkylthio, C₁-C₆-alkylcarbonylamino,    C₁-C₆-alkylaminocarbonyl, C₁-C₄-alkylsulphonylamino,    C₃-C₈-cycloalkylcarbonylamino, C₃-C₆-cycloalkylaminocarbonyl,    pyrrolyl, C₁-C₆-alkylaminocarbonylamino, heterocyclylcarbonyl,    heterocyclylcarbonylamino, heteroarylcarbonylamino, hydroxyl, phenyl    or heterocyclyl,    -   where    -   C₁-C₆-alkyl may optionally be substituted by hydroxyl, cyano,        amino, C₁-C₆-alkylaminocarbonylamino, C₁-C₆-alkylaminocarboxyl,        heterocyclyl or aryl,    -   C₁-C₆-alkylaminocarbonyl may optionally be substituted by        C₁-C₆-alkoxy or C₁-C₆-alkylamino,    -   C₁-C₆-alkylcarbonylamino may optionally be substituted by        C₁-C₆-alkoxy, and heterocyclyl may optionally be substituted by        oxo,-   A is oxygen or sulphur,-   the ring B is benzo or pyrido, each of which are optionally    substituted by radicals from the series halogen, cyano, formyl,    trifluoromethyl, trifluoromethoxy, nitro, amino, C₁-C₆-alkyl and    C₁-C₆-alkoxy, and-   E is C≡C, arylene and heteroarylene, where arylene and heteroarylene    may be substituted by radicals from the series halogen, cyano,    trifluoromethyl, trifluoromethoxy, nitro, amino, C₁-C₆-alkoxy and    C₁-C₆-alkyl,    and the solvates, salts or solvates of the salts of these compounds.

Solvates is the term used for the purposes of the invention for thoseforms of the compounds which form a complex with solvent molecules bycoordination in the solid or liquid state. Hydrates are a special formof solvates in which the coordination takes place with water.

Salts which are preferred for the purposes of the invention arephysiologically acceptable salts of the compounds of the invention.

Physiologically acceptable salts of the compounds (I) may be acidaddition salts of the compounds with mineral acids, carboxylic acids orsulphonic acids. Particularly preferred examples are salts withhydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid,methanesulphonic acid, ethanesulphonic acid, toluenesulphonic acid,benzenesulphonic acid, naphthalenedisulphonic acid, acetic acid,propionic acid, oxalic acid, lactic acid, tartaric acid, citric acid,fumaric acid, maleic acid or benzoic acid.

However, salts which may be mentioned are also salts with conventionalbases, such as, for example, alkali metal salts (e.g. sodium orpotassium salts), alkaline earth metal salts (e.g. calcium or magnesiumsalts) or ammonium salts derived from ammonia or organic amines such as,for example, monoethanolamine, diethanolamine; triethanolamine,arginine, lysine, dimethylaminoethanol, diethylamine, triethylamine,ethyldiisopropylamine, procaine, dibenzylamine, N-methylmorpholine,dihydroabietylamine, 1-ephenamine or methylpiperidine.

The compounds of the invention may exist in stereoisomeric forms(enantiomers, diastereomers). The invention therefore relates both tothe enantiomers or diastereomers and to respective mixtures thereof.These enantiomer and diastereomer mixtures can be separated in a knownmanner into the stereoisomerically pure constituents.

For the purposes of the present invention, the substituents generallyhave the following meaning:

C₁-C₆- and C₁-C₄-alkoxy are a straight-chain or branched alkoxy radicalhaving 1 to 6, preferably 1 to 4, particularly preferably 1 to 3, carbonatoms. Nonlimiting examples include methoxy, ethoxy, n-propoxy,isopropoxy, tert-butoxy, n-pentoxy and n-hexoxy.

C₁-C₆- and C₁-C₄-alkyl are a straight-chain or branched alkyl radicalhaving 1 to 6, preferably 1 to 4, particularly preferably 1 to 3, carbonatoms. Nonlimiting examples include methyl, ethyl, n-propyl, isopropyl,tert-butyl, n-pentyl and n-hexyl.

C₁-C₆- and C₁-C₄-alkylamino is a straight-chain or branched mono- ordialkylamino radical having 1 to 6, preferably having 1 to 4, carbonatoms per alkyl radical. Nonlimiting examples include methylamino,dimethylamino, ethylamino, diethylamino, n-propylamino,di-n-propylamino, isopropylamino, diisopropylamino, tert-butylamino,di-tert-butylamino, n-pentylamino, di-n-pentylamino, n-hexylamino,di-n-hexylamino, ethylmethylamino, isopropylmethylamino,n-butylethylamino, n-hexyl-i-pentylamino.

C₁-C₆- and C₁-C₄-alkylcarbonylamino is a straight-chain or branchedalkylcarbonylamino radical having 1 to 6, preferably having 1 to 4, andparticularly preferably having 1 to 3, carbon atoms. Nonlimitingexamples include methylcarbonyl-amino, ethylcarbonylamino,n-propylcarbonylamino, isopropylcarbonylamino, tert-butylcarbonylamino,n-pentylcarbonylamino and n-hexylcarbonylamino.

C₁-C₆- and C₁-C₄-alkylaminocarboxyl is a straight-chain or branchedmono- or dialkylaminocarboxyl radical having 1 to 6, preferably having 1to 4, particularly preferably having 1 to 3, carbon atoms per alkylradical. Nonlimiting examples include methylaminocarboxyl,dimethylaminocarboxyl, ethylaminocarboxyl, diethylaminocarboxyl,n-propylaminocarboxyl, di-n-propylaminocarboxyl,isopropyl-aminocarboxyl, diisopropylaminocarboxyl,tert-butylaminocarboxyl, di-tert-butylaminocarboxyl,n-pentylaminocarboxyl, di-n-pentylaminocarboxyl, n-hexylaminocarboxyl,di-n-hexylaminocarboxyl, ethylmethylaminocarboxyl,isopropyl-methylaminocarboxyl, n-butylethylaminocarboxyl,n-hexyl-i-pentylaminocarboxyl.

C₁-C₄- and C₁-C₄-alkylaminocarbonyl is a straight-chain or branchedmono- or dialkylaminocarbonyl radical having 1 to 6, preferably having 1to 4, particularly preferably having 1 to 3, carbon atoms per alkylradical. Nonlimiting examples include methylaminocarbonyl,dimethylaminocarbonyl, ethylaminocarbonyl, diethylaminocarbonyl,n-propylaminocarbonyl, di-n-propylaminocarbonyl,isopropyl-aminocarbonyl, diisopropylaminocarbonyl,tert-butylaminocarbonyl, di-tert-butylaminocarbonyl,n-pentylaminocarbonyl, di-n-pentylaminocarbonyl, n-hexylaminocarbonyl,di-n-hexylaminocarbonyl, ethylmethylaminocarbonyl,isopropylmethyl-aminocarbonyl, n-butylethylaminocarbonyl,n-hexyl-i-pentylaminocarbonyl.

C₁-C₆- and C₁-C₄-alkylaminocarbonylamino is a straight-chain or branchedmono- or dialkylaminocarbonylamino radical having 1 to 6, preferablyhaving 1 to 4, particularly preferably having 1 to 3, carbon atoms peralkyl radical. Nonlimiting examples include methylaminocarbonylamino,dimethylaminocarbonylamino, ethylaminocarbonyl-amino,diethylaminocarbonylamino, n-propylaminocarbonylamino,di-n-propylaminocarbonyl amino, isopropylaminocarbonylamino,diisopropylaminocarbonylamino, tert-butylaminocarbonylamino,di-tert-butylaminocarbonylamino, n-pentylaminocarbonylamino,di-n-pentylaminocarbonylamino, n-hexylaminocarbonylamino,di-n-hexylaminocarbonylamino, ethylmethylaminocarbonylamino,isopropylmethylaminocarbonylamino, n-butylethylaminocarbonylamino,n-hexyl-i-pentylaminocarbonylamino.

C₁-C₆-Alkylcarbonyl is a straight-chain or branched alkylcarbonylradical having 1 to 6, preferably having 1 to 4, carbon atoms.Nonlimiting examples include: acetyl, ethylcarbonyl, propylcarbonyl,isopropylcarbonyl, butylcarbonyl, isobutylcarbonyl, tert-butylcarbonyl,pentylcarbonyl and hexylcarbonyl.

C₁-C₄-Alkylsulphonylamino is a straight-chain or branchedalkylsulphonylamino radical having 1 to 4, preferably having 1 to 3,carbon atoms. Mention may be made by way of example and preferably of:methanesulphonylamino, ethanesulphonylamino, n-propanesulphonylamino,isopropanesulphonylamino, tert-butanesulphonylamino.

C₁-C₆- and C₁-C₄-alkoxycarbonyl is a straight-chain or branchedalkoxycarbonyl radical having 1 to 6, preferably having 1 to 4 andparticularly preferably having 1 to 3, carbon atoms. Nonlimitingexamples include methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl,isopropoxycarbonyl and tert-butoxycarbonyl.

C₁-C₆- and C₁-C₄-alkoxycarbonylamino is a straight-chain or branchedalkoxycarbonylamino radical having 1 to 6, preferably having 1 to 4 andparticularly preferably having 1 to 3, carbon atoms. Nonlimitingexamples include methoxycarbonylamino, ethoxycarbonylamino,n-propoxycarbonylamino, isopropoxycarbonylamino,tert-butoxycarbonylamino, n-pentoxycarbonylamino andn-hexoxycarbonylamino.

C₃-C₆-Cycloalkylaminocarbonyl is a 3- to 6-membered, preferably 5- to6-membered cycloalkylaminocarbonyl radical. Nonlimiting examples includecyclopropylaminocarbonyl, cyclobutylaminocarbonyl,cyclopentylaminocarbonyl, cyclohexylaminocarbonyl,cycloheptylaminocarbonyl and cyclooctylaminocarbonyl.

C₃-C₉- and C₅-C₆-cycloalkylcarbonylamino is a 3- to 8-membered,preferably 5- to 6-membered, cycloalkylcarbonylamino radical.Nonlimiting examples include cyclopropylcarbonylamino,cyclobutylcarbonylamino, cyclopentylcarbonylamino,cyclohexylcarbonylamino, cycloheptylcarbonylamino andcyclooctylcarboriylamino.

Heterocyclyl is a mono- or polycyclic, preferably mono- or bicyclic,nonaromatic radical having, as a rule, 4 to 10, preferably 5 to 8, ringatoms and up to 3, preferably 1.0 up to 2, hetero ring members from theseries N, O, S, SO, SO₂. The heterocyclyl radicals may be saturated orpartially unsaturated. Nonlimiting examples include 5 to 8-memberedmonocyclic saturated heterocyclyl radicals having up to two hetero ringatoms from the series O, N and S such as tetrahydrofuran-2-yl,piperazinyl, N-methylpiperazinyl, pyrrolidin-2-yl, pyrrolidin-3-yl,pyrrolinyl, piperidinyl, morpholinyl and perhydroazepinyl.

Heteroaryl is an aromatic, mono- or bicyclic radical having 5 to 10 ringatoms and up to 5 heteroatoms from the series S, O and/or N. Preferenceis given to 5- to 6-membered heteroaryls having up to 4 heteroatoms. Theheteroaryl radical may be bonded via a carbon atom or heteroatom.Nonlimiting examples include: thienyl, furyl, pyrrolyl, thiazolyl,oxadiazolyl, oxazolyl, isoxazolyl, imidazolyl, tetrazolyl, pyridyl,pyrimidinyl, pyridazinyl, indolyl, indazolyl, benzofuranyl,benzothiophenyl, quinolinyl, isoquinolinyl.

Heterocyclylcarbonylamino is a carbonylamino group which is linked to amono- or polycyclic, preferably mono- or bicyclic, nonaromatic radicalhaving; as a rule, 4 to 10, preferably 5 to 8, ring atoms and up to 3,preferably up to 2, hetero ring members from the series N, O, S, SO,SO₂. The heterocyclyl radicals may be saturated or partiallyunsaturated. Nonlimiting examples include carbonylamino groups linked to5- to 8-membered monocyclic saturated heterocyclyl radicals having up totwo hetero ring atoms from the series O, N and S such astetrahydrofuran-2-ylcarbonylamino, piperazinylcarbonylamino,N-methylpiperazinylcarbonylamino, pyrrolidin-2-ylcarbonylamino,pyrrolidin-3-ylcarbonylamino, pyrrolinylcarbonylamino,piperidinylcarbonylamino, morpholinylcarbonylamino andperhydroazepinylcarbonylamino.

Heteroarylcarbonylamino is a carbonylamino group which is linked to amono- or bicyclic aromatic radical having 5 to 10 ring atoms and up to 5heteroatoms from the series S, O and/or N. Preference is given to 5- to6-membered heteroaryls having up to 4 heteroatoms. The heteroarylradical may be bonded to the carbonylamino group via a carbon atom orheteroatom. Nonlimiting examples include: thienylcarbonylamino,furylcarbonylamino, pyrrolylcarbonylamino, thiazolylcarbonylamino,isoxazolylcarbonylamino, oxadiazolylcarbonylamino,oxazolylcarbonylamino, imidazolylcarbonylamino, tetrazolylcarbonylamino,pyridylcarbonylamino, pyrimidinylcarbonylamino,pyridazinylcarbonylamino, indolylcarbonylamino, indazolylcarbonylamino,benzofuranylcarbonylamino, benzothiophenylcarbonylamino,quinolinylcarbonylamino, isoquinolinylcarbonylamino.

Heterocyclylcarbonyl is a carbonyl group which is linked to a mono- orpolycyclic, preferably mono- or bicyclic, nonaromatic radical having, asa rule, 4 to 10, preferably 5 to 8, ring atoms and up to 3, preferablyup to 2, hetero ring members from the series N, O, S, SO, SO₂. Theheterocyclyl radicals may be saturated or partially unsaturated.Nonlimiting examples include carbonyl groups linked to 5- to 8-memberedmonocyclic saturated heterocyclyl radicals having up to two hetero ringatoms from the series O, N and S such as tetrahydrofuran-2-ylcarbonyl,piperazinylcarbonyl, N-methylpiperazinylcarbonyl,pyrrolidin-2-ylcarbonyl, pyrrolidin-3-ylcarbonyl, pyrrolinylcarbonyl,piperidinylcarbonyl, morpholinylcarbonyl and perhydroazepinylcarbonyl.

Aryl is a mono- to tricyclic aromatic, carbocyclic radical having, as arule, 6 to 10 carbon ring atoms. Nonlimiting examples include phenyl andnaphthyl.

Halogen is fluorine, chlorine, bromine and iodine. Preference is givento fluorine, chlorine and bromine, and particular preference to fluorineand chlorine.

C₁-C₆- and C₁-C₄-alkylthio are a straight-chain or branched alkylthioradical having 1 to 6, preferably 1 to 4, particularly preferably 1 to3, carbon atoms. Nonlimiting examples include methylthio, ethylthio,n-propylthio, isopropylthio, tert-butylthio, n-pentylthio andn-hexylthio.

When radicals in the compounds of the invention are optionallysubstituted, unless indicated otherwise the radicals may have one ormore identical or different substituents.

Preference is given to compounds of the formula (I) in which R¹ is(3R)-1-azabicyclo[2.2.2]oct-3-yl, and R², R³, R⁴, A, E and the ring Bhave the meanings indicated above, and the solvates, salts or solvatesof the salts of these compounds.

Preference is likewise given to compounds of the formula (I) in which R²is hydrogen or methyl, and R¹, R³, R⁴, A, E and the ring B have themeanings indicated above, and the solvates, salts or solvates of thesalts of these compounds.

Particular preference is given to compounds of the formula (I) in whichR² is hydrogen, and R¹, R³, R⁴, A, E and the ring B have the meaningsindicated above, and the solvates, salts or solvates of the salts ofthese compounds.

Preference is likewise given to compounds of the formula (I) in which R³is hydrogen or methyl, and R¹, R², R⁴, A, E and the ring B have themeanings indicated above, and the solvates, salts or solvates of thesalts of these compounds.

Particular preference is given to compounds of the formula (I) in whichR³ is hydrogen, and R¹, R², R⁴, A, E and the ring B have the meaningsindicated above, and the solvates, salts or solvates of the salts ofthese compounds.

Preference is likewise given to compounds of the formula (I) in which R⁴is hydrogen, fluorine, chlorine, bromine, trifluoromethoxy,hydroxymethyl, methoxy or 6-membered heterocyclyl, and R¹, R², R³, A, Eand the ring B have the meanings indicated above, and the solvates,salts or solvates of the salts of these compounds.

Preference is likewise given to compounds of the formula (I) in which Ais a sulphur atom, and R¹, R², R³, R⁴, E and the ring B have themeanings indicated above, and the solvates, salts or solvates of thesalts of these compounds.

Preference is likewise given to compounds of the formula (I) in which Ais an oxygen atom, and R¹, R², R³, R⁴, E and the ring B have themeanings indicated above, and the solvates, salts or solvates of thesalts of these compounds.

Preference is likewise given to compounds of the formula (I) in whichthe ring B is benzo which is optionally substituted by 1 to 3 radicalsfrom the series halogen, cyano, trifluoromethyl, trifluoromethoxy andC₁-C₄-alkyl, and R¹, R², R³, R⁴, A and E have the meanings indicatedabove, and the solvates, salts or solvates of the salts of thesecompounds.

Preference is likewise given to compounds of the formula (I) in which Eis phenylene which is optionally substituted by radicals from the seriesfluorine, chlorine, bromine, cyano, trifluoromethoxy, C₁-C₆-alkyl andC₁-C₆-alkoxy, and R¹, R², R³, R⁴, A and the ring B have the meaningsindicated above, and the solvates, salts or solvates of the salts ofthese compounds.

Preference is likewise given to compounds of the formula (I) in which

-   R¹ is 1-azabicyclo[2.2.2]oct-3-yl,-   R² is hydrogen or C₁-C₄-alkyl,-   R³ is hydrogen, fluorine, chlorine, bromine or C₁-C₄-alkyl,-   R⁴ is hydrogen, fluorine, chlorine, bromine, cyano, amino,    trifluoromethyl, trifluoromethoxy, C₁-C₄-alkyl, C₁-C₄-alkylcarbonyl,    C₁-C₄-alkylamino, formyl, hydroxycarbonyl, C₁-C₄-alkoxy,    C₁-C₄-alkoxycarbonyl, C₁-C₄-alkylthio, C₁-C₄-alkylcarbonylamino,    C₁-C₄-alkylaminocarbonyl, C₁-C₄-alkylsulphonylamino,    C₃-C₆-cycloalkylcarbonylamino, C₃-C₆-cycloalkylaminocarbonyl,    pyrrolyl, C₁-C₄-alkylaminocarbonylamino, heterocyclylcarbonyl,    heterocyclylcarbonylamino, heteroarylcarbonylamino, hydroxyl, phenyl    or heterocyclyl,    -   where C₁-C₄-alkyl may optionally be substituted by hydroxyl,        cyano, amino,        -   C₁-C₄-alkylaminocarbonylamino, C₁-C₄-alkylaminocarboxyl,            heterocyclyl or aryl,        -   C₁-C₄-alkylaminocarbonyl may optionally be substituted by            C₁-C₄-alkoxy or C₁-C₄-alkylamino,        -   C₁-C₄-alkylcarbonylamino may optionally be substituted by            C₁-C₄-alkoxy, and heterocyclyl may optionally be substituted            by oxo,-   A is oxygen or sulphur,-   the ring B is benzo or pyrido, each of which are optionally    substituted by radicals from the series halogen, cyano,    trifluoromethyl, trifluoromethoxy and C₁-C₄-alkyl, and-   E is C≡C, arylene and heteroarylene, where arylene and heteroarylene    may be substituted by radicals from the series halogen, cyano,    trifluoromethyl, trifluoromethoxy, nitro, amino, C₁-C₄-alkoxy and    C₁-C₄-alkyl,    and the solvates, salts or solvates of the salts of these compounds.

Preference is likewise given to compounds of the formula (I) in which

-   R¹ is 1-azabicyclo[2.2.2]oct-3-yl,-   R² and R³ are hydrogen,-   R⁴ is hydrogen, fluorine, chlorine, bromine, cyano, amino,    trifluoromethyl, trifluoromethoxy, C₁-C₄-alkyl, C₁-C₄-alkylcarbonyl,    C₁-C₄-alkylamino, formyl, hydroxycarbonyl, C₁-C₄-alkoxy,    C₁-C₄-alkoxycarbonyl, C₁-C₆-alkylthio, C₁-C₄-alkylcarbonylamino,    C₁-C₄-alkylaminocarbonyl, C₁-C₄-alkylsulphonylamino,    C₃-C₆-cycloalkylcarbonylamino, C₁-C₆-cycloalkylaminocarbonyl,    pyrrolyl, C₁-C₄-alkylaminocarbonylamino, heterocyclylcarbonyl,    heterocyclylcarbonylamino, heteroarylcarbonylamino, hydroxyl, phenyl    or heterocyclyl,    -   where C₁-C₄-alkyl may optionally be substituted by hydroxyl,        cyano, amino,        -   C₁-C₄-alkylaminocarbonylamino, C₁-C₄-alkylaminocarboxyl,            heterocyclyl or aryl,        -   C₁-C₄-alkylaminocarbonyl may optionally be substituted by            C₁-C₄-alkoxy or C₁-C₄-alkylamino,        -   C₁-C₄-alkylcarbonylamino may optionally be substituted by            C₁-C₄-alkoxy, and heterocyclyl may optionally be substituted            by oxo,-   A is oxygen,-   the ring B is benzo or pyrido, each of which are optionally    substituted by radicals from the series halogen, cyano,    trifluoromethyl, trifluoromethoxy and C₁-C₄-alkyl, and-   E is C≡C, arylene and heteroarylene, where arylene and heteroarylene    may be substituted by radicals from the series halogen, cyano,    trifluoromethyl, trifluoromethoxy, nitro, amino, C₁-C₄-alkoxy and    C₁-C₄-alkyl,    and the solvates, salts or solvates of the salts of these compounds.

Preference is likewise given to compounds of the formula (I) in which

-   R¹ is 1-azabicyclo[2.2.2]oct-3-yl,-   R² is hydrogen or C₁-C₆-alkyl,-   R³ is hydrogen, halogen or C₁-C₆-alkyl,-   R⁴ is hydrogen, halogen, cyano, amino, trifluoromethyl,    trifluoromethoxy, C₁-C₆-alkyl, C₁-C₆-alkylcarbonyl,    C₁-C₆-alkylamino, formyl, hydroxycarbonyl, C₁-C₆-alkoxy,    C₁-C₆-alkoxycarbonyl, C₁-C₆-alkylthio, C₁-C₆-alkylcarbonylamino,    C₁-C₄-alkylsulphonylamino, C₃-C₈-cycloalkylcarbonylamino, pyrrolyl,    C₁-C₆-alkylaminocarbonylamino, heterocyclylcarbonyl, phenyl or    heterocyclyl,    -   where C₁-C₆-alkyl may optionally be substituted by hydroxyl,        amino, C₁-C₆-alkylaminocarbonylamino, C₁-C₆-alkylaminocarboxyl,        heterocyclyl or aryl,        -   C₁-C₆-alkylcarbonylamino may optionally be substituted by            C₁-C₆-alkoxy, and        -   heterocyclyl may optionally be substituted by oxo,-   A is oxygen or sulphur,-   the ring B is benzo or pyrido, each of which are optionally    substituted by radicals from the series halogen, cyano, formyl,    trifluoromethyl, trifluoromethoxy, nitro, amino, C₁-C₆-alkyl and    C₁-C₆-alkoxy, and-   E is C≡C, arylene and heteroarylene, where arylene and heteroarylene    may be substituted by radicals from the series halogen, cyano,    trifluoromethyl, trifluoromethoxy, nitro, amino, C₁-C₆-alkoxy and    C₁-C₆-alkyl,    and the solvates, salts or solvates of the salts of these compounds.

Preference is likewise given to compounds of the formula (I) in which

-   R¹ is 1-azabicyclo[2.2.2]oct-3-yl,-   R² is hydrogen or C₁-C₆-alkyl,-   R³ is hydrogen, halogen or C₁-C₆-alkyl,-   R⁴ is hydrogen, halogen, cyano, trifluoromethyl, trifluoromethoxy,    C₁-C₆-alkyl, C₁-C₆-alkoxy or heterocyclyl, where alkyl is optionally    substituted by a hydroxyl radical,-   A is oxygen or sulphur,-   the ring B is benzo or pyrido, each of which are optionally    substituted by radicals from the series halogen, cyano,    trifluoromethyl, trifluoromethoxy, nitro; amino, C₁-C₆-alkyl and    C₁-C₆-alkoxy, and-   E is C≡C, arylene or heteroarylene, where arylene and heteroarylene    may be substituted by radicals from the series halogen, cyano,    trifluoromethyl, trifluoromethoxy, nitro, amino, C₁-C₆-alkyl and    C₁-C₆-alkoxy,    and the solvates, salts or solvates of the salts of these compounds.

Preference is likewise given to compounds of the formula

in which

-   R¹ is (3R)-1-azabicyclo[2.2.2]oct-3-yl,-   R² and R³ are, independently of one another, hydrogen or methyl,-   R⁴ is hydrogen, halogen, cyano, trifluoromethyl, trifluoromethoxy,    C₁-C₆-alkyl, C₁-C₆-alkoxy or heterocyclyl, where alkyl is optionally    substituted by a hydroxyl radical, and-   R^(B) is hydrogen, halogen, cyano, trifluoromethyl,    trifluoromethoxy, nitro, amino, C₁-C₆-alkyl or C₁-C₆-alkoxy,    and the solvates, salts or solvates of the salts of these compounds.

Very particular preference is likewise given to compounds of the formula(Ia) in which

-   R¹ is (3R)-1-azabicyclo[2.2.2]oct-3-yl,-   R² and R³ are hydrogen,-   R⁴ is hydrogen, fluorine, chlorine, bromine, trifluoromethoxy,    hydroxymethyl, methoxy or 6-membered heterocyclyl and-   R^(B) is hydrogen, halogen, cyano, trifluoromethyl, trifluoromethoxy    or C₁-C₄-alkyl,    and the solvates, salts or solvates of the salts of these compounds.

Preference is likewise given to compounds of the formula

in which

-   R¹ is (3R)-1-azabicyclo[2.2.2]oct-3-yl,-   R² and R³ are, independently of one another, hydrogen or methyl,-   R⁴ is hydrogen, halogen, cyano, trifluoromethyl, trifluoromethoxy,    C₁-C₆-alkyl, C₁-C₆-alkoxy or heterocyclyl, where alkyl is optionally    substituted by a hydroxyl radical, and-   R^(B) is hydrogen, halogen, cyano, trifluoromethyl,    trifluoromethoxy, nitro, amino, C₁-C₆-alkyl and C₁-C₆-alkoxy,    and the solvates, salts or solvates of the salts of these compounds.

Preference is likewise given to compounds of the formula (Ib) in which

-   R¹ is (3R)-1-azabicyclo[2.2.2]oct-3-yl,-   R² and R³ are hydrogen,-   R⁴ is hydrogen, fluorine, chlorine, bromine, trifluoromethoxy,    hydroxymethyl, methoxy or 6-membered heterocyclyl and-   R^(B) is hydrogen, halogen, cyano, trifluoromethyl, trifluoromethoxy    or C₁-C₄-alkyl,    and the solvates, salts or solvates of the salts of these compounds.

Preference is likewise given to compounds of the formula

in which

-   E is phenylene,-   R⁴ is C₁-C₆-alkoxy, aminomethyl, hydroxycarbonyl,    C₃-C₈-cycloalkylcarbonylamino, a group of the formula

-   -   where    -   R⁵ is C₁-C₆-alkyl,    -   n is zero, 1, 2, 3 or 4, or    -   5- to 6-membered heterocyclyl which is optionally substituted by        oxo,

-   A is sulphur or oxygen,    and the solvates, salts or solvates of the salts thereof.

The invention preferably relates to compounds of the formula (I) inwhich

-   E is phenylene,-   R⁴ is C₁-C₄-alkoxy, aminomethyl, hydroxycarbonyl,    C₃-C₆-cycloalkylcarbonylamino, a group of the formula

-   -   where    -   R⁵ is C₁-C₄-alkyl,    -   n is zero, 1 or 2, or    -   5- to 6-membered heterocyclyl which is optionally substituted by        oxo,

-   A is sulphur or oxygen,    and the solvates, salts or solvates of the salts thereof.

The invention particularly preferably relates to compounds of thefollowing formulae

and the solvates, salts or solvates of the salts of these compounds.

Very particular preference is given to combinations of two or more ofthe preferred ranges mentioned above.

The invention further relates to processes for the preparation of thecompounds of the invention, in which compounds of the formulaX¹-E-R⁴  (II),in which

-   R⁴ has the abovementioned meanings, and-   X¹ is —B(OH)₂ or

-   -   in the case where E is arylene or heteroarylene, and is hydrogen        in the case where E is —C≡C—,        are reacted with a compound of the formula

in which

-   R¹, R², R³, A and the ring B have the abovementioned meanings, and-   X² is triflate or halogen, preferably chlorine, bromine or iodine,    and where appropriate-   [A] the resulting compounds (I) are alkylated on the quinuclidine    nitrogen atom using appropriate alkylating reagents, or-   [B] the resulting compounds (I) are oxidized on the quinuclidine    nitrogen atom using suitable oxidizing agents,    and the resulting compounds (I) are converted into their solvates,    salts or solvates of the salts where appropriate with the    appropriate (i) solvents and/or (ii) bases or acids.

Reaction of the compounds (II) and (III) generally takes place in aninert solvent in the presence of a transition metal catalyst, in thepresence of a base and, where appropriate, in the presence of copper(I)iodide.

The process of the invention is preferably carried out in a temperaturerange from 70° C. to 110° C. under atmospheric pressure.

Examples of inert solvents are ethers such as dioxane, tetrahydrofuranor 1,2-dimethoxyethane, hydrocarbons such as benzene, xylene or toluene,nitroaromatic compounds such as nitrobenzene, where appropriateN-alkylated carboxamides such as dimethylformamide, dimethylacetamide,alkyl sulphoxides such as dimethyl sulphoxide or cyclic lactams such asN-methylpyrrolidone. Preference is given to solvents from the seriesdimethylformamide, dimethylacetamide, dimethyl sulphoxide and1,2-dimethoxyethane.

The transition metal catalysts preferably used are palladium(0) orpalladium(II) compounds, in particularbis(diphenylphosphino)ferrocenepalladium(II) chloride,dichlorobis(triphenylphosphine)palladium ortetrakis(triphenylphosphine)-palladium(0).

Preferred bases are alkali metal hydroxides or salts such as potassiumacetate, sodium hydroxide, sodium bicarbonate or sodium carbonate, whereappropriate in the form of their aqueous solutions.

Process steps [A] and [B] can be carried out in inert solvents and attemperatures from −30 to 50° C. and under atmospheric pressure.

Bases which can be employed for process step [A] are alkali metalhydrides such as potassium or sodium hydride, alkali metal hydroxidessuch as sodium or potassium hydroxide or alkali metal carbonates such assodium or potassium carbonate.

Alkylating reagents which can be employed for process step [A] are alkylhalides such as methyl iodide or benzyl halides such as benzyl bromide.

An oxidizing agent particularly suitable for process step [B] ishydrogen peroxide or metachloroperbenzoic acid.

The reactions metallized by transition metals can be carried out inanalogy to processes known from the literature, e.g. reaction withalkynes: cf. N. Krause et al., J. Org. Chem. 1998, 63, 8551; withketones, aromatic compounds and alkenes: cf. for example, A. Suzuki,Acc. Chem. Res. 1982, 15, 178ff; Miyaura et al. J. Am. Chem. Soc. 1989,111, 314; J. K. Stille, Angew. Chem. 1986, 98, 504 and with substitutedamines: cf. S. L. Buchwald et al., J. Organomet. Chem. 1999, 576, 125ff.(see also J. Tsuji, Palladium Reagents and Catalysts, Wiley, New York,1995).

The compounds (II) are known or can be synthesized in analogy to knownprocesses from the appropriate precursors.

The compounds (III) can be prepared by reacting compounds of the formulaR¹R²NH  (IV),in which R¹ and R² have the abovementioned meanings,with a compound of the formula

in which

-   R³, X², A and the ring B have the abovementioned meanings, and-   X³ is hydroxyl or halogen, preferably bromine or chlorine.

Reaction of the compounds (IV) and (V) takes place, if X³ is halogen,generally in inert solvents, where appropriate in the presence of abase, preferably in a temperature range from 0° C. to 50° C. underatmospheric pressure.

Examples of inert solvents are halohydrocarbons such as methylenechloride, trichloromethane, tetrachloromethane, trichloroethane,tetrachloroethane, 1,2-dichloroethane or trichloroethylene, ethers suchas diethyl ether, methyl tert-butyl ether, dioxane, tetrahydrofuran,glycol dimethyl ether or diethylene glycol dimethyl ether, hydrocarbonssuch as benzene, xylene, toluene, hexane, cyclohexane or petroleumfractions, nitroaromatic compounds such as nitromethane, carboxylicesters such as ethyl acetate, ketones such as acetone or 2-butanone,optionally N-alkylated carboxamides such as dimethylformamide ordimethylacetamide, alkyl sulphoxides such as dimethyl sulphoxide,carbonitriles such as acetonitrile or heteroaromatic compounds such aspyridine. Preference is given to dioxane, dimethylformamide or methylenechloride.

Examples of bases are alkali metal hydroxides such as sodium orpotassium hydroxide, alkali metal carbonates and bicarbonates such ascesium carbonate, sodium bicarbonate, sodium or potassium carbonate, oramides such as lithium diisopropylamide, alkylamines such astriethylamine or diisopropylethylamine, preferably diisopropylethylamineor triethylamine, and other bases such as DBU.

The reaction takes place, if X³ is hydroxyl, generally in inert solventsin the presence of condensing agents, where appropriate in the presenceof a base, preferably in a temperature range from 20 to 50° C. underatmospheric pressure.

The term “inert solvents” includes for example halohydrocarbons such asmethylene chloride, trichloromethane, tetrachloromethane,trichloroethane, tetrachloroethane, 1,2-dichloroethane ortrichloroethylene, ethers such as diethyl ether, methyl tert-butylether, dioxane, tetrahydrofuran, glycol dimethyl ether or diethyleneglycol dimethyl ether, hydrocarbons such as benzene, xylene, toluene,hexane, cyclohexane or petroleum fractions, nitroaromatic compounds suchas nitromethane, carboxylic esters such as ethyl acetate, ketones suchas acetone, optionally N-alkylated carboxamides such asdimethylformamide or dimethylacetamide, alkyl sulphoxides such asdimethyl sulphoxide, carbonitriles such as acetonitrile andheteroaromatic compounds such as pyridine. Preference is given totetrahydrofuran, dimethylformamide, 1,2-dichloroethane or methylenechloride.

Condensing agents for the purposes of the invention are, for example,carbodiimides such as, for example, N,N′-diethyl-, N,N′-dipropyl-,N,N′-diisopropyl-, N,N′-dicyclo-hexylcarbodiimide,N-(3-dimethylaminoisopropyl)-N′-ethylcarbodiimide hydrochloride (EDC),N-cyclohexylcarbodiimide-N-propyloxymethylpolystyrene (PS-carbodiimide);carbonyl compounds such as carbonyldiimidazole; 1,2-oxazolium compoundssuch as 2-ethyl-5-phenyl-1,2-oxazolium-3-sulphate or2-tert-butyl-5-methylisoxazolium perchlorate; acylamino compounds suchas 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline; in additionpropanephosphonic anhydride, isobutyl chloroformate,bis(2-oxo-3-oxazolidinyl)phosphoryl chloride,benzotriazolyloxy-tri(dimethylamino)phosphonium hexafluorophosphate,O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate(HBTU), 2-(2-oxo-1-(2H)-pyridyl)-1,1,3,3-tetramethyluroniumtetrafluoroborate (TPTU),O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluorophosphate (HATU),benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate(BOP), and mixtures thereof.

It may be advantageous where appropriate to use the condensing agent inthe presence of an auxiliary nucleophile such as, for example,1-hydroxybenzotriazole (HOBt).

Examples of bases are alkali metal carbonates and bicarbonates such as,for example, sodium or potassium carbonate or bicarbonate, organic basessuch as alkylamines, e.g. triethylamine, or N-methylmorpholine,N-methylpiperidine, 4-dimethylaminopyridine or diisopropylethylamine.

Particular preference is given to the combination ofN-(3-dimethylaminoisopropyl)-M-ethylcarbodiimide hydrochloride (EDC),1-hydroxybenzotriazole (HOBt) and triethylamine in dimethylformamide orof O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluorophosphate (HATU) and diisopropylethylamine indimethylformamide.

The compounds (IV) and (V) are known or can be synthesized in analogy toknown processes from the appropriate precursors (cf., for example,“Comprehensive Heterocyclic Chemistry”, Katritzky et al., editors;Elsevier, 1996).

Thus, for example, substituted benzothiophene-2-carboxylic acids can beobtained from appropriately substituted 2-halobenzaldehydes by reactionwith methyl mercaptoacetate (see, for example, A. J. Bridges et al.,Tetrahedron Lett. 1992, 33, 7499) and subsequent hydrolysis of theester:

Synthesis Scheme 1:

The corresponding pyrido derivatives can be synthesized starting from2-halobenzonitriles by reaction with methyl mercaptoacetate to give the3-amino-benzothiophene-2-carboxylic esters:

Synthesis Scheme 2:

The nitrogen atom shown in the ring may replace a CH group at one ofpositions 1 to 4 in the aromatic system.

The amino function can be removed by diazotization. Finally, the estercan be hydrolysed to give the target compound.

Substituted benzofuran-2-carboxylic acids can be obtained for example asdescribed by D. Bogdal et al., Tetrahedron 2000, 56, 8769.

The compounds of the invention are suitable for use as medicaments forthe treatment and/or prophylaxis of diseases in humans and animals.

They act as α7 nAChR agonists and show a valuable range ofpharmacological effects which could not have been predicted.

The compounds of the invention can, because of their pharmacologicalproperties, be employed alone or in combination with other activeingredients for the treatment and/or prevention of cognitiveimpairments, especially of Alzheimer's disease.

Because of their selective effect as α7 nAChR agonists, they areparticularly suitable for improving perception, concentration, learningor memory, especially after cognitive impairments like those occurringfor example in mild cognitive impairment, age-associated learning andmemory impairments, age-associated memory loss, vascular dementia,craniocerebral trauma, stroke, dementia occurring after strokes(post-stroke dementia), post-traumatic brain syndrome, generalconcentration impairments, concentration impairments in children withlearning and memory problems, attention deficit hyperactivity disorder,Alzheimer's disease, Lewy body dementia, dementia with degeneration ofthe frontal lobes, including Pick's syndrome, Parkinson's disease,progressive nuclear palsy, dementia with corticobasal degeneration,amyotrophic lateral sclerosis (ALS), Huntington's disease, multiplesclerosis, thalamic degeneration, Creutzfeld-Jakob dementia, HIVdementia, schizophrenia, schizophrenia with dementia or Korsakoff'spsychosis.

The compounds of the invention can be employed alone or in combinationwith other active ingredients for the prophylaxis and treatment of acuteand/or chronic pain (for a classification, see “Classification ofChronic Pain, Descriptions of Chronic Pain Syndromes and Definitions ofPain Terms”, 2nd edition, Meskey and Begduk, editors; IASP Press,Seattle, 1994), especially for the treatment of cancer-induced pain andchronic neuropathic pain like, for example, that associated withdiabetic neuropathy, postherpetic neuralgia, peripheral nerve damage,central pain (for example as a consequence of cerebral ischaemia) andtrigeminal neuralgia, and other chronic pain such as, for example,lumbago, backache (low back pain) or rheumatic pain. In addition, theseactive ingredients are also suitable for the therapy of primary acutepain of any origin and of secondary states of pain resulting therefrom,and for the therapy of states of pain which were formerly acute and havebecome chronic. The compounds of the invention can be employed alone orin combination with other active ingredients for the treatment ofschizophrenia.

The in vitro effect of the compounds of the invention can be shown inthe following assays:

1. Determination of the Affinity of Test Substances for α7 nAChR byInhibition of [³H]-Methyllycaconitine Binding to Rat Brain Membranes

The [³H]-methyllycaconitine binding assay is a modification of themethod described by Davies et al. in Neuropharmacol. 1999, 38, 679-690.

Rat brain tissue (hippocampus or whole brain) is homogenized inhomogenization buffer (10% w/v, 0.32 M sucrose, 1 mM EDTA, 0.1 mMphenylmethylsulphonyl fluoride (PMSF), 0.01% (w/v) NaN₃, pH 7.4, 4° C.)at 600 rpm in a glass homogenizer. The homogenate is centrifuged(1000×g, 4° C., 10 min) and the supernatant is removed. The pellet isresuspended (20% w/v) and the suspension is centrifuged (1000×g, 4° C.,10 min). The two supernatants are combined and centrifuged (15 000×g, 4°C., 30 min). The pellet obtained in this way is referred to as the P2fraction.

The P2 pellet is suspended in, binding buffer (50 mM Tris-HCl, 1 mMMgCl₂, 120 mM NaCl, 5 mM KCl, 2 mM CaCl₂, pH 7.4), and the suspension iscentrifuged (15 000×g, 4° C., 30 min), twice.

The residue is resuspended in binding buffer and incubated in a volumeof 250 (amount of membrane protein 0.1-0.5 mg) in the presence of 1-5 nM[³H]-methyllycaconitine 0.1% (w/v). BSA (bovine serum albumin) andvarious concentrations of the test substance at 21° C. for 2.5 h.Incubation is then carried out in the presence of 1 μM α-bungarotoxin or100 μM nicotine or 10 μM MLA (methyllycaconitine).

The incubation is stopped by adding 4 ml PBS (20 mM Na₂HPO₄, 5 mMKH₂PO₄, 150 mM NaCl, pH 7.4, 4° C.) and filtering through type A/E glassfibre filters (Gelman Sciences) which have previously been placed in0.3% (v/v) polyethyleneimine (PEI) for 3 h. The filters are washed twicewith 4 ml of PBS (4° C.), and the bound radioactivity is determined byscintillation measurement. All the assays are carried out in triplicate.The dissociation constant K_(i) of the test substance was determinedfrom the IC₅₀ of the compounds (concentration of the test substance atwhich 50% of the ligand bound to the receptor is displaced), thedissociation constant K_(D) and the concentration L of[³H]-methyllycaconitine using the equation K_(i)=IC₅₀/(1+L/K_(D)).

In place of [³H]-methyllycaconitine it is also possible to employ otherα7 nAChR-selective radioligands such as, for example,[¹²⁵I]-α-bungarotoxin or nonselective nAChR radioligands together withinhibitors of other nAChRs.

Representative in vitro data for the effects of the compounds of theinvention are shown in Table A:

TABLE A Example No. K_(i) (nM) 3 60 4 24 17 17 19 20 20 1.6 73 <1 75<0.1 76 3.3 90 14 102 62 108 17 116 17 130 26 149 97 150 35 151 88 154 3163 14 175 8.3 186 120

The suitability of the compounds of the invention for the treatment ofcognitive impairments can be shown in the following animal models:

2. Object Recognition Test

The object recognition test is a memory test. It measures the ability ofrats (and mice) to distinguish between familiar and unfamiliar objects.

The test is described by Blokland et al., NeuroReport 1998, 9,4205-4208; A. Ennaceur et al., Behav. Brain Res. 1988, 31, 47-59; A.Ennaceur et al., Psychopharmacology 1992, 109, 321-330; and Prickaertset al., Eur. J. Pharmacol. 1997, 337, 125-136.

In a first run, a rat is confronted in an otherwise empty observationarena of relatively large size by two identical objects. The rat willinvestigate, i.e. sniff round and touch; both objects extensively. In asecond run, after an interval of 24 hours, the rat is put in theobservation arena again. One of the familiar objects has now beenreplaced by a new, unfamiliar object. If a rat recognizes the familiarobject, it will concentrate on investigating the unfamiliar object.However, after 24 hours, a rat has normally forgotten which object itinvestigated in the first run, and it will therefore inspect bothobjects to the same extent. Administration of a substance with alearning- and memory-improving effect may lead to a rat recognizing theobject seen in the first run 24 hours previously as familiar. It willinvestigate the new, unfamiliar object in more detail than the familiarone. This memory ability is expressed in a discrimination index. Adiscrimination index of zero means that the rat investigates bothobjects, the old and the new, for equal times; that is to say it has notrecognized the old object and reacts to both objects as if they werenew. A discrimination index greater than zero means that the ratinspects the new object longer than the old one; that is to say the rathas recognized the old object.

3. Social Recognition Test:

The social recognition test is a test to examine the learning- ormemory-improving effect of test substances.

Adult rats housed in groups are placed singly in test cages 30 minutesbefore the start of the test. Four minutes before the start of the test,the test animal is put in an observation box. After this adaptationtime, a juvenile animal is put in with the test animal and the time forwhich the adult animal investigates the juvenile animal is measured for2 minutes (trial 1). All behaviours clearly directed at the young animalare measured, i.e. anogenital inspection, pursuit and fur care, duringwhich the old animal is no further than 1 cm from the young animal. Thejuvenile animal is then taken out, and the adult is left in its testcage (for 24-hour retention, the animal is returned to its home cage).The adult test animal is treated with test substance before or after thefirst test. Depending on the timing of the treatment, the learning orthe storage of the information about the young animal can be influencedby the substance. After a fixed period (retention), the test is repeated(trial 2). A larger difference between the investigation times measuredin trials 1 and 2 means that the adult animal has remembered the younganimal better.

The compounds of the invention are suitable for use as medicaments forhumans and animals.

The present invention also includes pharmaceutical preparations which,besides inert, nontoxic, pharmaceutically suitable excipients andcarriers, contain one or more compounds of the invention, or whichconsist of one or more compounds of the invention, and to processes forproducing these preparations.

The compounds of the invention are to be present in these preparationsin a concentration of from 0.1 to 99.5% by weight, preferably from 0.5to 95% by weight, of the complete mixture.

Besides the compounds of the invention, the pharmaceutical preparationsmay also contain other active pharmaceutical ingredients.

The abovementioned pharmaceutical preparations can be produced by knownmethods in a conventional way.

The novel active ingredients can be converted in a known manner intoconventional formulations such as tablets, coated tablets, pills,granules, aerosols, syrups, emulsions, suspensions and solutions, usinginert, nontoxic, pharmaceutically suitable excipients or solvents. Inthese cases, the therapeutically active compound should in each case bepresent in a concentration of about 0.5 to 90% by weight of theformulation, i.e. in amounts which are sufficient to reach the stateddose range.

The formulations are produced for example by extending the activeingredients with solvents and/or excipients, where appropriate with useof emulsifiers and/or dispersants, it being possible for example whenwater is used as diluent where appropriate to use organic solvents asauxiliary solvents.

Administration can take place in a conventional way, preferably orally,transdermally or parenterally, especially perlingually or intravenously.However, it can also take place by inhalation through the mouth or nose,for example with the aid of a spray, or topically via the skin.

It has generally proved advantageous to administer amounts of about0.001 to 10 mg/kg, on oral administration preferably about 0.005 to 3mg/kg, of body weight to achieve effective results.

It may, nevertheless, be necessary where appropriate to deviate from thestated amounts, in particular as a function of the body weight or of themode of administration, of the individual behaviour towards themedicament, the nature of its formulation and the time or interval overwhich administration takes place. Thus, it may be sufficient in somecases to make do with less than the aforementioned minimum amount,whereas in other cases the stated upper limit must be exceeded. Wherelarger amounts are administered, it may be advisable to divide theseinto a plurality of single doses over the day.

Unless indicated otherwise, all quantitative data relate to percentagesby weight. Solvent ratios, dilution ratios and concentration data ofliquid/liquid solutions are based in each case on volume. The statement“w/v” means “weight/volume”. Thus, for example, “10% w/v” means: 100 mlof solution or suspension contain 10 g of substance.

ABBREVIATIONS

-   conc. Concentrated-   DAD Diode array detector-   DBU 1,5-Diazabicyclo[4.3.0]non-5-ene-   DCI Desorption chemical ionization (in MS)-   DMAP 4-N,N-Dimethylaminopyridine-   DMF N,N-Dimethylformamide-   DMSO Dimethyl sulphoxide-   EDC N′-(3-Dimethylaminopropyl)-N-ethylcarbodiimide×HCl-   eq. equivalent(s)-   ESI Electrospray ionization (in MS)-   HATU O-(7-Azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium    hexafluorophosphate-   HOBt 1-Hydroxy-1H-benzotriazole×H₂O-   HPLC High pressure/high performance liquid chromatography-   LC-MS Liquid chromatography with coupled mass spectroscopy-   MS Mass spectroscopy-   NMR Nuclear magnetic resonance spectroscopy-   PBS Phosphate-buffered saline-   PdCl₂(dppf) Bis(diphenylphosphino)ferrocenepalladium(II) chloride-   PdCl₂(PPh₃)₂ Dichlorobis(triphenylphosphine)palladium-   Pd(PPh₃)₄ Tetrakis(triphenylphosphine)palladium(0)-   Ph Phenyl-   RT Room temperature-   R_(t) Retention time (in HPLC)-   TBTU O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium    tetrafluoroborate-   THF Tetrahydrofuran-   TRIS Tris(hydroxymethyl)aminomethane    HPLC and LC-MS Methods:    Method 1 (HPLC):

Instrument: HP 1100 with DAD; column: Kromasil RP-18, 60 mm×2 mm, 3.5μm; eluent: A=5 ml HClO₄/L H₂O, eluent B=acetonitrile; gradient: 0 min2% B, 0.5 min 2% B, 4.5 min 90% B, 6.5 min 90% B; flow rate: 0.75mL/min; temperature: 30° C.; detection: UV 210 nm.

Method 2 (LC-MS):

MS apparatus type: Micromass ZQ; HPLC apparatus type: Waters Alliance2790; column: symmetry C 18, 50 mm×2.1 mm, 3.5 μm; eluent B:acetonitrile+0.05% formic acid, eluent A: water+0.05% formic acid;gradient: 0 min 5% B→4.5 min 90% B→5.5 min 90% B; oven: 50° C.; flowrate: 1.0 mL/min; UV detection: 210 nm.

Method 3 (LC-MS):

Instrument: Micromass Platform LCZ, HP 1100; column: symmetry C18, 50mm×2.1 mm, 3.5 μm; eluent A: water+0.05% formic acid, eluent B:acetonitrile+0.05% formic acid; gradient: 0 min 90% A→4.0 min 10% A→6.0min 10% A; oven: 40° C.; flow rate: 0.5 mL/min; UV detection: 208-400nm.

Method 4 (LC-MS):

MS apparatus type: Micromass ZQ; HPLC apparatus type: Waters Alliance2790; column: Grom-Sil 120 ODS-4 HE 50 mm×2 mm, 3.0 μm; eluent B:acetonitrile+0.05% formic acid, eluent A: water+0.05% formic acid;gradient: 0.0 min 5% B→2.0 min 40% B→4.5 min 90% B→5.5 min 90% B; oven:45° C.; flow rate: 0.0 min 0.75 mL/min→4.5 min 0.75 mL/min→5.5 min 1.25mL/min; UV detection: 210 nm.

Method 5 (LC-MS):

MS instrument: Micromass TOF (LCT); HPLC instrument: 2-column switching,Waters 2690; column: YMC-ODS-AQ, 50 mm×4.6 mm, 3.0 μm; eluent A:water+0.1% formic acid, eluent B: acetonitrile+0.1% formic acid;gradient: 0.0 min 100% A→0.2 min 95% A→1.8 min 25% A→1.9 min 10% A→3.2min 10% A; oven: 40° C.; flow rate: 3.0 mL/min; UV detection: 210 nm.

Method 6 (LC-MS):

Flow injection, instrument: Micromass Platform LCZ+Quattro LCZ; eluentA: water+0.05% formic acid, eluent B: acetonitrile+0.05% formic acid;gradient: 0.0 min 30% A→1.0 min 30% A; flow rate: 0.2-0.3 mL/min; HPLC:instrument HP 1100; UV detection: DAD.

Method 7 (HPLC):

Instrument: HP 1100 with DAD; column: Kromasil RP-18, 60 mm×2 mm, 3.5μm; eluent A: 5 ml HClO₄/L H₂O, eluent B: acetonitrile; gradient: 0 min2% B→0.5 min 2% B→4.5 min 90% B→9 min 90% B; flow rate: 0.75 mL/min;temperature: 30° C.; UV detection: 210 nm.

Starting Compounds General Method A Synthesis of methyl1-benzothiophene-2-carboxylates

Under an argon atmosphere, 1.5 equivalents of sodium hydride (60% inliquid paraffin) are introduced into absolute DMSO (0.60-1.26 Msuspension). At room temperature, 1.1 equivalents of methylmercaptoacetate are slowly added dropwise to the reaction mixture, andit is left to stir at room temperature until evolution of hydrogenceases (about 15 min). 1.0 equivalent of the appropriate benzaldehydeare dissolved in absolute DMSO (1.60-3.36 M solution) and added at roomtemperature to the reaction mixture. The reaction mixture is stirreduntil the reaction is complete (about 5-10 min) and then poured intoice-water. The resulting precipitate is filtered off with suction, driedat 40° C. in vacuo overnight and reacted further as crude product.

General Method B Synthesis of 1-benzothiophene-2-carboxylic acids

A mixture of equal parts of THF and 2 N aqueous potassium hydroxidesolution (0.28-0.47 M solution) is added to the appropriate methyl1-benzothiophene-2-carboxylate. The reaction mixture is left to stir atroom temperature overnight. The THF is removed in vacuo, and the aqueousreaction mixture is acidified with concentrated hydrochloric acid. Theresulting precipitate is filtered off with suction and dried in vacuo at40° C.

General Method C Amide Linkage Between 3-quinuclidinamine and2-benzothiophene- or 2-benzo-furancarboxylic Acids

1.0 eq. of the appropriate enantiomeric 3-quinuclidinamine hydrochlorideis introduced together with 1 eq. of the carboxylic acid and 1.2 eq. ofHATU into DMF at 0° C. After addition of 1.2 eq. ofN,N-diisopropylethylamine, the mixture is stirred at RT. After 30 min.,a further 2.4 eq. of N,N-diisopropylethylamine are added and the mixtureis stirred at RT overnight.

EXAMPLE 1A 6-Bromo-1-benzofuran-2-carboxylic Acid

8.0 g (39.8 mmol) of 4-bromo-2-hydroxybenzaldehyde and 1.47 g (3.98mmol) of tetra-n-butylammonium iodide are mixed with 22 g (159.19 mmol)of anhydrous potassium carbonate. 9.07 g (83.57 mmol) of methylchloroacetate are added. The reaction mixture is heated at 130° C. for 4h and then cooled to 0° C. in an ice bath. 100 ml of THF and a solutionof 13.4 g (238.8 mmol) of potassium hydroxide in 50 ml of water areadded, and the mixture is then stirred at RT overnight. The THF isremoved under reduced pressure. The remaining aqueous phase is dilutedwith water and acidified with conc. hydrochloric acid. The precipitatedproduct is filtered off and dried under high vacuum. Silica gel 60(Merck, Darmstadt; eluent: toluene, toluene/acetic acid 50:1,toluene/acetic acid/methyl acetate 35:1:5) is used for finalpurification. The solvent is removed under reduced pressure. Finally,the last residues of solvent are removed under high vacuum. 3.8 g (40%of theory) of the title compound are isolated.

¹H-NMR (400 MHz, methanol-d₄): δ=7.91 (m, 1H), 7.61-7.51 (m, 3H).

HPLC (method 1): R_(t)=4.1 min:

MS (ESIpos): m/z=258 (M+NH₄)⁺.

EXAMPLE 2AN-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-6-bromo-1-benzofuran-2-carboxamide

3.8 g (15.77 mmol) of 6-bromobenzofuran-2-carboxylic acid (Example 1A),3.14 g (15.77 mmol) of (R)-3-aminoquinuclidine dihydrochloride, 7.19 g(18.92 mmol) of HATU, 7.34 g (56.76 mmol) of N,N-diisopropylethylamineand 50 ml of DMF are reacted by general method C. The crude product istaken up in methanol and shaken together with acidic ion exchanger(Dowex® WX2-200) for about 20 min. The loaded ion exchanger is washedsuccessively with methanol, dichloromethane and again with methanol. Theproduct is eluted with methanol/triethylamine 90:10. The solvent isremoved in a rotary evaporator under reduced pressure. Finally, the lastresidues of solvent are removed under high vacuum. 5.14 g (85% oftheory) of the title compound are isolated. For analysis, a small amountis converted into the hydrochloride with 4 N hydrogen chloride indioxane.

¹H-NMR (200 MHz, DMSO-d₆): δ=10.55 (br. s, 1H), 9.22 (d, 1H), 8.05 (s,1H), 7.75-7.55 (m, 3H), 4.43-4.29 (m, 1H), 3.70-3.55 (m, 1H), 3.45-3.10(m, 5H), 2.25-2.00 (m, 2H), 1.98-1.82 (m, 2H), 1.80-1.60 (m, 1H).

HPLC (method 1): R_(t)=3.9 min.

MS (ESIpos): m/z=349 (M+H)⁺.

LC-MS (method 2): R_(t)=1.49 min.

MS (ESIpos): m/z=349 (M+H)⁺.

EXAMPLE 3AN-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-5-bromo-1-benzofuran-2-carboxamideHydrochloride

240 mg (0.98 mmol) of 5-bromobenzofuran-2-carboxylic acid, 200 mg (0.98mmol) of (R)-3-aminoquinuclidine dihydrochloride, 450 mg (1.18 mmol) ofHATU, 460 mg (3.54 mmol) of N,N-diisopropylethylamine and 2.0 ml of DMFare reacted by general method C. The reaction mixture is purified bypreparative HPLC. Finally, an excess of 1N hydrochloric acid is added tothe product. The solvent is removed under reduced pressure. 202 mg (53%of theory) of the title compound are isolated.

¹H-NMR (200 MHz, DMSO-d₆): δ=9.38 (br. s, 1H), 8.88 (d, 1H), 7.60 (s,1H), 7.38-7.20 (m, 2H), 7.09 (dd, 1H), 4.43-4.29 (m, 1H), 3.70-3.55 (m,1H), 3.45-3.10 (m, 5H), 2.25-2.00 (m, 2H), 1.98-1.82 (m, 2H), 1.80-1.60(m, 1H).

MS (ESIpos): m/z=349 (M+H)⁺ (free base).

LC-MS (method 3): R_(t)=2.71 min.

MS (ESIpos): m/z=349 (M+H)⁺ (free base).

EXAMPLE 4A 7-Bromo-5-fluoro-1-benzofuran-2-carboxylic Acid

1.0 g (5.24 mmol) of 2-bromo-4-fluorophenol is introduced into 4.0 ml oftrifluoroacetic acid. 1.47 g (10.47 mmol) of hexamethylenetetramine areadded in portions over the course of 20 min. The mixture is then boiledunder reflux for 28 h. At RT, 6 ml of water and 3 ml of 50% strengthsulphuric acid are added. After 2 h, the mixture is extracted twice witha total of 60 ml of ethyl acetate. The combined organic phases arewashed four times with 1N hydrochloric acid and once with water. Dryingover magnesium sulphate is followed by removal of the solvent underreduced pressure. Finally, the last residues of solvent are removedunder high vacuum. The crude product (without further purification) and0.19 g (0.52 mmol) of tetra-n-butylammonium iodide are mixed with 2.9 g(20.96 mmol) of anhydrous potassium carbonate. 1.19 g (11.0 mmol) ofmethyl chloroacetate are added. The reaction mixture is heated at 130°C. for 4 h and then cooled to 0° C. in an ice bath. 18 ml of THF and asolution of 1.76 g (31.44 mmol) of potassium hydroxide in 18 ml of waterare added. The mixture is stirred at RT overnight. The solvent isremoved under reduced pressure. Dilution with water is followed byacidification with concentrated hydrochloric acid. The mixture isextracted twice with ethyl acetate. The combined organic phases aredried over magnesium sulphate, and the solvent is removed in a rotaryevaporator under reduced pressure. Silicagel 60 (Merck, Darmstadt;eluent: toluene/acetic acid 40:1) is used for purification. The solventis removed under reduced pressure. Finally, the last residues of solventare removed under high vacuum. 257 mg (19% of theory over the twostages) of the title compound are isolated.

¹H-NMR (400 MHz, methanol-d₄): δ=7.60 (m, 1H), 7.48-7.35 (m, H).

HPLC (method 1): R_(t)=4.1 min.

MS (ESIpos): m/z=276 (M+NH₄)⁺.

EXAMPLE 5AN-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-5-fluoro-7-bromo-1-benzofuran-2-carboxamide

143 mg (0.55 mmol) of 5-fluoro-7-bromo-1-benzofuran-2-carboxylic acid(Example 4A), 100 mg (0.50 mmol) of (R)-3-aminoquinuclidinedihydrochloride, 229.14 mg (0.6 mmol) of HATU, 234 mg (1.81 mmol) ofN,N-diisopropylethylamine and 2.0 ml of DMF are reacted by generalmethod C. DMF is removed under reduced pressure, and the crude productis dissolved in 1N sodium hydroxide solution. The aqueous phase isextracted with ethyl acetate, and the organic phase is washed withsaturated aqueous sodium chloride solution. The combined organic phasesare dried over magnesium sulphate, and the solvent is removed in arotary evaporator under reduced pressure. The crude product is taken upin methanol and shaken together with acidic ion exchanger (Dowex®WX2-200) for about 20 min. The loaded ion exchanger is washed threetimes with 30 ml of methanol each time, then with water, again withmethanol, with dichloromethane and finally again with methanol. Theproduct is eluted with methanol/triethylamine 95:5. The solvent isremoved in a rotary evaporator under reduced pressure. 181 mg (98% oftheory) of the title compound are isolated.

¹H-NMR (400 MHz, methanol-d₄): δ=7.59 (d, 1H), 7.53-7.46 (m, 2H),4.24-4.18 (m, 1H), 3.34-3.29 (m, 1H), 3.07-2.97 (m, 1H), 2.93-2.77 (m,4H), 2.13-2.05 (m, 1H), 1.98-1.86 (m, 1H), 1.84-1.75 (m, 2H), 1.63-1.53(m, 1H).

MS (ESIpos): m/z=367 (M+H)⁺.

LC-MS (method 3): R_(t)=2.92 min.

MS (ESIpos): m/z=367 (M+H)⁺.

EXAMPLE 6A Methyl 7-bromo-1-benzothiophene-2-carboxylate

Starting from 27.8 g (137.1 mmol) of 3-bromo-2-fluorobenzaldehyde, bygeneral method A with 8.2 g (205.7 mmol) of sodium hydride (60% inliquid paraffin) and 16.0 g (150.9 mmol) of methyl mercaptoacetate,20.57 g of a mixture of the title compound and the corresponding acid(about 1:1) is obtained.

EXAMPLE 7A 7-Bromo-1-benzothiophene-2-carboxylic Acid

Starting from 10.0 g (36.9 mmol) of methyl7-bromo-1-benzothiophene-2-carboxylate, by general method B 8.99 g(91.0% of theory) of the desired product are obtained.

¹H-NMR (200 MHz, DMSO-d₆): δ=13.76 (br. s, 1H), 8.28 (s, 1H), 8.07 (d,1H), 7.78 (d, 1H), 7.46 (dd, 1H).

HPLC (method 1): R_(t)=4.4 min.

EXAMPLE 8AN-(1-Azabicyclo[2.2.2]oct-3-yl)-7-bromo-1-benzothiophene-2-carboxamideHydrochloride

903.8 mg (3.52 mmol) of 7-bromo-1-benzothiophene-2-carboxylic acid(Example 7A), 700 mg (3.52 mmol) of (R)-3-aminoquinuclidinedihydrochloride, 1604.0 mg (4.22 mmol) of HATU, 1635.7 mg (12.66 mmol)of N,N-diisopropylethylamine and 7.0 ml of DMF are reacted by generalmethod C. The reaction mixture is purified by preparative HPLC. Theproduct is dissolved in a 1:1 mixture of 4 M hydrogen chloride indioxane and 1N hydrochloric acid and then concentrated and dried underhigh vacuum. 1087 mg (77% of theory) of the title compound are obtained.

¹H-NMR (200 MHz, DMSO-d₆): δ=10.01 (br. s, 1H), 9.15 (d, 1H), 8.47 (s,1H), 8.02 (m, 1H), 7.74 (m, 1H), 7.43 (dd, 1H), 4.34 (m, 1H), 3.80-3.10(m, 6H), 2.22 (m, 1H), 2.14 (m, 1H), 1.93 (m, 2H), 1.78 (m, 1H).

HPLC (method 1): R_(t)=4.1 min.

MS (ESIpos): m/z=365 (M+H)⁺ (free base).

EXAMPLE 9A Methyl 6-bromo-1-benzothiophene-2-carboxylate

Starting from 6.54 g (32.2 mmol) of 4-bromo-2-fluorobenzaldehyde, bygeneral method A with 1.93 g (48.3 mmol) of sodium hydride (60% inliquid paraffin) and 3.76 g (35.5 mmol) of methyl mercaptoacetate, 4.06g (46% of theory) of the title compound are obtained.

¹H-NMR (200 MHz, DMSO-d₆): δ=8.42 (d, 1H), 8.22 (s, 1H), 7.98 (d, 1H),7.65 (dd, 1H), 3.90 (s, 3H).

HPLC (method 1): R_(t)=5.3 min.

MS (ESIpos): m/z=270 (M⁺).

EXAMPLE 10A 6-Bromo-1-benzothiophene-2-carboxylic Acid

Starting from 4.0 g (14.8 mmol) of methyl6-bromo-1-benzothiophene-2-carboxylate (from Example 9A), by generalmethod B 3.55 g (94% of theory) of the desired product are obtained.

¹H-NMR (400 MHz, DMSO-d₆): δ=13.48 (br. s, 1H), 8.38 (s, 1H), 8.22 (s,1H), 7.96 (d, 1H), 7.63 (m, 1H).

HPLC (method 1): R_(t)=4.5 min.

EXAMPLE 11AN-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-6-bromo-1-benzothiophene-2-carboxamideHydrochloride

900.0 mg (3.50 mmol) of 6-bromo-1-benzothiophene-2-carboxylic acid(Example 10A), 697.0 mg (3.50 mmol) of (R)-3-aminoquinuclidinedihydrochloride, 1597.1 mg (4.20 mmol) of HATU, 1628.7 mg (12.60 mmol)of N,N-diisopropylethylamine and 8.0 ml of DMF are reacted by generalmethod C. The reaction mixture is purified by preparative HPLC. Theproduct is dissolved in a 1:1 mixture of 4 M hydrogen chloride indioxane and 1N hydrochloric acid, and the solution is then concentrated.Recrystallization from methanol/ethanol (1:10) affords 594 mg (42% oftheory) of the title compound in the form of yellowish-brown crystals.

¹H-NMR (300 MHz, DMSO-d₆): δ=9.81 (br. s, 1H), 8.76 (m, 1H), 8.33 (s,1H), 8.22 (s, 1H), 7.91 (d, 1H), 7.59 (dd, 1H), 4.15 (m, 1H), 3.51-2.93(m, 6H), 2.12-1.92 (m, 2H), 1.79 (m, 2H), 1.58 (m, 1H).

HPLC (method 1): R_(t)=4.1 min.

MS (ESIpos): m/z=364 (M⁺) (free base).

EXAMPLE 12A Methyl 5-bromo-1-benzothiophene-2-carboxylate

Starting from 2.99 g (14.7 mmol) of 5-bromo-2-fluorobenzaldehyde, bygeneral method A with 0.88 g (22.1 mmol) of sodium hydride (60%) and1.72 g (16.2 mmol) of methyl mercaptoacetate, 2.76 g (69.1% of theory)of the title compound are obtained.

¹H-NMR (200 MHz, DMSO-d₆): δ=8.29 (d, 1H), 8.18 (s, 1H), 8.08 (d, 1H),7.69 (dd, 1H), 3.90 (s, 3H).

HPLC (method 1): R_(t)=5.2 min.

MS (ESIpos): m/z=270 (M⁺).

EXAMPLE 13A 5-Bromo-1-benzothiophene-2-carboxylic Acid

Starting from 2.7 g (9.96 mmol) of methyl5-bromo-1-benzothiophene-2-carboxylate (from Example 12A), by generalmethod B 2.41 g (94% of theory) of the desired product are obtained.

¹H-NMR (400 MHz, DMSO-d₆): δ=13.67 (br. s, 1H), 8.27 (m, 1H), 8.10 (s,1H), 8.05 (d, 1H), 7.66 (dd, 1H).

HPLC (method 1): R_(t)=4.5 min.

EXAMPLE 14AN-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-5-bromo-1-benzothiophene-2-carboxamideHydrochloride

133.7 mg (0.52 mmol) of 5-bromo-1-benzothiophene-2-carboxylic acid(Example 13A), 155.4 mg (0.78 mmol) of (R)-3-aminoquinuclidinedihydrochloride, 296.7 mg (0.78 mmol) of HATU, 369.8 mg (2.86 mmol) ofN,N-diisopropylethylamine and 1.5 ml of DMF are reacted by generalmethod C. The reaction mixture is purified by preparative HPLC. Theproduct is dissolved in acetonitrile, and an excess of 1N hydrochloricacid is added. Finally, the solvent is removed. 175 mg (84% of theory)of the title compound are isolated.

¹H-NMR (200 MHz, DMSO-d₆): δ=9.44 (br. s, 1H), 8.95 (d, 1H), 8.30-8.10(m, 2H), 8.03 (d, 1H), 7.60 (m, 1H), 4.38-4.20 (m, 1H), 3.80-3.55 (m,1H), 3.42-3.05 (m, 5H), 2.25-2.00 (m, 2H), 1.98-1.62 (m, 3H).

HPLC (method 1): R_(t)=4.1 min.

MS (ESIpos): m/z=365 (M+H)⁺ (free base).

EXAMPLE 15A 4-(4-Bromophenyl)morpholine

A solution of 6.94 ml (134.8 mmol) of bromine in 25 ml of acetic acid isslowly added dropwise over a period of 40 min to a solution of 20 g(122.5 mmol) of N-phenylmorpholine in 170 ml of acetic acid at roomtemperature. After stirring at room temperature for 30 min, the reactionmixture is stirred into 750 ml of water and adjusted to pH 11 with 45%strength sodium hydroxide solution. The resulting precipitate isfiltered off with suction, washed with water and dried under highvacuum. Recrystallization from ethanol results in 18.6 g (62.9% oftheory) of the title compound.

¹H-NMR (200 MHz, DMSO-d₆): δ=7.37 (m, 2H), 6.89 (m, 2H), 3.73 (m, 4H),3.08 (m, 4H).

HPLC (method 1): R_(t)=3.9 min.

MS (ESIpos): m/z=242 (M+H)⁺.

EXAMPLE 16A 4-(4-Bromophenyl)-3-morpholinone

1.41 g (6.20 mmol) of benzyltriethylammonium chloride and 0.98 g (6.20mmol) of potassium permanganate are added to a solution of 500 mg (2.07mmol) of 4-(4-bromophenyl)morpholine (Example 15A) in 10 ml ofdichloromethane. After 5 h under reflux, the contents of the flask areconcentrated in vacuo, and the residue is purified by preparative HPLC.The concentrated product is dried under high vacuum. 217 mg (35.7% oftheory) of the title compound are obtained.

LC-MS (method 4): R_(t)=2.9 min, m/z=255 (M+).

EXAMPLE 17A 3-(4-Morpholinyl)phenyl Trifluoromethanesulphonate

2.18 ml (12.9 mmol) of trifluoromethanesulphonic anhydride are slowlyadded dropwise to a solution, cooled to −10° C., of 1.54 g (8.6 mmol) of3-(4-morpholinyl)-phenol and 3.59 ml (25.8 mmol) of triethylamine in 10ml of dichloromethane. The mixture is stirred at −10° C. for 30 min andthen at 0° C. for 30 min. It is washed successively with 10% strengthsodium bicarbonate solution, water and saturated sodium chloridesolution, dried over sodium sulphate and concentrated in vacuo, and theresidue is dried under high vacuum. 2.41 g (90.1% of theory) of thetitle compound are obtained.

¹H-NMR (200 MHz, CDCl₃): δ=7.28 (m, 1H), 6.88 (m, 1H), 6.73 (m, 2H),3.86 (m, 4H), 3.18 (m, 4H).

HPLC (method 1): R_(t)=4.8 min.

MS (ESIpos): m/z=312 (M+H)⁺.

EXAMPLE 18A 4-(4-Morpholinylcarbonyl)phenyl Trifluoromethanesulphonate

1.23 ml (7.24 mmol) of trifluoromethanesulphonic anhydride are slowlyadded dropwise to a solution, cooled to −10° C., of 1.0 g (4.83 mmol) of4-(4-morpholinylcarbonyl)phenol and 2.02 ml (14.48 mmol) oftriethylamine in 20 ml of dichloromethane. The mixture is stirred at−10° C. for 30 min and then at 0° C. for 30 min. It is washedsuccessively with 10% strength sodium bicarbonate solution, water andsaturated sodium chloride solution, dried over sodium sulphate andconcentrated in vacuo, and the residue is dried under high vacuum. 1.71g (94.6% of theory) of the title compound are obtained.

¹H-NMR (400 MHz, methanol-d₄): δ=7.62 (m, 2H), 7.49 (m, 2H), 3.86-3.34(m, 8H).

HPLC (method 1): R_(t)=4.2 min.

MS (ESIpos): m/z=357 (M+NH₄)⁺.

EXAMPLE 19A Methyl7-[4-(4-morpholinyl)phenyl]-1-benzothiophene-2-carboxylate

3.42 ml of 2 M sodium carbonate solution and 83.5 mg (0.11 mmol) ofPdCl₂(dppf) are added to a solution of 619.1 mg (2.28 mmol) of methyl7-bromo-1-benzothiophene-2-carboxylate (Example 6A) and 520 mg (2.51mmol) of 4-(4-morpholinyl)phenylboronic acid in 10 ml DMF. The mixtureis heated at 80° C. for 16 h. Cooling is followed by filtration throughkieselguhr and purification by preparative HPLC. The concentratedproduct is dried under high vacuum. 146.7 mg (16.4% of theory) of thetitle compound are obtained.

HPLC (method 1): R_(t)=4.6 min.

MS (ESIpos): m/z=354 (M+H)⁺.

EXAMPLE 20A 7-[4-(4-Morpholinyl)phenyl]-1-benzothiophene-2-carboxylicAcid

A solution of 330 mg (0.77 mmol) of methyl7-[4-(4-morpholinyl)phenyl]-1-benzothiophene-2-carboxylate (Example 19A)in 6 ml of a 1:1 mixture of methanol and 2N potassium hydroxide solutionis stirred at room temperature for 2 h and at 50° C. for 1 h. Thereaction mixture is concentrated in vacuo and, after addition of water,acidified with conc. hydrochloric acid. The resulting precipitate isfiltered off with suction, washed twice with water and dried under highvacuum. 292 mg of crude product are obtained and reacted without furtherpurification.

EXAMPLE 21A 7-(2-Methoxyphenyl)-1-benzofuran-2-carboxylic Acid

5.0 g (20.7 mmol) of 7-bromo-1-benzofuran-2-carboxylic acid (Example29A) and 3.78 g (24.9 mmol) of 2-methoxyphenylboronic acid areintroduced into 50 ml of DMF. Addition of 31.1 ml of 2 M sodiumcarbonate solution and 1.2 g (1.04 mmol) of Pd(PPh₃)₄ is followed byheating to 90° C. After 18 h, the solvent is distilled out. The residueis partitioned between 1N hydrochloric acid and ethyl acetate andextracted three times with 200 ml of ethyl acetate each time. Theorganic phase is dried over sodium sulphate and concentrated in vacuo.The residue is purified by flash chromatography (silica gel, mobilephase: dichloromethane/methanol/acetic acid 100:10:1). Concentration anddrying under high vacuum result in 2.97 g (53.2% of theory) of the titlecompound.

¹H-NMR (300 MHz, DMSO-d₆): δ=13.46 (s, 1H), 7.73 (dd, 1H), 7.59 (s, 1H),7.48-7.33 (m, 4H), 7.20 (d, 1H), 7.09 (m, 1H), 3.75 (s, 3H).

HPLC (method 1): R_(t)=4.5 min.

MS (ESIpos): m/z=286 (M+NH₄)⁺.

EXAMPLE 22AN-[(3S)-1-Azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzothiophene-2-carboxamideHydrochloride

3.58 g (18.7 mmol) of EDC, 2.52 g (18.7 mmol) of HOBt and 7.8 ml (56mmol) of triethylamine are added to a solution, cooled to 0° C., of 4.0g (15.6 mmol) of 7-bromo-1-benzothiophene-2-carboxylic acid (Example 7A)and 3.10 g (15.6 mmol) of (S)-3-aminoquinuclidine dihydrochloride in 50ml of DMF. The mixture is stirred at room temperature for 18 h. Thereaction is stopped by adding 10% strength sodium bicarbonate solution.The precipitate resulting after addition of ethyl acetate is filteredoff. The aqueous phase is extracted with ethyl acetate, the combinedorganic phases are dried over sodium sulphate and concentrated, and theresidue is dried under high vacuum. 4.70 g (68% of theory) of the titlecompound are obtained. The spectroscopic data agree with those of theenantiomeric compound (Example 8A).

EXAMPLE 23AN-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-6-(4-formylphenyl)-1-benzothiophene-2-carboxamideHydrochloride

200 mg (0.50 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-bromo-1-benzothiophene-2-carboxamidehydrochloride (Example 11A) and 74.6 mg (0.50 mmol) of4-formylphenylboronic acid are introduced into 2 ml of DMF. Addition of0.75 ml of 2 M sodium carbonate solution and 20.3 mg (0.02 mmol) ofPdCl₂(dppf) is followed by heating to 80° C. After 18 h, the reactionmixture is filtered through kieselguhr and purified by preparative HPLC.The product fractions are concentrated, mixed with a 5:1 mixture ofmethanol and 4 N hydrogen chloride in dioxane and again concentrated.Drying under high vacuum results in 163.8 mg (75.0% of theory) of thetitle compound.

¹H-NMR (200 MHz, DMSO-d₆): δ=10.09 (s, 1H), 10.07 (br. s, 1H), 9.10 (d,1H), 8.50 (m, 1H), 8.37 (s, 1H), 8.15-7.97 (m, 5H), 7.87 (dd, 1H), 4.33(m, 1H), 3.68 (m, 1H), 3.45-3.12 (m, 5H), 2.23 (m, 1H), 2.16 (m, 1H),1.91 (m, 2H), 1.76 (m, 1H).

HPLC (method 1): R_(t)=4.1 min.

MS (ESIpos): δ=391 (M+H)⁺ (free base).

EXAMPLE 24A Methyl 6-cyano-1-benzothiophene-2-carboxylate

4.08 g (23.2 mmol) of 4-cyano-2-nitrobenzaldehyde, 2.46 g (23.2 mmol) ofmethyl mercaptoacetate and 6.46 ml (46.4 mmol) of triethylamine areheated in 12.3 ml of DMSO at 80° C. for 2.5 h. The reaction solution isadded to 400 ml of ice-water. The precipitate resulting after additionof 4 ml of acetic acid is filtered off with suction, washed twice withwater and dried in vacuo at 50° C. overnight. 4.19 g (83.2% of theory)of the title compound are obtained.

¹H-NMR (200 MHz, DMSO-d₆): δ=8.73 (d, 1H), 8.32 (s, 1H), 8.21 (d, 1H),7.85 (dd, 1H), 3.92 (s, 3H).

HPLC (method 1): R_(t)=4.4 min.

MS (ESIpos): m/z=218 (M+H)⁺.

EXAMPLE 25A 6-Cyano-1-benzothiophene-2-carboxylic Acid

In accordance with general method B, 0.49 g (61.6% of theory) of thedesired product is obtained starting from 0.6 g (2.76 mmol) of methyl6-cyano-1-benzothiophene-2-carboxylate (Example 24A).

HPLC (method 1): R_(t)=3.9 min.

MS (ESIpos): m/z=222 (M+H)⁺.

EXAMPLE 26AN-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-6-cyano-1-benzothiophene-2-carboxamideHydrochloride

320.8 mg (1.1 mmol) of 6-cyano-1-benzothiophene-2-carboxylic acid(Example 25A), 200 mg (1.0 mmol) of (R)-3-aminoquinuclidinedihydrochloride, 458.3 mg (1.21 mmol) of HATU, 467.3 mg (3.62 mmol) ofN,N-diisopropylethylamine and 4.0 ml of DMF are reacted by generalmethod C. The reaction mixture is purified by preparative HPLC. Theproduct is dissolved in a mixture of methanol and 4 M hydrogen chloridein dioxane and then concentrated and dried under high vacuum. 222.1 mg(64% of theory) of the title compound are obtained.

¹H-NMR (300 MHz, DMSO-d₆): δ=9.80 (m, 1H), 9.12 (d, 1H), 8.68 (s, 1H),8.37 (s, 1H), 8.16 (d, 1H), 7.83 (dd, 1H), 4.33 (m, 1H), 3.76-3.05 (m,6H), 2.23 (m, 1H), 2.13 (m, 1H), 1.92 (m, 2H), 1.76 (m, 1H).

HPLC (method 1): R_(t)=3.6 min.

MS (ESIpos): m/z=312 (M+H)⁺ (free base).

EXAMPLE 27A6-[(Z)-Amino(hydroxyimino)methyl]-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzothiophene-2-carboxamideDihydrochloride

800 mg (2.0 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-cyano-1-benzothiophene-2-carboxamidehydrochloride (Example 26A), 278.1 mg (4.0 mmol) of hydroxylaminehydrochloride and 829.5 mg (6.0 mmol) of potassium carbonate are heatedin 8 ml of an 8:1 mixture of water and ethanol at 80° C. for 3 h. Themixture is purified by column chromatography on silica gel (mobilephase: dichloromethane/methanol/25% ammonia solution 100:20:4). Theproduct fractions are combined, concentrated, mixed with methanol and 4M hydrogen chloride in dioxane, then again concentrated and dried underhigh vacuum. 447.3 mg (53.6% of theory) of the title compound areobtained.

¹H-NMR (200 MHz, DMSO-d₆): δ=11.15 (m, 1H), 10.22 (m, 1H), 9.36 (d, 1H),8.52 (s, 1H), 8.46 (m, 1H), 8.14 (d, 1H), 7.73 (dd, 1H), 4.33 (m, 1H),3.93-3.10 (m, 6H), 2.32-2.05 (m, 2H), 1.93 (m, 2H), 1.75 (m, 1H).

HPLC (method 1): R_(t)=2.9 min.

MS (ESIpos): δ=345 (M+H)⁺ (free base).

EXAMPLE 28A 3-Bromo-2-hydroxybenzaldehyde

20.0 g (115.6 mmol) of 2-bromophenol are introduced into 500 ml of dryacetonitrile. 16.84 g (176.87 mmol) of dry magnesium chloride, 23.4 g ofparaformaldehyde granules and 41.9 ml (300.6 mmol) of triethylamine areadded. The reaction mixture is heated under reflux for 4 h and, aftercooling to 0° C., 300 ml of 2N hydrochloric acid are added. The aqueousphase is extracted three times with 200 ml of diethyl ether each time.The organic phase is dried over magnesium sulphate, and the solvent isremoved in vacuo. 24 g (64% of theory, 62% pure according to HPLC) ofthe title compound are isolated and reacted further without furtherpurification.

HPLC (method 1): R_(t)=4.25 min.

MS (ESIpos): m/z=202 (M+H)⁺.

EXAMPLE 29A 7-Bromo-1-benzofuran-2-carboxylic Acid

13.5 g (40.3 mmol) of 3-bromo-2-hydroxybenzaldehyde (Example 28A, 62%pure) are heated together with 9.18 g (84.62 mmol) of methylchloroacetate, 1.49 g (4.03 mmol) of tetra-n-butylammonium iodide and22.28 g (161.18 mmol) of potassium carbonate at 130° C. for 6 h. Aftercooling to RT, 100 ml of water and 100 ml of THF, and 13.57 g (241.77mmol) of potassium hydroxide are added, and the mixture is stirred at RTovernight. The solvent is removed under reduced pressure, and theresidue is taken up in 400 ml of water and washed four times with atotal of 400 ml of diethyl ether. While cooling in ice, the pH isadjusted to 0 with concentrated hydrochloric acid and five extractionswith a total of 700 ml of ethyl acetate are carried out. The organicphase is washed with 100 ml of saturated sodium chloride solution andthen dried over magnesium sulphate. The crude product is completelyfreed of residual solvents under high vacuum and is stirred with 80 mlof diethyl ether. The product is filtered off and washed with a littleice-cold diethyl ether. 4.8 g (47% of theory) of the title compound areisolated.

¹H-NMR (200 MHz, DMSO-d₆): δ=13.5 (br. s, 1H), 7.86-7.72 (m, 2H), 7.79(s, 1H), 7.31 (t, 1H).

MS (DCI/NH₃): m/z=258 (M+NH₄)⁺.

EXAMPLE 30AN-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzofuran-2-carboxamide

5.20 g (21.57 mmol) of 7-bromobenzofuran-2-carboxylic acid (Example29A), 4.3 g (21.57 mmol) of (R)-3-aminoquinuclidine dihydrochloride,9.84 g (25.89 mmol) of HATU, 13.53 ml (74.68 mmol) ofN,N-diisopropylethylamine and 21 ml of DMF are reacted by general methodC. The solvent is removed under reduced pressure, and the crude productis taken up in 100 ml of ethyl acetate and washed 15 times with a totalof 1.5 l of 1N sodium hydroxide solution. The organic phase is driedover magnesium sulphate and freed of solvent. 5.2 g (69% of theory) ofthe title compound are isolated.

¹H-NMR (300 MHz, DMSO-d₆): δ=8.48 (d, 1H), 7.85-7.65 (m, 3H), 7.25 (t,1H), 3.95 (m, 1H), 3.15 (m, 1H), 2.95 (m, 1H), 2.80-2.60 (m, 4H), 1.90(m, 1H), 1.70 (m, 1H), 1.58 (m, 2H), 1.35 (m, 1H).

HPLC (method 1): R_(t)=3.79 min.

MS (ESIpos): m/z=349 (M+H)⁺

[α]²⁰ _(D)=26.9° (c=0.50, methanol).

In some exemplary embodiments, the corresponding hydrochloride isemployed and is obtained by mixing the title compound with a 5:1 mixtureof methanol and 1N hydrochloric acid and then concentrating and dryingunder high vacuum.

EXAMPLE 31AN-[(3S)-1-Azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzofuran-2-carboxamide

4.0 g (16.59 mmol) of 7-bromobenzofuran-2-carboxylic acid (Example 29A),3.3 g (16.59 mmol) of (S)-3-aminoquinuclidine dihydrochloride, 7.57 g(19.91 mmol) of HATU, 10.41 ml (59.74 mmol) of N,N-diisopropylethylamineand 21 ml of DMF are reacted by general method C. The solvent is removedunder reduced pressure, and the crude product is taken up in 100 ml ofethyl acetate and washed 15 times with a total of 1.5 l of 1N sodiumhydroxide solution. The organic phase is dried over magnesium sulphateand freed of solvent. 5.0 g (85% of theory) of the title compound areisolated.

The analytical data agree with those of Example 30A.

[α]²⁰ _(D)=−28.0° (c=0.1, methanol).

EXAMPLE 32A 2-(4-Morpholinyl)phenyl trifluoromethanesulphonate

2.78 ml (16.4 mmol) of trifluoromethanesulphonic anhydride are slowlyadded dropwise to a solution, cooled to −10° C., of 2 g (10.9 mmol) of2-(4-morpholinyl)-phenol and 4.57 ml (32.8 mmol) of triethylamine in 15ml of dichloromethane. The mixture is stirred at −10° C. for 30 min andthen at 0° C. for 30 min. It is washed successively with 10% strengthsodium bicarbonate solution, water and saturated sodium chloridesolution, dried over sodium sulphate and concentrated in vacuo, and theresidue is dried under high vacuum. 3.48 g (87.6% of theory) of thetitle compound are obtained.

HPLC (method 1): R_(t)=4.9 min.

MS (ESIpos): m/z=312 (M+H)⁺.

EXAMPLE 33AN-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-6-(3-formylphenyl)-1-benzothiophene-2-carboxamideHydrochloride

200 mg (0.50 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-bromo-1-benzothiophene-2-carboxamidehydrochloride (Example 11A) and 74.6 mg (0.50 mmol) of3-formylphenylboronic acid are introduced into 1 ml of DMF. Addition of0.75 ml of 2 M sodium carbonate solution and 20.3 mg (0.02 mmol) ofPdCl₂(dppf) is followed by heating to 80° C. After 18 h, the reactionmixture is filtered through kieselguhr and purified by preparative HPLC.The product fractions are concentrated, mixed with a 5:1 mixture ofmethanol and 4N hydrogen chloride in dioxane and again concentrated.Drying under high vacuum results in 92.4 mg (39.5% of theory) of thetitle compound.

HPLC (method 1): R_(t)=4.11 min.

MS (ESIpos): m/z=391 (M+H)⁺ (free base).

EXEMPLARY EMBODIMENTS General Method D

1.5 eq. of bis(pinacolato)diboron, 3.25 eq. of dry potassium acetate,1.3 eq. of the substituted haloaromatic compound or of the substitutedaryl trifluoromethane-sulphonate are dissolved in DMF (about 1 ml/mmolof haloaromatic compound or aryl trifluoromethanesulphonate). Argon ispassed through the reaction mixture for 15 minutes and then 0.05 eq. ofPdCl₂(dppf) is added and the mixture is heated at 90° C. for 2 h. Then1.0 eq. of the appropriate bromine-substitutedN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]benzothiophene-2-carboxamide orN-[(3R)-1-azabicyclo-[2.2.2]oct-3-yl]benzofuran-2-carboxamide, 5 eq. ofaqueous 2 M sodium carbonate solution and a further 0.05 eq. ofPdCl₂(dppf) are added. The reaction mixture is heated at 90° C. for 6-12h. Purification takes place by preparative HPLC. The resulting product(free base) is dissolved in methanol, and an excess of 1N hydrochloricacid is added. The solvent is removed under reduced pressure.

General Method E

A solution of 50 mg (0.11 mmol) of3-(2-{[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]carbonyl}-1-benzothien-7-yl)benzoicacid hydrochloride (Example 75), 103 mg (0.27 mmol) of HATU and 52.5 mg(0.41 mmol) of N,N-diisopropylethylamine in 0.5 ml of DMF is addeddropwise to a 2N solution of an amine (0.23 mmol) in DMF. After 16 h atroom temperature, 0.1 ml of water is added to the reaction mixture,which is then filtered and purified by preparative HPLC. The productfractions are combined and, after addition of 2 ml of 1N hydrochloricacid, concentrated in vacuo and dried under high vacuum.

General Method F

0.24 mmol of acid chloride and 84 μl (0.60 mmol) of triethylamine areadded to a solution of 50 mg (0.12 mmol) ofN-((3R)-quinuclidin-3-yl)-7-(3-amino-phenyl)benzo[b]thiophene-2-carboxamidehydrochloride (Example 21) in 0.5 ml of DMF. After one hour at roomtemperature, 0.5 ml of 1N sodium hydroxide solution and 15 ml of ethylacetate are added to the reaction mixture, which is then filtered. Theconcentrated organic phase is purified by preparative HPLC. The productfractions are combined and, after addition of 1N hydrochloric acid,again concentrated in vacuo and dried under high vacuum.

EXAMPLE 1N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-6-[2-(hydroxymethyl)phenyl]-1-benzofuran-2-carboxamide

A mixture of 130 mg (0.86 mmol) of 2-(hydroxymethyl)phenylboronic acid,200 mg (0.57 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-bromo-1-benzofuran-2-carboxamide(Example 2A), 1.72 ml (1.72 mmol) of 1N sodium hydroxide solution, 40 mg(0.06 mmol) of 1,1′-bis(diphenylphosphino)ferrocenepalladium(II)chloride and 2 ml of DMF is heated at 80-85° C. for 18 h. The solvent isremoved under reduced pressure. The crude product is purified on silicagel 60 (Merck, Darmstadt; eluent: dichloromethane,dichloromethane/methanol 20:1, dichloromethane/methanol-/ammonia80:20:2). The solvent is removed under reduced pressure. Finally, thelast residues of solvent are removed under high vacuum. 149 mg (63% oftheory) of the title compound are isolated.

¹H-NMR (200 MHz, CDCl₃): δ=7.71-7.28 (m, 8H), 6.77 (d, 1H), 4.62 (s,2H), 4.28-4.12 (m, 1H), 3.56-3.38 (m, 1H), 3.04-2.78 (m, 4H), 2.75-2.59(m, 1H), 2.16-2.02 (m, 1H), 1.93-1.66 (m, 3H), 1.66-1.45 (m, 1H).

HPLC (method 1): R_(t)=3.6 min.

LC-MS (method 2): R_(t)=1.49 min.

MS (ESIpos): m/z=377 (M+H)⁺.

EXAMPLE 2N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-6-[3-(hydroxymethyl)phenyl]-1-benzofuran-2-carboxamide

A mixture of 130 mg (0.86 mmol) of 3-(hydroxymethyl)phenylboronic acid,200 mg (0.57 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-bromo-1-benzofuran-2-carboxamide(Example 2A), 1.72 ml (1.72 mmol) of 1N sodium hydroxide solution, 40 mg(0.06 mmol) of 1,1′-bis(diphenylphosphino)ferrocenepalladium(II)chloride and 2 ml of DMF is heated at 80-85° C. for 18 h. The solvent isremoved under reduced pressure. The crude product is purified on silicagel 60 (Merck, Darmstadt; eluent: dichloromethane,dichloromethane/methanol 20:1, dichloromethane/methanol-/ammonia80:20:2). The solvent is removed under reduced pressure. Finally, thelast residues of solvent are removed under high vacuum. 127 mg (54% oftheory) of the title compound are isolated.

¹H-NMR (200 MHz, CDCl₃): δ=7.86 (d, 1H), 7.72-7.28 (m, 7H), 6.77 (d,1H), 4.62 (s, 2H), 4.28-4.12 (m, 1H), 3.56-3.38 (m, 1H), 3.04-2.78 (m,4H), 2.75-2.59 (m, 1H), 2.16-2.02 (m, 1H), 1.93-1.66 (m, 3H), 1.66-1.45(m, 1H).

HPLC (method 1): R_(t)=3.5 min.

LC-MS (method 2): R_(t)=1.50 min.

MS (ESIpos): m/z=377 (M+H)⁺.

EXAMPLE 3N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-6-[4-(hydroxymethyl)phenyl]-1-benzofuran-carboxamide

A mixture of 130 mg (0.86 mmol) of 4-(hydroxymethyl)phenylboronic acid,200 mg (0.57 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-bromo-1-benzofuran-2-carboxamide(Example 2A), 1.72 ml (1.72 mmol) of 1N sodium hydroxide solution, 40 mg(0.06 mmol) of 1,1′-bis(diphenylphosphino)ferrocenepalladium(II)chloride and 2 ml of DMF is heated at 80-85° C. for 18 h. The solvent isremoved under reduced pressure. The crude product is purified on silicagel 60 (Merck, Darmstadt; eluent: dichloromethane,dichloromethane/methanol 20:1, dichloromethane/methanol-/ammonia80:20:2). The solvent is removed under reduced pressure. Finally, thelast residues of solvent are removed under high vacuum. 55 mg (23% oftheory) of the title compound are isolated.

¹H-NMR (200 MHz, CDCl₃): δ=7.83 (d, 1H), 7.69-7.28 (m, 7H), 6.77 (d,1H), 4.62 (s, 2H), 4.28-4.12 (m, 1H), 3.56-3.38 (m, 1H), 3.04-2.78 (m,4H), 2.75-2.59 (m, 1H), 2.16-2.02 (m, 1H), 1.93-1.66 (m, 3H), 1.66-1.45(m, 1H).

HPLC (method 1): R_(t)=3.5 min.

LC-MS (method 2): R_(t)=1.46 min.

MS (ESIpos): m/z=377 (M+H)⁺.

EXAMPLE 4N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-6-[4-(4-morpholinyl)phenyl]-1-benzofuran-2-carboxamide

A mixture of 180 mg (0.86 mmol) of 4-(4-morpholinyl)phenylboronic acid,200 mg (0.57 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-bromo-1-benzofuran-2-carboxamide(Example 2A), 1.72 ml (1.72 mmol) of 1N sodium hydroxide solution, 40 mg(0.06 mmol) of 1,1′-bis(diphenylphosphino)ferrocenepalladium(II)chloride and 2 ml of DMF is heated at 80-85° C. for 18 h. The solvent isremoved under reduced pressure. The crude product is purified on silicagel 60 (Merck, Darmstadt; eluent: dichloromethane,dichloromethane/methanol 20:1, dichloromethane/methanol-/ammonia80:20:2). The solvent is removed under reduced pressure. Finally, thelast residues of solvent are removed under high vacuum. 79 mg (32% oftheory) of the title compound are isolated.

¹H-NMR (200 MHz, CDCl₃): δ=7.84-7.29 (m, 7H); 6.99 (d, 1H), 6.84-6.70(m, 1H), 4.28-4.13 (m, 1H), 3.97-3.83 (m, 2H), 3.59-3.36 (m, 1H),3.29-3.13 (m, 2H), 3.04-2.78 (m, 4H), 2.75-2.59 (m, 1H), 2.16-2.02 (m,1H), 1.93-1.66 (m, 3H), 1.66-1.45 (m, 1H).

HPLC (method 1): R_(t)=3.5 min.

LC-MS (method 2): R_(t)=1.74 min.

MS (ESIpos): m/z=432 (M+H)⁺.

EXAMPLE 5N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-6-[4-(methoxy)phenyl]-1-benzofuran-2-carboxamide

A mixture of 130 mg (0.86 mmol) of 4-methoxyphenylboronic acid, 200 mg(0.57 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-bromo-1-benzofuran-2-carboxamide(Example 2A), 1.72 ml (1.72 mmol) of 1N sodium hydroxide solution, 40 mg(0.06 mmol) of 1,1′-bis(diphenylphosphino)ferrocenepalladium(II)chloride and 2 ml of DMF is heated at 80-85° C. for 18 h. The solvent isremoved under reduced pressure. The crude product is purified on silicagel 60 (Merck, Darmstadt; eluent: dichloromethane,dichloromethane/methanol 20:1, dichloromethane/methanol-/ammonia80:20:2). The solvent is removed under reduced pressure. Finally, thelast residues of solvent are removed under high, vacuum. 160 mg (68% oftheory) of the title compound are isolated.

¹H-NMR (200 MHz, CDCl₃): δ=7.84-7.75 (m, 1H), 7.62-7.45 (m, 5H), 6.99(m, 2H), 6.84-6.70 (m, 1H), 4.28-4.13 (m, 1H), 3.87 (s, 3H), 3.59-3.36(m, 1H), 3.04-2.78 (m, 4H), 2.75-2.59 (m, 1H), 2.16-2.02 (m, 1H),1.93-1.66 (m, 3H), 1.66-1.45 (m, 1H).

HPLC (method 1): R_(t)=4.0 min.

LC-MS (method 3): R_(t)=3.2 min.

MS (ESIpos): m/z=377 (M+H)⁺.

EXAMPLE 6N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-6-[3-(methoxy)phenyl]-1-benzofuran-2-carboxamide

A mixture of 130 mg (0.86 mmol) of 3-methoxyphenylboronic acid, 200 mg(0.57 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-bromo-1-benzofuran-2-carboxamide(Example 2A), 1.72 ml (1.72 mmol) of 1N sodium hydroxide solution, 40 mg(0.06 mmol) of 1,1′-bis(diphenylphosphino)ferrocenepalladium(II)chloride and 2 ml of DMF is heated at 80-85° C. for 18 h. The solvent isremoved under reduced pressure. The crude product is purified on silicagel 60 (Merck, Darmstadt; eluent: dichloromethane,dichloromethane/methanol 20:1, dichloromethane/methanol-/ammonia80:20:2). The solvent is removed under reduced pressure. Finally, thelast residues of solvent are removed under high vacuum. 151 mg (64% oftheory) of the title compound are isolated.

¹H-NMR (200 MHz, CDCl₃): δ=7.90-7.80 (m, 1H), 7.72-7.08 (m, 5H),6.95-6.85 (m, 1H), 6.84-6.70 (m, 1H), 4.28-4.13 (m, 1H), 3.87 (s, 3H),3.59-3.36 (m, 1H), 3.04-2.78 (m, 4H), 2.75-2.59 (m, 1H), 2.16-2.02 (m,1H), 1.93-1.66 (m, 3H), 1.66-1.45 (m, 1H).

HPLC (method 1): R_(t)=4.0 min.

LC-MS (method 2): R_(t)=1.87 min.

MS (ESIpos): m/z=377 (M+H)⁺.

EXAMPLE 7N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-6-(4-fluorophenyl)-1-benzofuran-2-carboxamide

A mixture of 120 mg (0.86 mmol) of 4-fluorophenylboronic acid, 200 mg(0.57 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-bromo-1-benzofuran-2-carboxamide(Example 2A), 1.72 ml (1.72 mmol) of 1N sodium hydroxide solution, 40 mg(0.06 mmol) of 1,1′-bis(diphenylphosphino)ferrocenepalladium(II)chloride and 2 ml of DMF is heated at 80-85° C. for 18 h. The solvent isremoved under reduced pressure. The crude product is purified on silicagel 60 (Merck, Darmstadt; eluent: dichloromethane,dichloromethane/methanol 20:1, dichloromethane/methanol-/ammonia80:20:2). The solvent is removed under reduced pressure. Finally, thelast residues of solvent are removed under high vacuum. 155 mg (68% oftheory) of the title compound are isolated.

¹H-NMR (200 MHz, CDCl₃): δ=7.99 (s, 1H), 7.64-7.46 (m, 5H), 7.22-7.07(m, 2H), 6.84-6.70 (m, 1H), 4.28-4.13 (m, 1H), 3.59-3.36 (m, 1H),3.04-2.78 (m, 4H), 2.75-2.59 (m, 1H), 2.16-2.02 (m, 1H), 1.93-1.66 (m,3H), 1.66-1.45 (m, 1H).

HPLC (method 1): R_(t)=4.1 min.

LC-MS (method 2): R_(t)=1.92 min.

MS (ESIpos): m/z=365 (M+H)⁺.

EXAMPLE 8N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-6-(4-trifluoromethoxyphenyl)-1-benzofuran-2-carboxamide

A mixture of 180 mg (0.86 mmol) of 4-(trifluoromethoxy)phenylboronicacid, 200 mg (0.57 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-bromo-1-benzofuran-2-carboxamide(Example 2A), 1.72 ml (1.72 mmol) of 1N sodium hydroxide solution, 40 mg(0.06 mmol) of 1,1′-bis(diphenylphosphino)ferrocenepalladium(II)chloride and 2 ml of DMF is heated at 80-85° C. for 18 h. The solvent isremoved under reduced pressure. The crude product is purified on silicagel 60 (Merck, Darmstadt; eluent: dichloromethane,dichloromethane/methanol 20:1, dichloromethane/methanol/ammonia80:20:2). The solvent is removed under reduced pressure. Finally, thelast residues of solvent are removed under high vacuum. 155 mg (68% oftheory) of the title compound are isolated.

¹H-NMR (200 MHz; CDCl₃): δ=7.82 (s, 1H), 7.72-7.45 (m, 5H), 7.36-7.27(m, 2H), 6.84-6.70 (m, 1H), 4.28-4.13 (m, 1H), 3.59-3.36 (m, 1H),3.04-2.78 (m, 4H), 2.75-2.59 (m, 1H), 2.16-2.02 (m, 1H), 1.93-1.66 (m,3H), 1.66-1.45 (m, 1H).

HPLC (method 1): R_(t)=4.4 min.

LC-MS (method 2): R_(t)=2.22 min.

MS (ESIpos): m/z=431 (M+H)⁺.

EXAMPLE 9N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-6-(3-hydroxy-1-propynyl)-1-benzofuran-2-carboxamide

A mixture of 289 mg (5.15 mmol) of propargyl alcohol, 150 mg (0.43 mmol)ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-bromo-1-benzofuran-2-carboxamide(Example 2A), 1.6 mg (0.01 mmol) of copper(I) iodide, 15 mg (0.02 mmol)of bis(triphenylphosphine)palladium(II) chloride, 61 mg (0.86 mmol) ofpyrrolidine and 1 ml of THF is heated under reflux overnight. The crudeproduct is mixed with 10 ml of 1N sodium hydroxide solution andextracted three times with a total of 100 ml of ethyl acetate. Thecombined organic phases are dried over magnesium sulphate, and thesolvent is removed under reduced pressure. The crude product is purifiedon silica gel 60 (Merck, Darmstadt; eluent:dichloromethane/triethylamine 100:1, thendichloromethane/methanol/triethylamine 100:1:1 todichloromethane/methanol-/triethylamine 100:10:1). The solvent isremoved under reduced pressure. Finally, the last residues of solventare removed under high vacuum. 40 mg (27% of theory) of the titlecompound are isolated.

HPLC (method 1): R_(t)=3.3 min.

LC-MS (method 3): R_(t)=2.6 min.

MS (ESIpos): m/z=325 (M+H)⁺.

EXAMPLE 10N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-5-fluoro-7-(4-fluorophenyl)-1-benzofuran-2-carboxamide

A mixture of 40 mg (0.29 mmol) of 4-fluorophenylboronic acid, 70 mg(0.19 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-5-fluoro-7-bromo-1-benzofuran-2-carboxamide(Example 5A), 0.57 ml (0.57 mmol) of 1N sodium hydroxide solution, 14 mg(0.02 mmol) of 1,1′-bis(diphenylphosphino)ferrocenepalladium(II)chloride and 2 ml of DMF is heated at 85° C. overnight. The solvent isremoved under reduced pressure. The crude product is mixed with 1Nsodium hydroxide solution and extracted three times with a total of 100ml of ethyl acetate. The combined organic phases are dried overmagnesium sulphate, and the solvent is removed under reduced pressure.The crude product is taken up in methanol and shaken together withacidic ion exchanger (Dowex® WX2-200) for about 20 min. The loaded ionexchanger is washed three times with 30 ml of methanol each time, thenwith water, again with methanol, with dichloromethane, again withmethanol, with THF and finally once more with methanol. The product iseluted with methanol/triethylamine 95:5. The solvent is removed in arotary evaporator under reduced pressure. Silica gel 60 (Merck,Darmstadt; eluent: dichloromethane/triethylamine 100:1, thendichloromethane/methanol/triethylamine 100:1:1 todichloromethane/methanol-/triethylamine 100:10:1) is used for finalpurification. The solvent is removed under reduced pressure. Finally,the last residues of solvent are removed under high vacuum. 51 mg (70%of theory) of the title compound are isolated.

¹H-NMR (400 MHz, methanol-d₄): δ=7.99-7.90 (m, 2H), 7.59 (s, 1H),7.45-7.35 (m, 2H), 7.30-7.22 (m, 2H), 4.24-4.18 (m, 1H), 3.34-3.29 (m,1H), 3.07-2.97 (m, 1H), 2.93-2.77 (m, 4H), 2.13-2.05 (m, 1H), 1.98-1.86(m, 1H), 1.84-1.75 (m, 2H), 1.63-1.53 (m, 1H).

HPLC (method 1): R_(t)=43 min.

LC-MS (method 3): R_(t)=3.08 min.

MS (ESIpos): m/z=383 (M+H)⁺.

EXAMPLE 11N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-5-fluoro-7-(4-trifluoromethoxyphenyl)-1-benzofuran-2-carboxamide

A mixture of 40 mg (0.29 mmol) of 4-(trifluoromethoxy)phenylboronicacid, 70 mg (0.19 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-5-fluoro-7-bromo-1-benzofuran-2-carboxamide(Example 5A), 0.57 ml (0.57 mmol) of 1N sodium hydroxide solution, 14 mg(0.02 mmol) of 1,1′-bis(diphenyl-phosphino)ferrocenepalladium(II)chloride and 2 ml of DMF is heated at 85° C. overnight. The solvent isremoved under reduced pressure. The crude product is mixed with 1Nsodium hydroxide solution and extracted three times with a total of 100ml of ethyl acetate. The combined organic phases are dried overmagnesium sulphate, and the solvent is removed under reduced pressure.The crude product is taken up in methanol and shaken together withacidic ion exchanger (Dowex® WX2-200) for about 20 min. The loaded ionexchanger is washed three times with 30 ml of methanol each time, thenwith water, again with methanol, with dichloromethane, again withmethanol, with THF and finally once more with methanol. The product iseluted with methanol/triethylamine 95:5. The solvent is removed in arotary evaporator under reduced pressure. Silica gel 60 (Merck,Darmstadt; eluent:dichloromethane/triethylamine 100:1, thendichloromethane/methanol/triethylamine 100:1:1 todichloromethane/methanol/triethylamine 100:10:1) is used for finalpurification. The solvent is removed under reduced pressure. Finally,the last residues of solvent are removed under high vacuum. 52 mg (61%of theory) of the title compound are isolated.

¹H-NMR (400 MHz, methanol-d₄): δ=8.08-8.00 (m, 2H), 7.59 (s, 1H),7.49-741 (m, 4H), 4.24-4.18 (m, 1H), 3.34-3.29 (m, 1H), 3.07-2.97 (m,1H), 2.93-2.77 (m, 4H), 2.13-2.05 (m, 1H), 1.98-1.86 (m, 1H), 1.84-1.75(m, 2H), 1.63-1.53 (m, 1H).

HPLC (method 1): R_(t)=4.6 min.

LC-MS (method 3): R_(t)=3.37 min.

MS (ESIpos): m/z=449 (M+H)⁺.

EXAMPLE 12N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-5-phenyl-1-benzothiophene-2-carboxamidehydrochloride

0.15 ml of 2 M aqueous sodium carbonate solution and 4.1 mg (0.005 mmol)of PdCl₂(dppf) are added to a mixture of 40 mg (0.10 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-5-bromo-1-benzothiophene-2-carboxamidehydrochloride (Example 14A) and 12.1 mg (0.10 mmol) of phenylboronicacid in 1 ml of DMF. The reaction mixture is heated at 80° C. for 14 h,filtered through kieselguhr and evaporated to dryness. Purification ofthe crude product by preparative HPLC, subsequent addition of 1Nhydrochloric acid and drying under high vacuum result in 7.3 mg (18% oftheory) of the title compound.

HPLC (method 1): R_(t)=4.2 min.

MS (ESIpos): m/z=363 (M+H)⁺ (free base).

EXAMPLE 13N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-6-phenyl-1-benzothiophene-2-carboxamidehydrochloride

0.15 ml of 2 M aqueous sodium carbonate solution and 4.1 mg (0.005 mmol)of PdCl₂(dppf) are added to a mixture of 40 mg (0.10 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-bromo-1-benzothiophene-2-carboxamidehydrochloride (Example 11A) and 12.1 mg (0.10 mmol) of phenylboronicacid in 1 ml of DMF. The reaction mixture is heated at 80° C. for 14 h,filtered through kieselguhr and evaporated to dryness. Purification ofthe crude product by preparative HPLC, subsequent addition of 1Nhydrochloric acid and drying under high vacuum result in 14.5 mg (37% oftheory) of the title compound.

¹H-NMR (200 MHz, DMSO-d₆): δ=9.91 (m, 1H), 9.02 (d, 1H), 8.38 (m, 1H),8.32 (m, 1H), 8.06 (d, 1H), 7.78 (m, 3H), 7.58-7.37 (m, 3H), 4.32 (m,1H), 3.78-3.03 (m, 6H), 2.28-2.05 (m, 2H), 1.93 (m, 2H), 1.78 (m, 1H).

HPLC (method 1): R_(t)=4.2 min.

MS (ESIpos): m/z=363 (M+H)⁺ (free base).

EXAMPLE 14N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-6-(3-methoxyphenyl)-1-benzothiophene-2-carboxamideHydrochloride

0.3 ml of 2 M aqueous sodium carbonate solution and 4.1 mg (0.005 mmol)of PdCl₂(dppf) are added to a mixture of 40 mg (0.10 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-bromo-1-benzothiophene-2-carboxamidehydrochloride (Example 11A) and 15.1 mg (0.10 mmol) of3-methoxyphenylboronic acid in 1 ml of DMF. The reaction mixture isheated at 80° C. for 14 h, filtered through kieselguhr and evaporated todryness. Purification of the crude product by preparative HPLC,subsequent addition of 1N hydrochloric acid and drying under high vacuumresult in 25.5 mg (57% of theory) of the title compound.

¹H-NMR (200 MHz, DMSO-d₆): δ=9.70 (s, 114), 8.97 (d, 1H), 8.38 (m, 1H),8.28 (m, 1H), 7.99 (m, 1H), 7.78 (m, 1H), 7.37 (m, 3H), 6.98 (m, 1H),4.33 (m, 1H), 3.86 (s, 3H), 3.79-3.12 (m, 6H), 2.28-2.00 (m, 2H),1.99-1.68 (m, 3H).

HPLC (method 1): R_(t)=4.2 min.

MS (ESIpos): m/z=393 (M+H)⁺ (free base).

EXAMPLE 15N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-6-(3-hydroxy-1-propynyl)-1-benzothiophene-2-carboxamide

120 mg (0.30 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-bromo-1-benzothiophene-2-carboxamidehydrochloride (Example 11A), 10.5 mg (0.01 mmol) of PdCl₂(PPh₃)₂ and 4.6mg (0.02 mmol) of copper(I) iodide are dissolved in 1.5 ml oftriethylamine/DMF (2:1) under argon and stirred at 60° C. for 1 h.Addition of 25.1 mg (0.45 mmol) of propargyl alcohol is followed byheating at 70° C. for a further 16 h. Cooling is followed by filtrationthrough kieselguhr and purification by preparative HPLC, concentrationand drying of the product under high vacuum. 12 mg (11% of theory) ofthe title compound are obtained.

¹H-NMR (200 MHz, DMSO-d₆): δ=8.73 (d, 1H), 8.20 (m, 2H), 7.96 (d, 1H),7.46 (dd, 1H), 4.34 (s, 2H), 4.09 (m, 1H), 3.32 (m, 1H), 3.16-2.77 (m,5H), 1.99 (m, 1H), 1.91 (m, 1H), 1.70 (m, 2H), 1.49 (m, 1H).

HPLC (method 1): R_(t)=3.4 min.

MS (ESIpos): m/z=341 (M+H)⁺.

EXAMPLE 16N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-phenyl-1-benzothiophene-2-carboxamideHydrochloride

0.14 ml of 2 M aqueous sodium carbonate solution and 5.7 mg (0.007 mmol)of PdCl₂(dppf) are added to a mixture of 56 mg (0.14 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzothiophene-2-carboxamidehydrochloride (Example 8A) and 18.7 mg (0.15 mmol) of phenylboronic acidin 1 ml of DMF. The reaction mixture is heated to 80° C. After 3 h atthis temperature, a further 5.7 mg (0.007 mmol) of PdCl₂(dppf) areadded, and the mixture is stirred at 80° C. for a further 12 h. Thereaction mixture is filtered through kieselguhr and evaporated todryness. Purification of the crude product by preparative HPLC,subsequent addition of 1N hydrochloric acid and drying under high vacuumresult in 10.6 mg (18% of theory) of the title compound.

HPLC (method 1): R_(t)=4.2 min.

MS (ESIpos): m/z=363 (M+H)⁺ (free base).

EXAMPLE 17N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-(3-methoxyphenyl)-1-benzothiophene-2-carboxamideHydrochloride

0.16 ml of 2 M aqueous sodium carbonate solution and 4.2 mg (0.005 mmol)of PdCl₂(dppf) are added to a mixture of 49 mg (0.10 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzothiophene-2-carboxamidehydrochloride (Example 8A) and 15.8 mg (0.10 mmol) of3-methoxyphenylboronic acid in 1 ml of DMF. The reaction mixture isheated at 80° C. for 14 h, then filtered through kieselguhr andevaporated to dryness. Purification of the crude product by preparativeHPLC, subsequent addition of 1N hydrochloric acid and drying under highvacuum result in 8.0 mg (18% of theory) of the title compound.

HPLC (method 1): R_(t)=4.2 min.

MS (ESIpos): m/z=393 (M+H)⁺ (free base).

EXAMPLE 18N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-(2-methoxyphenyl)-1-benzothiophene-2-carboxamideHydrochloride

0.22 ml of 2 M aqueous sodium, carbonate solution and 6.1 mg (0.007mmol) of PdCl₂(dppf) are added to a mixture of 60 mg (0.15 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzothiophene-2-carboxamidehydrochloride (Example 8A) and 22.7 mg (0.15 mmol) of2-methoxyphenylboronic acid in 1 ml of DMF. The reaction mixture isheated at 80° C. for 14 h, then filtered through kieselguhr andevaporated to dryness. Purification of the crude product by preparativeHPLC, subsequent addition of 1N hydrochloric acid and drying under highvacuum result in 12.8 mg (18% of theory) of the title compound.

HPLC (method 1): R_(t)=4.2 min.

MS (ESIpos): m/z=393 (M+H)⁺ (free base).

EXAMPLE 19N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[4-(4-morpholinyl)phenyl]-1-benzothiophene-2-carboxamideHydrochloride

0.22 ml of 2 M aqueous sodium carbonate solution and 6.1 mg (0.007 mmol)of PdCl₂(dppf) are added to a mixture of 60 mg (0.15 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzothiophene-2-carboxamidehydrochloride (Example 8A) and 30.9 mg (0.15 mmol) of4-(4-morpholinyl)phenylboronic acid in 1 ml of DMF. The reaction mixtureis heated to 80° C. After 4.5 h, a further 6.1 mg (0.007 mmol) ofPdCl₂(dppf) are added. After a further 12 h, the reaction mixture isfiltered through kieselguhr and evaporated to dryness. The crude productis purified by preparative HPLC. The product is dissolved in methanol,and an excess of 4N hydrogen chloride in dioxane is added. Drying underhigh vacuum results in 20.6 mg (25% of theory) of the title compound.

¹H-NMR (300 MHz, methanol-d₄): δ=8.21 (s, 1H), 7.97. (m, 2H), 7.93 (s,1H), 7.83 (m, 2H), 7.57 (dd, 1H), 7.52 (m, 1H), 4.46 (m, 1H), 4.13 (m,4H), 3.83 (m, 1H), 3.78 (m, 4H), 3.49 (m, 1H), 3.43-3.17 (m, 4H), 2.38(m, 1H), 2.28 (m, 1H), 2.10 (m, 2H), 1.96 (m, 1H).

HPLC (method 1): R_(t)=4.3 min.

MS (ESIpos): m/z=448 (M+H)⁺ (free base).

EXAMPLE 20N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[4-(hydroxymethyl)phenyl]-1-benzothiophene-2-carboxamideHydrochloride

60 mg (0.15 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzothiophene-2-carboxamidehydrochloride (Example 8A) and 22.7 mg (0.15 mmol) of4-(hydroxymethyl)phenylboronic acid are introduced into 1 ml of DMF.Addition of 0.22 ml of 2 M aqueous sodium carbonate solution and 6.1 mg(0.01 mmol) of PdCl₂(dppf) is followed by heating to 80° C. After 14 h,the reaction mixture is filtered through kieselguhr and evaporated todryness. The crude product is purified by preparative HPLC. The productis dissolved in methanol and an excess of 4N hydrogen chloride indioxane is added. Drying under high vacuum results in 9 mg (9% oftheory) of the title compound.

HPLC (method 1): R_(t)=3.8 min.

MS (ESIpos): m/z=393 (M+H)⁺ (free base).

The compounds listed in the following table are obtained in an analogousmanner:

TABLE 2

MS (ESIpos): Example R_(t) [min.] m/z [M + H]⁺ No. R (method 5) (freebase) 21

1.27 378 22

1.51 393 23

1.46 405 24

1.44 391 25

1.51 420 26

1.45 391 27

1.53 420 28

1.46 405 29

1.59 410 30

1.48 369 31

1.61 431 32

1.52 381 33

1.6 453 34

1.48 388 35

1.45 388 36

1.53 399 37

1.52 399 38

1.54 410 39

1.51 381 40

1.6 410 41

1.43 353 42

1.58 408 43

1.52 424 44

1.42 405 45

1.48 424 46

1.53 411 47

1.56 408 48

1.58 395 49

1.43 391 50

1.38 397

EXAMPLE 517-[3-(Acetylamino)phenyl]-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzothiophene-2-carboxamideHydrochloride

0.75 ml of 2 M aqueous sodium carbonate solution and 20.3 mg (0.02 mmol)of PdCl₂(dppf) are added to a mixture of 200 mg (0.50 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzothiophene-2-carboxamidehydrochloride (Example 8A) and 89.1 mg (0.50 mmol) of3-(acetamido)phenylboronic acid in 2 ml of DMF. The reaction mixture isheated at 80° C. for 17 h. A further 89.1 mg (0.50 mmol) of3-(acetamido)phenylboronic acid, 1.5 ml of 1N sodium hydroxide solutionand 81.3 mg (0.1 mmol) of PdCl₂(dppf) are added, and the mixture isheated at 80° C. for a further 18 h. After cooling, it is filteredthrough kieselguhr and purified by preparative HPLC. The resulting crudeproduct is further purified by flash chromatography on silica gel(mobile phase: dichloromethane/methanol/ammonia 100:10:2). The productfractions are concentrated, taken up in a 5:1 mixture of methanol and 1Nhydrochloric acid and again concentrated. Drying under high vacuumresults in 243.2 mg (86.6% of theory) of the title compound.

¹H-NMR (300 MHz, DMSO-d₆): δ=10.16 (s, 1H), 10.10 (br. s, 1H), 9.03 (d,1H), 8.38 (s, 1H), 8.06 (m, 1H), 7.98 (dd, 1H), 7.65 (m, 1H), 7.59 (dd,1H), 7.51 (m, 1H), 7.48 (m, 1H), 7.37 (m, 1H), 4.33 (m, 1H), 3.66 (m,1H), 3.45-3.13 (m, 5H), 2.22 (m, 1H), 2.14 (m, 1H), 2.08 (s, 3H), 1.91(m, 2H), 1.75 (m, 1H).

HPLC (method 1): R_(t)=3.9 min.

MS (ESIpos): m/z=420 (M+H)⁺ (free base).

EXAMPLE 52N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-6-[4-(4-morpholinyl)phenyl]-1-benzothiophene-2-carboxamideHydrochloride

100 mg (0.25 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-bromo-1-benzothiophene-2-carboxamidehydrochloride (Example 11A) and 51.5 mg (0.25 mmol) of4-morpholinophenylboronic acid are introduced into 1 ml of DMF. Additionof 0.37 ml of 2 M sodium carbonate solution and 10.2 mg (0.01 mmol) ofPdCl₂(dppf) is followed by heating to 80° C. After 16 h, a further 51.5mg (0.25 mmol) of 4-morpholinophenylboronic acid, 0.37 ml of 2 M sodiumcarbonate solution and 10.2 mg (0.01 mmol) of PdCl₂(dppf) are added. Themixture is heated at 80° C. for a further 4 h. After cooling, thereaction mixture is filtered through kieselguhr and purified bypreparative HPLC. The product fractions are concentrated and, afteraddition of a 5:1 mixture of methanol and 4 M hydrogen chloride indioxane, again concentrated. Drying under high vacuum results in 83 mg(69% of theory) of the title compound.

¹H-NMR (200 MHz, DMSO-d₆): δ=10.20 (br. s, 1H), 9.07 (d, 1H), 8.33 (s,1H), 8.27 (s, 1H), 7.97 (d, 1H), 7.71 (m, 3H), 7.10 (m, 2H), 4.33 (m,1H), 3.78 (m, 4H), 3.73-3.07 (m, 10H), 2.22 (m, 1H), 2.17 (m, 1H), 1.93(m, 2H), 1.75 (m, 1H).

HPLC (method 1): R_(t)=3.8 min.

MS (ESIpos): m/z=448 (M+H)⁺ (free base).

EXAMPLE 53N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-6-(5-methyl-1,2,4-oxadiazol-3-yl)-1-benzothiophene-2-carboxamideHydrochloride

154 mg (0.37 mmol) of6-[amino(hydroxyimino)methyl]-N-[(3R)-1-azabicyclo[2.2.2]-oct-3-yl]-1-benzothiophene-2-carboxamidedihydrochloride (Example 27A) are dissolved in 2 ml of DMF and 0.75 mlof THF. 250 mg of 4 Å molecular sieves are added, and the mixture isstirred at room temperature for 30 min. Addition of 44.4 mg (1.11 mmol)of sodium hydride (60% suspension in mineral oil) is followed by heatingat 60° C. for 20 min and then cooling to room temperature. A solution of90 μl (1.11 mmol) of methyl acetate in 1 ml of THF is then added to thereaction mixture, after which it is heated at 80° C. for 14 h. Additionof a further 29.6 mg (0.74 mmol) of sodium hydride (60% suspension inmineral oil) and 0.88 ml (11.1 mmol) of methyl acetate in 1 ml of THF isfollowed by heating at 70° C. for a further 24 h. The reaction isstopped by adding water. Purification takes place by preparative HPLC.The product fractions are concentrated and, after addition of a 5:1mixture of methanol and 4N hydrogen chloride in dioxane, againconcentrated. Drying under high vacuum results in 41.9 mg (23.6% oftheory) of the title compound.

¹H-NMR (300 MHz, DMSO-d₆): δ=10.15 (br. s, 1H), 9.14 (d, 1H), 8.70 (m,1H), 8.41 (s, 1H), 8.13 (d, 1H), 8.05 (m, 1H), 4.34 (m, 1H), 3.75-3.13(m, 6H), 2.70 (s, 3H), 2.23 (m, 1H), 2.15 (m, 1H), 1.92 (m, 2H), 1.77(m, 1H).

HPLC (method 1): R_(t)=3.8 min.

MS (ESIpos): m/z=369 (M+H)⁺ (free base).

EXAMPLE 54N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-6-[2-(hydroxymethyl)phenyl]-1-benzothiophene-2-carboxamideHydrochloride

100 mg (0.25 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-bromo-1-benzothiophene-2-carboxamidehydrochloride (Example 11A) and 37.8 mg (0.25 mmol) of2-(hydroxymethyl)phenylboronic acid are introduced into 1 ml of DMF.Addition of 0.37 ml of 2 M sodium carbonate solution and 10.2 mg (0.01mmol) of PdCl₂(dppf) is followed by heating to 80° C. After 14 h, thereaction mixture is filtered through kieselguhr and purified byseparation twice by preparative HPLC. The product fractions areconcentrated and, after addition of a 5:1 mixture of methanol and 4Nhydrogen chloride in dioxane, again concentrated. Drying under highvacuum results in 27 mg (24.4% of theory) of the title compound.

¹H-NMR (200 MHz, DMSO-d₆): δ=10.10 (br. s, 1H), 9.06 (d, 1H), 8.36 (s,1H), 8.02 (m, 2H), 7.61 (m, 1H), 7.54-7.36 (m, 4H), 4.43 (s, 2H), 4.33(m, 1H), 3.67 (m, 1H), 3.55-3.12 (m, 5H), 2.23 (m, 1H), 2.16 (m, 1H),1.92 (m, 2H), 1.77 (m, 1H).

HPLC (method 1): R_(t)=3.9 min.

MS (ESIpos): m/z=393 (M+H)⁺ (free base).

EXAMPLE 55N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-6-(5-phenyl-1,2,4-oxadiazol-3-yl)-1-benzothiophene-2-carboxamideHydrochloride

110 mg (0.26 mmol) of6-[amino(hydroxyimino)methyl]-N-[(3R)-1-azabicyclo-[2.2.2]oct-3-yl]-1-benzothiophene-2-carboxamidedihydrochloride (Example 27A) are dissolved in 2 ml of DMF and 0.75 mlof THF. 250 mg of 4 Å molecular sieves are added and the mixture isstirred at room temperature for 30 min. Addition of 31.2 mg (0.79 mmol)of sodium hydride (60% suspension in mineral oil) is followed by heatingat 60° C. for 20 min and then cooling to room temperature. A solution of100 μl (0.79 mmol) of methyl benzoate in 1 ml of THF is added to thereaction mixture, and it is heated at 80° C. for 14 h. A further 20.8 mg(0.52 mmol) of sodium hydride (60% suspension in mineral oil) and 0.99ml (7.91 mmol) of methyl benzoate in 1 ml of THF are added, and themixture is heated at 70° C. for a further 24 h. The reaction is stoppedby adding water. Purification takes place by preparative HPLC. Theproduct fractions are concentrated and, after addition of a 5:1 mixtureof methanol and 4N hydrogen chloride in dioxane, again concentrated.Drying under high vacuum results in 45.7 mg (32% of theory) of the titlecompound.

HPLC (method 1): R_(t)=4.5 min.

MS (ESIpos): m/z=431 (M+H)⁺ (free base).

EXAMPLE 56N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-6-(5-benzyl-1,2,4-oxadiazol-3-yl)-1-benzothiophene-2-carboxamideHydrochloride

110 mg (0.26 mmol) of6-[amino(hydroxyimino)methyl]-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzothiophene-2-carboxamidedihydrochloride (Example 27A) are dissolved in 2 ml of DMF and 0.75 mlof THF. 250 mg of 4 Å molecular sieves are added, and the mixture isstirred at room temperature for 30 min. Addition of 31.2 mg (0.79 mmol)of sodium hydride (60% suspension in mineral oil) is followed by heatingat 60° C. for 20 min and then cooling to room temperature. A solution of110 μl (0.79 mmol) of methyl phenylacetate in 1 ml of THF is added, andthe mixture is heated at 80° C. for 14 h. Addition of a further 20.8 mg(0.52 mmol) of sodium hydride (60% suspension in mineral oil) and 1.14ml (7.91 mmol) of methyl phenylacetate in 1 ml of THF is followed byheating at 70° C. for a further 24 h. The reaction is stopped by addingwater. Purification takes place by preparative HPLC. The productfractions are concentrated and, after addition of a 5:1 mixture ofmethanol and 4N hydrogen chloride in dioxane, again concentrated. Dryingunder high vacuum results in 4.1 mg (3% of theory) of the titlecompound.

¹H-NMR (300 MHz, methanol-d₄): δ=8.63 (s, 1H), 8.11 (m, 2H), 8.04 (d,1H), 7.43-7.27 (m, 5H), 4.47 (m, 1H), 4.38 (s, 2H), 3.87 (m, 1H),3.52-3.20 (m, 5H); 2.40 (m, 1H), 2.28 (m, 1H), 2.11 (m, 2H), 1.97 (m,1H).

HPLC (method 1): R_(t)=4.4 min.

MS (ESIpos): m/z=445 (M+H)⁺ (free base).

EXAMPLE 57N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-6-[4-(4-morpholinylmethyl)phenyl]-1-benzothiophene-2-carboxamideDihydrochloride

330 mg (3.75 mmol) of morpholine and 40 mg (0.56 mmol) of sodiumcyanoborohydride are successively added to a solution of 80 mg (0.19mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-(4-formylphenyl)-1-benzothiophene-2-carboxamidehydrochloride (Example 23A) in 1.5 ml of a 6:1 mixture of methanol andacetic acid. 2 h at room temperature and 6 h at 80° C. are followed bypurification by preparative HPLC. The product fractions are concentratedand, after addition of a 5:1 mixture of methanol and 1N hydrochloricacid, again concentrated. Drying under high vacuum results in 87.7 mg(88% of theory) of the title compound.

¹H-NMR (400 MHz, DMSO-d₆): δ=11.26 (br. s, 1H), 10.29 (br. s, 1H), 9.18(d, 1H), 8.41 (m, 2H), 8.06 (d, 1H), 7.89 (m, 2H), 7.81 (d, 1H), 7.74(m, 2H), 4.39 (m, 2H), 4.34 (m, 1H), 4.05-3.03 (m, 6H), 2.23 (m, 1H),2.16 (m, 1H), 1.92 (m, 2H), 1.76 (m, 1H).

HPLC (method 1): R_(t)=3.5 min.

MS (ESIpos): m/z=462 (M+H)⁺ (free base).

EXAMPLE 58N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[4-(dimethylamino)phenyl]-1-benzothiophene-2-carboxamideHydrochloride

0.33 ml of 2 M sodium carbonate solution and 9.1 mg (0.01 mmol) ofPdCl₂(dppf) are added to a mixture of 100 mg (0.22 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzothiophene-2-carboxamidehydrochloride (Example 8A) and 36.8 mg (0.22 mmol) of4-(dimethylamino)phenylboronic acid in 1 ml of DMF. The reaction mixtureis heated at 80° C. for 16 h. A further 36.8 mg (0.22 mmol) of4-(dimethylamino)phenylboronic acid, 36.5 mg (0.04 mmol) of PdCl₂(dppf)and 0.67 ml of 1N sodium hydroxide solution are added, and the mixtureis heated at 80° C. for a further 3 h. Cooling is followed by filtrationthrough kieselguhr and purification by preparative HPLC. The productfractions are concentrated, taken up in a 5:1 mixture of methanol and 1Nhydrochloric acid and again concentrated. Drying under high vacuumresults in 50.6 mg (47% of theory) of the title compound.

¹H-NMR (300 MHz, methanol-d₄): δ=8.26 (s, 1H), 7.95 (m, 3H), 7.80 (m,2H), 7.58 (dd, 1H), 7.53 (m, 1H), 4.46 (m, 1H), 3.82 (m, 1H), 3.51 (m,1H), 3.45-3.16 (m, 0.10H), 2.37 (m, 1H), 2.29 (m, 1H), 2.10 (m, 2H),1.95 (m, 1H).

HPLC (method 1): R_(t)=3.6 min.

MS (ESIpos): m/z=406 (M+H)⁺ (free base).

EXAMPLE 59N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-(2-thienyl)-1-benzothiophene-2-carboxamideFormate

100 mg (0.25 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzothiophene-2-carboxamidehydrochloride (Example 8A) and 31.9 mg (0.25 mmol) of 2-thiopheneboronicacid are introduced into 1.5 ml of DMF. Addition of 0.37 ml of 2 Msodium carbonate solution and 9.11 mg (0.01 mmol) of PdCl₂(dppf) isfollowed by heating to 85° C. After 14 h, the reaction mixture isfiltered through kieselguhr and purified by preparative HPLC (eluent A:acetonitrile, eluent B: water+0.1% formic acid; gradient: 10% A→95% A).The product fractions are concentrated and dried under high vacuum. 30mg (28% of theory) of the title compound are obtained.

¹H-NMR (200 MHz, DMSO-d₆): δ=8.80 (d, 1H), 8.33 (s, 1H), 8.23 (s, 1H),7.97 (m, 1H), 7.72 (m, 3H), 7.55 (dd, 1H), 7.28 (dd, 1H), 4.12 (m, 1H),3.36 (m, 1H), 3.18-2.80 (m, 5H), 2.03 (m, 1H), 1.95 (m, 1H), 1.74 (m,2H), 1.52 (m, 1H).

HPLC (method 1): R_(t)=4.2 min.

MS (ESIpos): m/z=369 (M+H)⁺ (free base).

EXAMPLE 607-(5-Acetyl-2-thienyl)-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzothiophene-2-carboxamideHydrochloride

100 mg (0.25 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzothiophene-2-carboxamidehydrochloride (Example 8A) and 42.3 mg (0.25 mmol) of5-acetyl-2-thienylboronic acid are introduced into 1.5 ml of DMF.Addition of 0.37 ml of 2 M sodium carbonate solution and 9.11 mg (0.01mmol) of PdCl₂(dppf) is followed by heating to 85° C. After 14 h, thereaction mixture is filtered through kieselguhr and purified bypreparative HPLC. The product fractions are concentrated, taken up in a5:1 mixture of methanol and 1N hydrochloric acid, again concentrated anddried under high vacuum. 52 mg (46% of theory) of the title compound areobtained.

¹H-NMR (200 MHz, DMSO-d₆): δ=10.25 (br: s, 1H), 9.23 (d, 1H), 8.49 (s,1H), 8.08 (d, 1H), 8.06 (m, 1H), 7.89 (m, 1H), 7.82 (d, 1H), 7.61 (dd,1H), 4.36 (m, 1H), 3.73-3.13 (m, 5H), 2.60 (s, 3H), 2.23 (m, 1H), 2.15(m, 1H), 1.93 (m, 2H), 1.76 (m, 1H).

HPLC (method 1): R_(t)=4.1 min.

MS (ESIpos): m/z=411 (M+H)⁺ (free base).

EXAMPLE 61N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[4-(6-oxo-2-piperidinyl)phenyl]-1-benzothiophene-2-carboxamideHydrochloride

123.4 mg (0.49 mmol) of 6-(4-bromophenyl)-2-piperidinone, 142.2 mg (0.56mmol) of bis(pinacolato)diboron, 146.6 mg (1.49 mmol) of potassiumacetate, 13.7 mg (0.02 mmol) of PdCl₂(dppf), 150 mg (0.37 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzothiophene-2-carboxamidehydrochloride (Example 8A), 0.93 ml of 2 M sodium carbonate solution anda further 13.7 mg (0.02 mmol) of PdCl₂(dppf) in 2 ml of DMF are reactedby general method D. Drying under high vacuum results in 7.3 mg (4% oftheory) of the title compound.

HPLC (method 1): R_(t)=3.9 min.

MS (ESIpos): m/z=460 (M+H)⁺ (free base).

EXAMPLE 62N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[3-(hydroxymethyl)phenyl]-1-benzothiophene-2-carboxamideHydrochloride

200 mg (0.45 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzothiophene-2-carboxamidehydrochloride (Example 8A) and 74.6 mg (0.49 mmol) of3-(hydroxymethyl)phenylboronic acid are introduced into 3 ml of DMF.Addition of 0.67 ml of 2 M sodium carbonate solution and 1.8.2 mg (0.02mmol) of PdCl₂(dppf) is followed by heating to 80° C. After 14 h, thereaction mixture is filtered through kieselguhr and purified byseparation by preparative HPLC. The product fractions are concentratedand, after addition of a 5:1 mixture of methanol and 4N hydrogenchloride in dioxane, again concentrated. Drying under high vacuumresults in 40 mg (19% of theory) of the title compound.

¹H-NMR (300 MHz, DMSO-d₆): δ=10.47 (br. s, 1H), 9.17 (d, 1H), 8.47 (s,1H), 7.96 (d, 1H), 7.67 (s, 1H), 7.63-7.47 (m, 4H), 7.43 (d, 1H), 4.61(s, 2H), 4.33 (m, 1H), 3.62 (m, 1H), 3.39 (m, 2H), 3.20 (m, 3H), 2.11(m, 1H), 2.15 (m, 1H), 1.91 (m, 2H), 1.75 (m, 1H).

HPLC (method 1): R_(t)=3.9 min.

MS (ESIpos): m/z=393 (M+H)⁺ (free base).

EXAMPLE 63N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[2-(4-morpholinyl)phenyl]-1-benzothiophene-2-carboxamideHydrochloride

100 mg (0.41 mmol) of 4-(2-bromophenyl)morpholine, 121.0 mg (0.48 mmol)of bis(pinacolato)diboron, 101.3 mg (1.03 mmol) of potassium acetate,11.6 mg (0.02 mmol) of PdCl₂(dppf), 127.6 mg (0.32 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzothiophene-2-carboxamidehydrochloride (Example 8A), 0.79 ml of 2 M sodium carbonate solution anda further 11.6 mg (0.02 mmol) of PdCl₂(dppf) in 2 ml of DMF are reactedby general method D. Drying under high vacuum results in 38.9 mg (48% oftheory) of the title compound.

¹H-NMR (200 MHz, DMSO-d₆): δ=10.20 (br. s, 1H), 9.04 (d, 1H), 8.36 (s,1H), 7.93 (dd, 1H), 7.55 (m, 2H), 7.45 (d, 1H), 7.37 (dd, 1H), 7.17 (m,2H), 4.32 (m, 1H), 3.62 (m, 1H), 3.48-3.10 (m, 9H), 2.69 (m, 4H), 2.19(m, 1H), 2.10 (m, 1H), 1.90 (m, 2H), 1.73 (m, 1H).

HPLC (method 1): R_(t)=4.3 min.

MS (ESIpos): m/z=448 (M+H)⁺ (free base).

EXAMPLE 642-(2-{[(3R)-1-Azabicyclo[2.2.2]oct-3-ylamino]carbonyl}-1-benzothien-7-yl)-benzylEthylcarbamate Hydrochloride

32.5 μl (0.23 mmol) of triethylamine and 16.6 mg (0.23 mmol) of ethylisocyanate are added to a suspension of 50 mg (0.12 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(hydroxymethyl)phenyl]-1-benzothiophene-2-carboxamidehydrochloride (Example 131) in 1 ml of a 5:1 mixture of THF and DMF.After 18 h at room temperature, a further 16.6 mg (0.23 mmol) of ethylisocyanate and a catalytic amount of 4-N,N-dimethylaminopyridine areadded. The mixture is stirred at room temperature for a further 18 h.The reaction mixture is concentrated in vacuo and purified bypreparative HPLC. The product fractions are concentrated and, afteraddition of a 5:1 mixture of methanol and 1N hydrochloric acid, againconcentrated. Drying under high vacuum results in 28 mg (47% of theory)of the title compound.

HPLC (method 1): R_(t)=4.2 min.

MS (ESIpos): m/z=464 (M+H)⁺ (free base).

EXAMPLE 65 2-(2-[(3R)-1-Azabicyclo[2.2.2]oct-3-ylaminocarbonyl]-1-benzothien-7-yl)benzyl Methylcarbamate Hydrochloride

32.5 μl (0.23 mmol) of triethylamine and 13.3 mg (0.23 mmol) of methylisocyanate are added to a suspension of 50 mg (0.12 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(hydroxymethyl)phenyl]-1-benzothiophene-2-carboxamidehydrochloride (Example 131) in 1 ml of a 5:1 mixture of THF and DMF.After 18 h at room temperature, a further 13.3 mg (0.23 mmol) of methylisocyanate and a catalytic amount of 4-N,N-dimethylaminopyridine areadded. The mixture is stirred at room temperature for a further 18 h.The reaction mixture is concentrated in vacuo and purified bypreparative HPLC. The product fractions are concentrated and, afteraddition of a 5:1 mixture of methanol and 1N hydrochloric acid, againconcentrated. Drying under high vacuum results in 18 mg (30% of theory)of the title compound.

¹H-NMR (400 MHz, methanol-d₄): δ=8.18 (s, 1H), 7.95 (m, 1H), 7.63-7.42(m, 4H), 7.38 (m, 2H), 4.42 (m, 1H), 3.81 (m, 1H), 3.47 (m, 1H),3.40-3.25 (m, 4H), 2.57 (m, 3H), 2.37 (m, 1H), 2.26 (m, 1H), 2.09 (m,2H), 1.94 (m, 1H).

LC-MS (method 4): R_(t)=2.7 min., m/z=464 (M+H)⁺ (free base).

EXAMPLE 66N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[4-(2-oxo-1-pyrrolidinyl)phenyl]-1-benzothiophene-2-carboxamideHydrochloride

116.5 mg (0.49 mmol) of 1-(4-bromophenyl)-2-pyrrolidinone, 142.2 mg(0.56 mmol) of bis(pinacolato)diboron, 119.1 mg (1.21 mmol) of potassiumacetate, 13.7 mg (0.02 mmol) of PdCl₂(dppf), 150 mg (0.37 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzothiophene-2-carboxamidehydrochloride (Example 8A), 0.93 ml of 2 M sodium carbonate solution anda further 13.7 mg (0.02 mmol) of PdCl₂(dppf) in 2 ml of DMF are reactedby general method D. Drying under high vacuum results in 71 mg (39% oftheory) of the title compound.

¹H-NMR (400 MHz, methanol-d₄): δ=8.16 (s, 1H), 7.91 (d, 1H), 7.80 (m,2H), 7.75 (m, 2H), 7.54 (dd, 1H), 7.51 (dd, 1H), 4.46 (m, 1H), 4.01 (m,2H), 3.85 (m, 1H), 3.47 (m, 1H), 3.42-3.26 (m, 4H), 2.65 (m, 2H), 2.39(m, 1H), 2.24 (m, 3H), 2.10 (m, 2H), 1.96 (m, 1H).

HPLC (method 1): R_(t)=4.0 min.

MS (ESIpos): m/z=446 (M+H)⁺ (free base).

EXAMPLE 67N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[4-(1-piperazinyl)phenyl]-1-benzothiophene-2-carboxamideDihydrochloride

165.6 mg (0.49 mmol) of tert-butyl4-(4-bromophenyl)-1-piperazinecarboxylate, 142.2 mg (0.56 mmol) ofbis(pinacolato)diboron, 119.1 mg (1.21 mmol) of potassium acetate, 13.7mg (0.02 mmol) of PdCl₂(dppf), 150 mg (0.37 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzothiophene-2-carboxamidehydrochloride (Example 8A), 0.93 ml of 2 M sodium carbonate solution anda further 13.7 mg (0.02 mmol) of PdCl₂(dppf) in 2 ml of DMF are reactedby general method D. The compound purified by preparative HPLC isdissolved in 3 ml of methanol and, after addition of 3 ml of 4 Mhydrogen chloride in dioxane, stirred at room temperature for 30 min.The contents of the flask are concentrated in vacuo, and the residue isazeotropically distilled with toluene twice. Drying under high vacuumresults in 54 mg (28% of theory) of the title compound.

¹H-NMR (300 MHz, methanol-d₁): δ=8.17 (s, 1H), 7.87 (dd, 1H), 7.66 (m,2H), 7.52 (dd, 1H), 7.45 (dd, 1H), 7.18 (m, 2H), 4.45 (m, 1H), 3.83 (m,1H), 3.75-3.13 (m, 13H), 2.38 (m, 1H), 2.28 (m, 1H), 2.10 (m, 2H), 1.95(m, 1H).

HPLC (method 1): R_(t)=3.7 min.

MS (ESIpos): m/z=447 (M+H)⁺ (free base).

EXAMPLE 68N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[4-(3-oxo-4-morpholinyl)phenyl]-1-benzothiophene-2-carboxamideHydrochloride

120 mg (0.39 mmol) of 4-(4-bromophenyl)-3-morpholinone, 115.3 mg (0.45mmol) of bis(pinacolato)diboron, 96.6 mg (0.98 mmol) of potassiumacetate, 11.1 mg (0.02 mmol) of PdCl₂(dppf), 121.6 mg (0.30 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzothiophene-2-carboxamidehydrochloride (Example 8A), 0.76 ml of 2 M sodium carbonate solution anda further 11.1 mg (0.02 mmol) of PdCl₂(dppf) in 2 ml of DMF are reactedby general method D. Drying under high vacuum results in 24 mg (16% oftheory) of the title compound.

¹H-NMR (400 MHz, methanol-d₄): δ=8.17 (s, 1H), 7.93 (d, 1H), 7.80 (m,2H), 7.55 (m, 4H), 4.46 (m, 1H), 4.33 (s, 2H), 4.09 (m, 2H), 3.88 (m,2H), 3.84 (m, 1H), 3.47 (m, 1H), 3.41-3.26 (m, 4H), 2.39 (m, 1H), 2.28(m, 1H), 2.10 (m, 2H), 1.95 (m, 1H).

HPLC (method 1): R_(t)=3.8 min.

MS (ESIpos): m/z=462 (M+H)⁺ (free-base).

EXAMPLE 69N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[3-(1-pyrrolidinyl)phenyl]-1-benzothiophene-2-carboxamideHydrochloride

109.8 mg (0.49 mmol) of 1-(3-bromophenyl)pyrrolidine, 142.2 mg (0.56mmol) of bis(pinacolato)diboron, 119.1 mg (1.21 mmol) of potassiumacetate, 13.7 mg (0.02 mmol) of PdCl₂(dppf), 150.0 mg (0.37 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzothiophene-2-carboxamidehydrochloride (Example 8A), 0.93 ml of 2 M sodium carbonate solution anda further 13.7 mg (0.02 mmol) of PdCl₂(dppf) in 2 ml of DMF are reactedby general method D. Drying under high vacuum results in 88.4 mg (51% oftheory) of the title compound.

¹H-NMR (200 MHz, DMSO-d₆): δ=10.28 (br. s, 1H), 9.11 (d, 1H), 8.42 (s,1H), 7.95 (dd, 1H), 7.55 (m, 2H), 7.36 (dd, 1H), 6.96 (d, 1H), 6.87 (s,1H), 6.68 (m, 1H), 4.33 (m, 1H), 3.80-3.10 (m, 10H), 2.21 (m, 1H), 2.11(m, 1H), 2.95 (m, 6H), 1.75 (m, 1H).

HPLC (method 1): R_(t)=4.2 min.

MS (ESIpos): m/z=432 (M+H)⁺ (free base).

EXAMPLE 70N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[3-(4-morpholinyl)phenyl]-1-benzothiophene-2-carboxamideHydrochloride

151.1 mg (0.49 mmol) of 3-(4-morpholinyl)phenyltrifluoromethanesulphonate (Example 17A), 142.2 mg (0.56 mmol) ofbis(pinacolato)diboron, 119.1 mg (1.21 mmol) of potassium acetate, 13.7mg (0.02 mmol) of PdCl₂(dppf), 150.0 mg (0.37 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzothiophene-2-carboxamidehydrochloride (Example 8A), 0.93 ml of 2 M sodium carbonate solution anda further 13.7 mg (0.02 mmol) of PdCl₂(dppf) in 2 ml of DMF are reactedby general method D. Drying under high vacuum results in 125.3 mg (68%of theory) of the title compound.

¹H-NMR (400 MHz, methanol-d₄): δ=8.26 (s, 1H), 7.99 (m, 2H), 7.86 (d,1H), 7.75 (m, 2H), 7.59 (m, 2H), 4.47 (m, 1H), 4.10 (m, 4H), 3.83 (m,1H), 3.76 (m, 4H), 3.73 (m, 1H), 3.52 (m, 1H), 3.37 (m, 3H), 2.38 (m,1H), 2.29 (m, 1H), 2.10 (m, 2H), 1.96 (m, 1H).

HPLC (method 1): R_(t)=3.9 min.

MS (ESIpos): m/z=448 (M+H)⁺ (free base).

EXAMPLE 71N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[4-(1-pyrrolidinyl)phenyl]-1-benzothiophene-2-carboxamideDihydrochloride

109.8 mg (0.49 mmol) of 1-(4-bromophenyl)pyrrolidine, 142.2 mg (0.56mmol) of bis(pinacolato)diboron, 119.1 mg (1.21 mmol) of potassiumacetate, 13.7 mg (0.02 mmol) of PdCl₂(dppf), 150.0 mg (0.37 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzothiophene-2-carboxamidehydrochloride (Example 8A), 0.93 ml of 2 M sodium carbonate solution anda further 13.7 mg (0.02 mmol) of PdCl₂(dppf) in 2.5 ml of DMF arereacted by general method D. Drying under high vacuum results in 24.8 mg(13% of theory) of the title compound.

¹H-NMR (400 MHz, methanol-d₄): δ=8.26 (s, 1H), 7.98 (d, 1H), 7.92 (m,2H); 7.75 (m, 2H), 7.58 (dd, 1H), 7.53 (d, 1H), 4.47 (m, 1H), 3.92-3.76(m, 5H), 3.51 (m, 1H), 3.45-3.18 (m, 4H), 2.42-2.23 (m, 6H), 2.10 (m,2H), 1.96 (m, 1H).

HPLC (method 1): R_(t)=4.1 min.

MS (ESIpos): m/z=432 (M+H)⁺ (free base).

EXAMPLE 72N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[4-(4-morpholinylcarbonyl)phenyl]-1-benzothiophene-2-carboxamideHydrochloride

164.7 mg (0.49 mmol) of 4-(4-morpholinylcarbonyl)phenyltrifluoromethane-sulphonate (Example 18A), 142.2 mg (0.56 mmol) ofbis(pinacolato)diboron, 119.1 mg (1.21 mmol) of potassium acetate, 13.7mg (0.02 mmol) of PdCl₂(dppf), 150.0 mg (0.37 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzothiophene-2-carboxamidehydrochloride (Example 8A), 0.93 ml of 2 M sodium carbonate solution anda further 13.7 mg (0.02 mmol) of PdCl₂(dppf) in 2.5 ml of DMF arereacted by general method D. An initial purification by preparative HPLCis followed by column chromatography on silica gel (mobile phase:dichloromethane/methanol/ammonia 90:9:1). Drying under high vacuumresults in 24.8 mg (13% of theory) of the title compound.

¹H-NMR (400 MHz, methanol-d₄): δ=8.22 (s, 1H), 7.97 (d, 1H), 7.83 (m,2H), 7.62 (m, 2H), 7.55 (m, 2H), 4.47 (m, 1H), 3.90-3.26 (m, 14H), 2.38(m, 1H), 2.28 (m, 1H), 2.10 (m, 2H), 1.96 (m, 1H).

HPLC (method 1): R_(t)=3.8 min.

MS (ESIpos): m/z=476 (M+H)⁺ (free base).

EXAMPLE 737-[2-(Aminomethyl)phenyl]-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzothiophene-2-carboxamideDihydrochloride

534.2 mg (1.87 mmol) of tert-butyl 2-bromobenzylcarbamate, 474.1 mg(1.87 mmol) of bis(pinacolato)diboron, 397.0 mg (4.04 mmol) of potassiumacetate, 45.5 mg (0.06 mmol) of PdCl₂(dppf), 500 mg (1.24 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzothiophene-2-carboxamidehydrochloride (Example 8A), 3.11 ml of 2 M sodium carbonate solution anda further 45.5 mg (0.06 mmol) of PdCl₂(dppf) in 6.0 ml of DMF arereacted by general method D. Purification by preparative HPLC isfollowed by concentration of the combined product fractions, taking upin methanol, addition of 1N hydrochloric acid, and stirring at roomtemperature for 30 min. Concentration and drying under high vacuumresult in 121 mg (20% of theory) of the title compound.

HPLC (method 1): R_(t)=3.6 min.

MS (ESIpos): m/z=392 (M+H)⁺ (free base).

EXAMPLE 74N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-{3-[(2,2-dimethylpropanoyl)amino]phenyl}-1-benzothiophene-2-carboxamideHydrochloride

143.5 mg (0.56 mmol) of N-(3-bromophenyl)-2,2-dimethylpropanamide, 142.2mg (0.56 mmol) of bis(pinacolato)diboron, 119.1 mg (1.21 mmol) ofpotassium acetate, 13.7 mg (0.02 mmol) of PdCl₂(dppf), 150.0 mg (0.37mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzothiophene-2-carboxamidehydrochloride (Example 8A), 0.93 ml of 2 M sodium carbonate solution anda further 13.7 mg (0.02 mmol) of PdCl₂(dppf) in 2.0 ml of DMF arereacted by general method D. An initial purification by preparative HPLCis followed by column chromatography on silica gel (mobile phase:dichloromethane/methanol/ammonia 90:9:1). Drying under high vacuumresults in 32.4 mg (17% of theory) of the title compound.

¹H-NMR (400 MHz, methanol-d₄): δ=8.16 (s, 1H), 8.01 (m, 1H), 7.92 (m,1H), 7.63-7.48 (m, 3H), 7.47 (m, 2H), 4.44 (m, 1H), 3.84 (m, 1H), 3.47(m, 1H), 3.41-3.27 (m, 4H), 2.38 (m, 1H), 2.28 (m, 1H), 2.10 (m, 2H),1.96 (m, 1H), 1.32 (s, 9H).

HPLC (method 1): R_(t)=4.3 min.

MS (ESIpos): m/z=462 (M+H)⁺ (free base).

EXAMPLE 753-(2-{[(3R)-1-Azabicyclo[2.2.2]oct-3-ylamino]carbonyl}-1-benzothien-7-yl)-benzoicAcid Hydrochloride

200 mg (0.50 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzothiophene-2-carboxamidehydrochloride (Example 8A) and 82.6 mg (0.50 mmol) of3-carboxyphenylboronic acid are introduced into 1.5 ml of DMF. Additionof 0.78 ml of 2. M sodium carbonate solution and 20.3 mg (0.02 mmol) ofPdCl₂(dppf) is followed by heating at 60° C. After 18 h, a further 20.3mg (0.02 mmol) of PdCl₂(dppf) are added, and the mixture is heated at90° C. for a further 18 h. After cooling, the reaction mixture isfiltered through kieselguhr and purified by preparative HPLC. Theproduct fractions are concentrated and, after addition of a 3:1 mixtureof acetonitrile and 1N hydrochloric acid, again concentrated. Dryingunder high vacuum results in 103 mg (45% of theory) of the titlecompound.

¹H-NMR (300 MHz, DMSO-d₆): δ=10.28 (br. s, 1H), 9.13 (d, 1H), 8.46 (s,1H), 8.29 (m, 1H), 8.08-7.95 (m, 3H), 7.71 (dd, 1H), 7.60 (m, 2H), 4.33(m, 1H), 3.85-3.12 (m, 6H), 2.22 (m, 1H), 2.15 (m, 1H), 1.91 (m, 2H),1.75 (m, 1H).

HPLC (method 1): R_(t)=3.9 min.

MS (ESIpos): m/z=407 (M+H)⁺ (free base).

EXAMPLE 76N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[2-({[(methylamino)carbonyl]amino}-methyl)phenyl]-1-benzothiophene-2-carboxamideHydrochloride

51.0 μl (0.37 mmol) of triethylamine and 43.5 μl (0.73 mmol) of methylisocyanate are added to a suspension of 85 mg (0.18 mmol) of7-[2-(aminomethyl)phenyl]-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzothiophene-2-carboxamidedihydrochloride (Example 73) in 1 ml of a 5:1 mixture of THF and DMF.After 18 h at room temperature, the reaction mixture is concentrated invacuo and purified by preparative HPLC. The product fractions areconcentrated and, after addition of a 5:1 mixture of methanol and 1Nhydrochloric acid, again concentrated. Drying under high vacuum resultsin 65.5 mg (74% of theory) of the title compound.

¹H-NMR (400 MHz, methanol-d₄): δ=8.18 (s, 1H), 7.94 (d, 1H), 7.58-7.44(m, 3H), 7.43-7.29 (m, 3H), 4.43 (m, 1H), 4.15 (m, 2H), 3.82 (m, 1H),3.47 (m, 1H), 3.41-3.27 (m, 4H), 2.62 (s, 3H), 2.37 (m, 1H), 2.26 (m,1H), 2.08 (m, 2H), 1.94 (m, 1H).

HPLC (method 1): R_(t)=3.8 min.

LC-MS (method 4): R_(t)=2.5 min.

MS (ESIpos): m/z=448 (M+H)⁺ (free base).

EXAMPLE 77N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[3-(1H-pyrrol-1-yl)phenyl]-1-benzothiophene-2-carboxamideHydrochloride

124.4 mg (0.56 mmol) of 1-(3-bromophenyl)-1H-pyrrole, 142.2 mg (0.56mmol) of bis(pinacolato)diboron, 119.1 mg (1.21 mmol) of potassiumacetate, 13.7 mg (0.02 mmol) of PdCl₂(dppf), 150.0 mg (0.37 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzothiophene-2-carboxamidehydrochloride (Example 8A), 0.93 ml of 2 M sodium carbonate solution anda further 13.7 mg (0.02 mmol) of PdCl₂(dppf) in 2.0 ml of DMF arereacted by general method D. Drying under high vacuum results in 86.9 mg(48% of theory) of the title compound.

¹H-NMR (400 MHz; DMSO-d₆): δ=9.92 (br. s, 1H), 9.03 (d, 1H), 8.39 (m,1H), 8.02 (m, 1H), 7.88 (s, 1H), 7.77-7.57 (m, 5H), 7.49 (m, 2H), 6.31(m, 2H), 4.32 (m, 1H), 3.67 (m, 1H), 3.57-3.13 (m, 5H), 2.21 (m, 1H),2.13 (m, 1H), 1.90 (m, 2H), 1.75 (m, 1H).

HPLC (method 1): R_(t)=4.5 min.

MS (ESIpos): m/z=428 (M+H)⁺ (free base).

EXAMPLE 78N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[3-(4-morpholinylcarbonyl)phenyl]-1-benzothiophene-2-carboxamideHydrochloride

103 mg (0.27 mmol) of HATU and 70.8 (0.41 mmol) ofN,N-diisopropylethylamine are added to a solution of 50 mg (0.11 mmol)of3-(2-{[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]carbonyl}-1-benzothien-7-yl)benzoicacid hydrochloride (Example 75) and 19.7 μl (0.23 mmol) of morpholine in0.5 ml of DMF at 0° C. The mixture is stirred at room temperature for 18h. After purification by preparative HPLC, the product fractions areconcentrated and, after addition of a 3:1 mixture of acetonitrile and 1Nhydrochloric acid, again concentrated. Drying under high vacuum resultsin 43 mg (74% of theory) of the title compound.

¹H-NMR (200 MHz, DMSO-d₆): δ=10.66 (br. s, 1H), 9.33 (d, 1H), 8.56 (s,1H), 7.98 (dd, 1H), 7.87-7.45 (m, 6H), 4.34 (m, 1H), 3.87-3.06 (m, 14H),2.18 (m, 2H), 1.90 (m, 2H), 1.74 (m, 1H).

HPLC (method 1): R_(t)=3.8 min.

MS (ESIpos): m/z=476 (M+H)⁺ (free base).

EXAMPLE 79N-[(3S)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[4-(4-morpholinyl)phenyl]-1-benzothiophene-2-carboxamideHydrochloride

330.7 mg (0.87 mmol) of HATU and 112.4 mg (0.87 mmol) ofN,N-diisopropylethylamine are added to a mixture of 144.3 mg (0.72 mmol)of S-3-aminoquinuclidine dihydrochloride and 300 mg (0.72 mmol) of7-[4-(4-morpholinyl)-phenyl]-1-benzothiophene-2-carboxylic acid (Example20A) in 3 ml of DMF at 0° C. After 30 min at 0° C., a further 224.8 mg(1.74 mmol) of N,N-diisopropylethylamine are added, and the mixture isstirred at room temperature for 19 h. The reaction solution is mixedwith a little water and acetonitrile and purified by preparative HPLC.The product fractions are concentrated and, after addition of a 3:1mixture of methanol and 1N hydrochloric acid, again concentrated. Dryingunder high vacuum results in 158 mg (45% of theory) of the titlecompound.

The spectroscopic data agree with those of the enantiomeric compound(Example 19).

EXAMPLE 80N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[3-(4-morpholinyl)phenyl]-1-benzofuran-2-carboxamideHydrochloride

151.1 mg (0.49 mmol) of 3-(4-morpholinyl)phenyltrifluoromethanesulphonate (Example 17A), 142.2 mg (0.56 mmol) ofbis(pinacolato)diboron, 119.1 mg (1.21 mmol) of potassium acetate, 13.7mg (0.02 mmol) of PdCl₂(dppf), 144 mg (0.37 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzofuran-2-carboxamidehydrochloride (Example 30A), 0.93 ml of 2 M sodium carbonate solutionand a further 13.7 mg (0.02 mmol) of PdCl₂(dppf) in 2 ml of DMF arereacted by general method D. Drying under high vacuum results in 32 mg(18% of theory) of the title compound.

¹H-NMR (300 MHz, DMSO-d₆): δ=10.27 (br. s, 1H), 8.96 (d, 1H), 7.85 (s,1H), 7.78 (m, 1H), 7.68 (m, 1H), 7.62 (m, 1H), 7.43 (m, 3H), 7.17 (m,1H), 4.36 (m, 1H), 3.82 (m, 4H), 3.63 (m, 1H), 3.44-3.10 (m, 9H), 2.22(m, 1H), 2.12 (m, 1H), 1.91 (m, 2H), 1.75 (m, 1H).

HPLC (method 1): R_(t)=3.8 min.

MS (ESIpos): m/z=432 (M+H)⁺ (free base).

EXAMPLE 817-(3-Aminophenyl)-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzothiophene-2-carboxamideHydrochloride

200 mg (0.50 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzothiophene-2-carboxamidehydrochloride (Example 8A) and 68.2 mg (0.50 mmol) of3-aminophenylboronic acid are introduced into 1.5 ml of DMF. Addition of0.78 ml of 2 M sodium carbonate solution and 20.3 mg (0.02 mmol) ofPdCl₂(dppf) is followed by heating at 60° C. for 18 h. After cooling,the reaction mixture is filtered through kieselguhr and purified byseparation by preparative HPLC. The product fractions are concentratedand, after addition of a 3:1 mixture of acetonitrile and 1N hydrochloricacid, again concentrated. Drying under high vacuum results in 201 mg(98% of theory) of the title compound.

¹H-NMR (200 MHz, DMSO-d₆): δ=10.63 (br. s, 1H), 9.33 (d, 1H), 8.57 (s,1H), 8.00 (dd, 1H), 7.76-7.58 (m, 4H), 7.55 (m, 1H), 7.43 (m, 1H), 4.34(m, 1H), 3.62 (m, 1H), 3.42 (m, 2H), 3.19 (m, 3H), 2.19 (m, 2H), 1.90(m, 2H), 1.73 (m, 1H).

HPLC (method 1): R_(t)=3.5 min.

MS (ESIpos): m/z=378 (M+H)⁺ (free base).

EXAMPLE 82N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-{3-[(methoxyacetyl)amino]phenyl}-1-benzothiophene-2-carboxamideHydrochloride

96.4 mg (0.25 mmol) of HATU and 71.5 μl (0.41 mmol) ofN,N-diisopropylethylamine are added to a solution of 50 mg (0.12 mmol)of7-(3-aminophenyl)-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzothiophene-2-carboxamidehydrochloride (Example 81) and 18.5 μl (0.24 mmol) of methoxyacetic acidin 0.5 ml of DMF at 0° C. The mixture is stirred at room temperature for3 h. Purification by preparative HPLC is followed by concentration ofthe product fractions and, after addition of a 3:1 mixture ofacetonitrile and 1 N hydrochloric acid, concentration again. Dryingunder high vacuum results in 7 mg (11% of theory) of the title compound.

¹H-NMR (300 MHz, DMSO-d₆): δ=10.13 (br. s, 1H), 9.97 (s, 1H), 9.04 (d,1H), 8.39 (s, 1H), 8.13 (m, 1H), 7.98 (d, 1H), 7.76 (d, 1H), 7.58 (dd,1H), 7.50 (m, 2H), 7.42 (m, 1H), 4.33 (m, 1H), 4.03 (s, 2H), 3.66 (m,1H), 3.56-3.12 (m, 8H), 2.22 (m, 1H), 2.14 (m, 1H), 1.91 (m, 2H), 1.75(m, 1H).

HPLC (method 1): R_(t)=4.0 min.

MS (ESIpos): m/z=450 (M+H)⁺ (free base).

EXAMPLE 83N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[4-(2-oxo-1-pyrrolidinyl)phenyl]-1-benzofuran-2-carboxamideHydrochloride

161.9 mg (0.67 mmol) of 1-(4-bromophenyl)-2-pyrrolidinone, 197.5 mg(0.78 mmol) of bis(pinacolato)diboron, 165.4 mg (1.69 mmol) of potassiumacetate, 19.0 mg (0.03 mmol) of PdCl₂(dppf), 200 mg (0.52 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzofuran-2-carboxamidehydrochloride (Example 30A), 1.30 ml of 2 M sodium carbonate solutionand a further 19.0 mg (0.03 mmol) of PdCl₂(dppf) in 2.5 ml of DMF arereacted by general method D. Drying under high vacuum results in 166.6mg (65% of theory) of the title compound.

¹H-NMR (200 MHz, DMSO-d₆): δ=10.06 (br. s, 1H), 8.96 (d, 1H), 7.97 (m,1H), 7.94 (s, 1H), 7.83 (m, 3H), 7.78 (dd, 1H), 7.69 (dd, 1H), 7.43 (dd,1H), 4.33 (m, 1H), 4.00-3.75 (m, 2H), 3.66 (m, 1H), 3.49-3.10 (m, 5H),2.55 (m, 2H), 2.23 (m, 1H), 2.10 (m, 3H), 1.91 (m, 2H), 1.75 (m, 1H).

HPLC (method 1): R_(t)=4.0 min.

MS (ESIpos): m/z=430.5 (M+H)⁺ (free base).

EXAMPLE 847-[3-(Acetylamino)phenyl]-N-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzothiophene-2-carboxamideHydrochloride

0.67 ml of 2 M sodium carbonate solution and 18.3 mg (0.02 mmol) ofPdCl₂(dppf) are added to a mixture of 200 mg (0.45 mmol) ofN-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzothiophene-2-carboxamidehydrochloride (Example 22A) and 80.2 mg (0.45 mmol) of3-(acetamido)phenylboronic acid in 2 ml of DMF. The reaction mixture isheated at 80° C. for 17 h. A further 40.1 mg (0.22 mmol) of3-(acetamido)phenylboronic acid, 1.34 ml of 1N sodium hydroxide solutionand 73.2 mg (0.09 mmol) of PdCl₂(dppf) are added, and the mixture isheated at 70° C. for a further 18 h. Cooling is followed by filtrationthrough kieselguhr and purification by preparative HPLC. The productfractions are concentrated, taken up in a 5:1 mixture of methanol and 1Nhydrochloric acid and again concentrated. Drying under high vacuumresults in 124.5 mg (59% of theory) of the title compound.

The spectroscopic data agree with those of the enantiomeric compound(Example 51).

EXAMPLE 85N-[(3S)-1-Azabicyclo[2.2.2]oct-3-yl]-7-(3-methoxyphenyl)-1-benzothiophene-2-carboxamideHydrochloride

0.67 ml of 2 M aqueous sodium carbonate solution and 18.3 mg (0.02 mmol)of PdCl₂(dppf) are added to a mixture of 200 mg (0.45 mmol) ofN-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzothiophene-2-carboxamidehydrochloride (Example 22A) and 68.1 mg (0.45 mmol) of3-methoxyphenylboronic acid in 2 ml of DMF. The reaction mixture isheated at 80° C. for 17 h, filtered through kieselguhr and evaporated todryness. A purification by preparative HPLC is followed by columnchromatography on silica gel (mobile phase:dichloromethane/methanol-/ammonia 90:9:1). The product fractions areconcentrated, taken up in a 5:1 mixture of methanol and 1N hydrochloricacid and again concentrated. Drying under high vacuum results in 97.7 mg(48% of theory) of the title compound.

¹H-NMR (200 MHz, DMSO-d₆): δ=10.25 (br. s, 1H), 9.11 (d, 1H), 8.42 (s,1H), 7.97 (dd, 1H), 7.56 (m, 2H), 7.47 (d, 1H), 7.30 (d, 1H), 7.24 (m,1H), 7.06 (m, 1H), 4.32 (m, 1H), 3.83 (s, 3H), 3.63 (m, 1H), 3.49-3.10(m, 5H), 2.20 (m, 1H), 2.13 (m, 1H), 1.90 (m, 2H), 1.74 (m, 1H).

The analytical data agree with those of the enantiomeric compound(Example 17).

EXAMPLE 864-(2-{[(3R)-1-Azabicyclo[2.2.2]oct-3-ylamino]carbonyl}-1-benzofuran-7-yl)-benzoicAcid Hydrochloride

150 mg (0.43 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzofuran-2-carboxamidehydrochloride (Example 30A) and 71.3 mg (0.43 mmol) of4-carboxyphenylboronic acid are introduced into 1.5 ml of DMF. Additionof 0.64 ml of 2 M sodium carbonate solution and 17.5 mg (0.02 mmol) ofPdCl₂(dppf) is followed by heating at 80° C. for 18 h. After cooling,the reaction mixture is filtered through kieselguhr, and the filtrate isconcentrated and partitioned between water and ethyl acetate. Theaqueous phase is washed with ethyl acetate and then concentrated. Thecrude product is purified by preparative HPLC. The product fractions arecombined and concentrated and, after addition of a 3:1 mixture ofacetonitrile and 1N hydrochloric acid, again concentrated. The crudeproduct is stirred with acetonitrile. The precipitate is filtered offwith suction and dried under high vacuum to result in 37 mg (20% oftheory) of the title compound.

¹H-NMR (300 MHz, DMSO-d₆): δ=10.37 (br. s, 1H), 9.15 (d, 1H), 8.08 (m,4H), 7.93 (s, 1H), 7.85 (dd, 1H), 7.76 (dd, 1H), 7.47 (dd, 1H), 4.36 (m,1H), 3.77-3.32 (m, 3H), 3.32 (m, 3H), 2.23 (m, 1H), 2.12 (m, 1H), 1.92(m, 2H), 1.76 (m, 1H).

HPLC (method 1): R_(t)=3.9 min.

MS (ESIpos): m/z=391 (M+H)⁺ (free base).

EXAMPLE 87N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[3-(trifluoromethoxy)phenyl]-1-benzofuran-2-carboxamideHydrochloride

200 mg (0.52 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzofuran-2-carboxamidehydrochloride (Example 30A) and 106.8 mg (0.52 mmol) of3-(trifluoromethoxy)phenylboronic acid are introduced into 2.0 ml ofDMF. Addition of 0.78 ml of 2 M sodium carbonate solution and 21.2 mg(0.03 mmol) of PdCl₂(dppf) is followed by heating at 70° C. for 17 h.After cooling, the reaction mixture is filtered through kieselguhr andpurified by preparative HPLC. The product fractions are combined andconcentrated and, after addition of a 5:1 mixture of methanol and 1Nhydrochloric acid, again concentrated. Drying under high vacuum resultsin 48.8 mg (20% of theory) of the title compound.

¹H-NMR (200 MHz, DMSO-d₆): δ=10.18 (br. s, 1H), 9.00 (d, 1H), 7.95 (m,2H), 7.89 (s, 1H), 7.86 (m, 1H), 7.77 (m, 1H), 7.68 (m, 1H), 7.47 (m,2H), 4.34 (m, 1H), 3.65 (m, 1H), 3.35 (m, 2H), 3.23 (m, 3H), 2.22 (m,1H), 2.12 (m, 1H), 1.92 (m, 2H), 1.76 (m, 1H).

HPLC (method 1): R_(t)=4.5 min.

MS (ESIpos): m/z=431 (M+H)⁺ (free base).

EXAMPLE 88N-[(3S)-1-Azabicyclo[2.2.2]oct-3-yl]-7-(2-methoxyphenyl)-1-benzothiophene-2-carboxamideHydrochloride

0.67 ml of 2 M sodium carbonate solution and 18.3 mg (0.02 mmol) ofPdCl₂(dppf) are added to a mixture of 200 mg (0.45 mmol) ofN-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzothiophene-2-carboxamidehydrochloride (Example 22A) and 68.1 mg (0.45 mmol) of2-methoxyphenylboronic acid in 2 ml of DMF. The reaction mixture isheated at 70° C. for 17 h and, after cooling, filtered throughkieselguhr and purified by preparative HPLC. The product fractions areconcentrated, taken up in a 5:1 mixture of methanol and 1N hydrochloricacid and again concentrated. Drying under high vacuum results in 112 mg(58% of theory) of the title compound.

¹H-NMR (400 MHz, DMSO-d₆): δ=10.38 (br. s, 1H), 9.07 (d, 1H), 8.38 (s,1H), 7.95 (m, 1H), 7.50 (dd, 1H), 7.47 (m, 1H), 7.37 (m, 2H), 7.20 (d,1H), 7.09 (dd, 1H), 4.31 (m, 1H), 3.73 (s, 3H), 3.62 (m, 1H), 3.35 (m,2H), 3.19 (m, 3H), 2.19 (m, 1H), 2.13 (m, 1H), 1.90 (m, 2H), 1.73 (m,1H).

The other analytical data agree with those of the enantiomeric compound(Example 18).

EXAMPLE 89N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[3-(hydroxymethyl)phenyl]-1-benzofuran-carboxamideHydrochloride

150 mg (0.43 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzofuran-2-carboxamidehydrochloride (Example 30A) and 65.3 mg (0.43 mmol) of3-(hydroxymethyl)phenylboronic acid are introduced into 1.5 ml of DMF.Addition of 0.64 ml of 2 M sodium carbonate solution and 17.5 mg (0.02mmol) of PdCl₂(dppf) is followed by heating at 60° C. for 18 h. Afurther 17.5 mg (0.02 mmol) of PdCl₂(dppf) are added and the mixture isstirred at 90° C. for a further 18 h. After cooling, the reactionmixture is filtered through kieselguhr. A first purification bypreparative HPLC is followed by column chromatography on silica gel(mobile phase: dichloromethane/methanol/ammonia 90:9:1). The productfractions are combined and concentrated and, after addition of a 5:1mixture of methanol and 4N hydrogen chloride in dioxane, againconcentrated. Drying under high vacuum results in 45 mg (24% of theory)of the title compound.

¹H-NMR (400 MHz, methanol-d₄): δ=7.98 (m, 1H), 7.74 (m, 2H), 7.65 (m,2H), 7.52 (dd, 1H), 7.42 (m, 2H), 4.72 (s, 2H), 4.51 (m, 1H), 3.87-3.26(m, 6H), 2.39 (m, 1H), 2.23 (m, 1H), 2.10 (m, 2H), 1.95 (m, 1H).

HPLC (method 1): R_(t)=3.9 min.

MS (ESIpos): m/z=377 (M+H)⁺ (free base).

EXAMPLE 90N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[4-(3-oxo-4-morpholinyl)phenyl]-1-benzofuran-2-carboxamideHydrochloride

205.4 mg (0.70 mmol) of 4-(4-bromophenyl)-3-morpholinone (Example 16A),204.4 mg (0.81 mmol) of bis(pinacolato)diboron, 171.2 mg (1.74 mmol) ofpotassium acetate, 19.6 mg (0.03 mmol) of PdCl₂(dppf), 207 mg (0.54mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzofuran-2-carboxamidehydrochloride (Example 30A), 1.34 ml of 2 M sodium carbonate solutionand a further 19.6 mg (0.03 mmol) of PdCl₂(dppf) in 2 ml of DMF arereacted by general method D. Drying under high vacuum results in 233 mg(85% of theory) of the title compound.

¹H-NMR (200 MHz, DMSO-d₆): δ=10.32 (br. s, 1H), 9.07 (d, 1H), 7.95 (m,3H), 7.80 (dd, 1H), 7.70 (dd, 1H), 7.59 (m, 2H), 7.44 (dd, 1H), 4.33 (m,1H), 4.26 (s, 2H), 4.02 (m, 2H), 3.83 (m, 2H), 3.64 (m, 1H), 3.37 (m,2H), 3.21 (m, 3H), 2.23 (m, 1H), 2.11 (m, 1H), 1.91 (m, 2H), 1.74 (m,1H).

HPLC (method 1): R_(t)=4.5 min.

MS (ESIpos): m/z=446 (M+H)⁺ (free base).

EXAMPLE 91N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[2-(4-morpholinyl)phenyl]-1-benzofuran-2-carboxamideHydrochloride

225 mg (0.93 mmol) of 2-(4-morpholinyl)phenyl trifluoromethanesulphonate(Example 32A), 272 mg. (1.07 mmol) of bis(pinacolato)diboron, 228 mg(2.33 mmol) of potassium acetate, 26 mg (0.04 mmol) of PdCl₂(dppf), 250mg (0.72 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzofuran-2-carboxamide(Example 30A), 1.8 ml of 2 M sodium carbonate solution and a further 26mg (0.04 mmol) of PdCl₂(dppf) in 2 ml of DMF are reacted by generalmethod D. Drying under high vacuum results in 82 mg (24% of theory) ofthe title compound.

¹H-NMR (400 MHz, DMSO-d₆): δ=9.76 (s, 1H), 8.82 (d, 1H), 7.79 (s, 1H),7.77 (d, 1H), 7.55 (d, 1H), 7.46-7.37 (m, 3H), 7.23-7.14 (m, 2H), 4.33(m, 1H), 3.83-3.04 (m, 6H), 3.55 (s, 4H), 2.68 (s, 4H), 2.16 (m, 1H),2.04 (m, 1H), 1.95-1.84 (m, 2H), 1.79-1.67 (m, 1H).

HPLC (method 1): R_(t)=4.1 min.

MS (ESIpos): m/z=432 (M+H)⁺ (free base).

EXAMPLE 92N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[4-(4-morpholinyl)phenyl]-1-benzofuran-2-carboxamideHydrochloride

444 mg (2.15 mmol) of 4-(4-morpholinyl)phenylboronic acid and 4.3 ml of1N sodium hydroxide solution are added to a mixture of 500 mg (0.143mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzofuran-2-carboxamidehydrochloride (Example 30A) and 105 mg (0.14 mmol) of PdCl₂(dppf) in 5ml of DMF. The reaction mixture is heated at 100° C. overnight. Thesolvent is removed under reduced pressure, and the crude product istaken up in methanol and filtered through kieselguhr. Purification takesplace by preparative HPLC. The product fractions are concentrated anddissolved in methanol, and an excess of 1N hydrochloric acid is added.The solvent is removed under reduced pressure. Drying under high vacuumresults in 393 mg (59% of theory) of the title compound.

¹H-NMR (200 MHz, DMSO-d₆): δ=10.45 (s, 1H), 9.10 (d, 1H), 7.91 (s, 1H),7.87 (d, 1H), 7.75-7.55 (m, 2H), 7.40 (t, 1H), 7.18 (d, 2H), 4.40 (m,1H), 3.80 (m, 4H), 3.75-3.00 (m, 6H), 3.20 (m, 4H), 2.30-2.02 (m, 2H),2.00-1.62 (m, 3H).

HPLC (method 1): R_(t)=3.79 min.

MS (ESIpos): m/z=432 (M+H)⁺ (free base).

EXAMPLE 93N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-5-[4-(4-morpholinyl)phenyl]-1-benzofuran-2-carboxamideHydrochloride

177 mg (0.86 mmol) of 4-(4-morpholinyl)phenylboronic acid and 2.15 ml of1N sodium hydroxide solution are added to a mixture of 250 mg (0.72mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-5-bromo-1-benzofuran-2-carboxamide(Example 3A) and 52 mg (0.07 mmol) of PdCl₂(dppf) in 3 ml of DMF. Thereaction mixture is heated at 90° C. overnight. The solvent is removedunder reduced pressure, and the crude product is taken up in methanoland filtered through kieselguhr. Purification takes place by preparativeHPLC. The product fractions are concentrated and dissolved inacetonitrile/water, and an excess of 1N hydrochloric acid is added. Thesolvent is removed under reduced pressure. Drying under high vacuumresults in 23 mg (7% of theory) of the title compound.

¹H-NMR (200 MHz, DMSO-d₆): δ=10.40 (s, 1H), 9.15 (d, 1H), 7.98 (s, 1H),7.76-7.68 (m, 2H), 7.67-7.58 (m, 2H), 7.20-7.10 (d, 2H), 4.45 (m, 1H),3.80 (m, 4H), 3.75-3.30 (m, 6H), 3.20 (m, 4H), 2.30-2.02 (m, 2H),2.00-1.62 (m, 3H).

HPLC (method 1): R_(t)=3.52 min.

MS (ESIpos): m/z=432 (M+H)⁺ (free base).

EXAMPLE 94N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-5-[4-(hydroxymethyl)phenyl]-1-benzofuran-2-carboxamide

110 mg (0.73 mmol) of 4-(hydroxymethyl)phenylboronic acid and 1.46 ml of1N sodium hydroxide solution are added to a mixture of 170 mg (0.49mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-5-bromo-1-benzofuran-2-carboxamide(Example 3A) and 35 mg (0.05 mmol) of PdCl₂(dppf) in 2 ml of DMF. Thereaction mixture is heated at 85° C. overnight. The solvent is removedunder reduced pressure. Addition of a mixture of 1N sodium hydroxidesolution and ethyl acetate to the residue is followed by extraction ofthe aqueous phase once more with ethyl acetate. The combined organicphases are washed twice with each of 1N sodium hydroxide solution andsaturated sodium chloride solution, dried over magnesium sulphate andconcentrated in a rotary evaporator under reduced pressure. The crudeproduct is taken up in methanol and shaken together with acidic ionexchanger (Dowex® WX2-200) for about 20 min. The loaded ion exchanger iswashed three times with 30 ml of methanol each time, then with DMF,again with methanol, with dichloromethane, again with methanol, withwater and finally with methanol again. The product is eluted withmethanol/triethylamine 95:5. The solvent is removed in a rotaryevaporator under reduced pressure. 148 mg (80% of theory) of the titlecompound are isolated.

¹H-NMR (200 MHz, CDCl₃): δ=7.85 (s, 1H), 7.70-7.35 (m, 7H), 6.77 (d,1H), 4.62 (s, 2H), 4.28-4.12 (m, 1H), 156-3.38 (m, 1H), 3.04-2.78 (m,4H), 2.75-2.59 (m, 1H), 2.16-2.02 (m, 1H), 1.93-1.66 (m, 3H), 1.66-1.50(m, 1H).

HPLC (method 1): R_(t)=3.65 min.

MS (ESIpos): m/z=377 (M+H)⁺.

EXAMPLE 95N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-5-[2-(hydroxymethyl)phenyl]-1-benzofuran-2-carboxamide

110 mg (0.73 mmol) of 2-(hydroxymethyl)phenylboronic acid and 1.46 ml of1N sodium hydroxide solution are added to a mixture of 170 mg (0.49mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-5-bromo-1-benzofuran-2-carboxamide(Example 3A) and 35 mg (0.05 mmol) of PdCl₂(dppf) in 2 ml of DMF. Thereaction mixture is heated at 85° C. overnight. The solvent is removedunder reduced pressure. Addition of a mixture of 1N sodium hydroxidesolution and ethyl acetate to the residue is followed by extraction ofthe aqueous phase once more with ethyl acetate. The combined organicphases are washed twice with each of 1N sodium hydroxide solution andsaturated sodium chloride solution, dried over magnesium sulphate andconcentrated in a rotary evaporator under reduced pressure. The crudeproduct is taken up in methanol and shaken together with acidic ionexchanger (Dowex® WX2-200) for about 20 min. The loaded ion exchanger iswashed three times with 30 ml of methanol each: time, then with DMF,again with methanol, with dichloromethane, again with methanol, withwater and finally with methanol again. The product is eluted withmethanol/triethylamine 95:5. The solvent is removed in a rotaryevaporator under reduced pressure. 140 mg (76% of theory) of the titlecompound are isolated.

¹H-NMR (300 MHz, CDCl₃): δ=7.70-7.25 (m, 8H), 6.75 (d, 1H), 4.62 (s,2H), 4.28-4.12 (m, 1H), 3.56-3.38 (m, 1H), 3.04-2.78 (m, 4H), 2.75-2.59(m, 1H), 2.16-2.02 (m, 1H), 1.93-1.66 (m, 3H), 1.66-1.50 (m, 1H).

HPLC (method 1): R_(t)=3.76 min.

MS (ESIpos): m/z=377 (M+H)⁺.

EXAMPLE 96N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-5-[4-(dimethylamino)phenyl]-1-benzofuran-2-carboxamide

0.120 mg (0.73 mmol) of 4-(dimethylamino)phenylboronic acid and 1.46 mlof 1N sodium hydroxide solution are added to a mixture of 170 mg (0.49mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-5-bromo-1-benzofuran-2-carboxamide(Example 3A) and 35 mg (0.05 mmol) of PdCl₂(dppf) in 2 ml of DMF. Thereaction mixture is heated at 85° C. overnight. The solvent is removedunder reduced pressure. Addition of a mixture of 1N sodium hydroxidesolution and ethyl acetate to the residue is followed by extraction ofthe aqueous phase once more with ethyl acetate. The combined organicphases are washed twice with each of 1N sodium hydroxide solution andsaturated sodium chloride solution, dried over magnesium sulphate andconcentrated in a rotary evaporator under reduced pressure. The crudeproduct is taken up in methanol and shaken together with acidic ionexchanger (Dowex® WX2-200) for about 20 min. The loaded ion exchanger iswashed three times with 30 ml of methanol each time, then with DMF,again with methanol, with dichloromethane, again with methanol, withwater and finally with methanol again. The product is eluted withmethanol/triethylamine 95:5. The solvent is removed in a rotaryevaporator under reduced pressure. 138 mg (73% of theory) of the titlecompound are isolated.

¹H-NMR (200 MHz, CDCl₃): δ=7.78 (d, 1H) 7.70-7.39 (m, 4H), 6.88-6.75 (m,3H), 4.28-4.12 (m, 1H), 3.56-3.38 (m, 1H), 3.04-2.78 (m, 4H), 3.00 (s,6H), 2.75-2.59 (m, 1H), 2.16-2.02 (m, 1H), 1.93-1.66 (m, 3H), 1.66-1.50(m, 1H).

HPLC (method 1): R_(t)=3.36 min.

MS (ESIpos): m/z=390 (M+H)⁺.

EXAMPLE 97N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-5-[4-(methoxy)phenyl]-1-benzofuran-2-carboxamideHydrochloride

130 mg (0.86 mmol) of 4-(methoxy)phenylboronic acid and 2.15 ml of 1Nsodium hydroxide solution are added to a mixture of 250 mg (0.72 mmol)ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-5-bromo-1-benzofuran-2-carboxamide(Example 3A) and 52 mg (0.07 mmol) of PdCl₂(dppf) in 3 ml of DMF. Thereaction mixture is heated at 90° C. overnight. The solvent is removedunder reduced pressure, and the crude product is taken up in methanoland filtered through kieselguhr. Purification takes place by preparativeHPLC. The product fractions are mixed with an excess of 1N hydrochloricacid. The solvent is removed under reduced pressure. Drying under highvacuum results in 127 mg (39% of theory) of the title compound.

¹H-NMR (200 MHz, DMSO-d₆): δ=9.90 (s, 1H), 9.10 (d, 1H), 7.95 (m, 2H),7.75-7.60 (m, 4H), 7.10-7.02 (m, 2H), 4.40 (m, 1H), 3.85 (m, 3H),3.75-3.00 (m, 6H), 320 (m, 4H), 2.30-2.02 (m, 2H), 2.00-1.62 (m, 3H).

HPLC (method 1): R_(t)=4.15 min.

MS (ESIpos): m/z=377. (M+H)⁺ (free base).

EXAMPLE 98N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-5-[3-(methoxy)phenyl]-1-benzofuran-carboxamideHydrochloride

130 mg (0.86 mmol) of 3-(methoxy)phenylboronic acid and 2.15 ml of 1Nsodium hydroxide solution are added to a mixture of 250 mg (0.72 mmol)ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-5-bromo-1-benzofuran-2-carboxamide(Example 3A) and 52 mg (0.07 mmol) of PdCl₂(dppf) in 3 ml of DMF. Thereaction mixture is heated at 90° C. overnight. The solvent is removedunder reduced pressure, and the crude product is taken up in methanoland filtered through kieselguhr. Purification takes place by preparativeHPLC. The product fractions are mixed with an excess of 1N hydrochloricacid. The solvent is removed under reduced pressure. Drying under highvacuum results in 208 mg (63% of theory) of the title compound.

¹H-NMR (300 MHz, DMSO-d₆): δ=10.0 (s, 1H), 9.10 (d, 1H), 8.05 (s, 1H),7.80-7.65 (m, 3H), 7.42-7.18 (m, 3H), 6.93 (m, 1H), 4.35 (m, 1H), 3.85(s, 3H), 3.75-3.00 (m, 6H), 3.20 (m, 4H), 2.30-2.02 (m, 2H), 2.00-1.62(m, 3H).

HPLC (method 1): R_(t)=4.19 min.

MS (ESIpos): m/z=377 (M+H)⁺ (free base).

EXAMPLE 99N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[4-(methoxy)phenyl]-1-benzofuran-carboxamideHydrochloride

130 mg (0.86 mmol) of 4-(methoxy)phenylboronic acid and 2.58 ml of 1Nsodium hydroxide solution are added to a mixture of 300 mg (0.86 mmol)ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzofuran-2-carboxamide(Example 30A) and 63 mg (0.09 mmol) of PdCl₂(dppf) in 4 ml of DMF. Thereaction mixture is heated at 95° C. overnight. The solvent is removedunder reduced pressure, and the crude product is taken up in methanoland filtered through kieselguhr. Purification takes place by preparativeHPLC. The product fractions are mixed with an excess of 1N hydrochloricacid. The solvent is removed under reduced pressure. Drying under highvacuum results in 165 mg (47% of theory) of the title compound.

¹H-NMR (300 MHz, DMSO-d₆): δ=10.4 (s, 1H), 9.00 (d, 1H), 8.05 (s, 1H),7.90-7.82 (m, 3H), 7.75 (d, 1H), 7.62 (d, 1H), 7.40 (t, 1H), 7.15-7.05(m, 2H), 4.35 (m, 1H), 3.85 (s, 3H), 3.65 (m, 1H), 3.48-3.30 (m, 2H),3.25-3.10 (m, 3H), 2.25 (m, 1H), 2.18-2.05 (m, 1H), 1.98-1.88 (m, 2H),1.80-1.63 (m, 1H).

HPLC (method 1): R_(t)=4.18 min.

MS (ESIpos): m/z=377 (M+H)⁺ (free base).

EXAMPLE 100N-[(3S)-1-Azabicyclo[2.2.2]oct-3-yl]-7-(2-methoxyphenyl)-1-benzofuran-2-carboxamideHydrochloride

3.4 g (8.95 mmol) of HATU and 2.34 ml (13.42 mmol) ofN,N-diisopropylethylamine are added to a mixture of 890 mg (4.47 mmol)of S-3-aminoquinuclidine dihydrochloride and 1000 mg (3.73 mmol) of7-(2-methoxyphenyl)-1-benzofuran-2-carboxylic acid (Example 21A) in 10ml of DMF at 0° C. After stirring at room temperature for 18 h, thereaction solution is purified by preparative HPLC. The product fractionsare concentrated and, after addition of 5 ml of 1N hydrochloric acid,again concentrated. Drying under high vacuum results in 209 mg (13.6% oftheory) of the title compound.

The analytical data agree with those of the enantiomeric compound(Example 102).

EXAMPLE 101N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[3-(methoxy)phenyl]-1-benzofuran-2-carboxamideHydrochloride

98 mg (0.64 mmol) of 3-(methoxy)phenylboronic acid and 1.29 ml of 1Nsodium hydroxide solution are added to a mixture of 150 mg (0.43 mmol)ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzofuran-2-carboxamide(Example 30A) and 31 mg (0.04 mmol) of PdCl₂(dppf) in 2 ml of DMF. Thereaction mixture is heated at 90° C. overnight. The solvent is removedunder reduced pressure, and the crude product is taken up in methanoland filtered through kieselguhr. Purification takes place by preparativeHPLC. The product is dissolved in methanol and mixed with an excess of1N hydrochloric acid. The solvent is removed under reduced pressure, andthe residue is recrystallized from a little isopropanol. Drying underhigh vacuum results in 159 mg (85% of theory) of the title compound.

¹H-NMR (400 MHz, DMSO-d₆): δ=10.05 (s, 1H), 8.95 (d, 1H), 7.85 (s, 1H),7.80 (d, 1H), 7.70 (d, 1H), 7.50-7.40 (m, 4H), 7.00 (m, 1H), 4.35 (m,1H), 3.85 (s, 3H), 3.65 (m, 1H), 3.48-3.30 (m, 2H), 3.25-3.15 (m, 3H),2.25 (m, 1H), 2.18-2.05 (m, 1H), 1.98-1.88 (m, 2H), 1.80-1.63 (m, 1H).

HPLC (method 1): R_(t)=4.21 min.

MS (ESIpos): m/z=377 (M+H)⁺ (free base).

EXAMPLE 102N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamideHydrochloride

Method a):

98 mg (0.64 mmol) of 2-(methoxy)phenylboronic acid and 0.1.29 ml of 1Nsodium hydroxide solution are added to a mixture of 150 mg (0.43 mmol)ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzofuran-2-carboxamide(Example 30A) and 31 mg (0.04 mmol) of PdCl₂(dppf) in 2 ml of DMF. Thereaction mixture is heated at 85° C. overnight. The solvent is removedunder reduced pressure, and the crude product is taken up in methanoland filtered through kieselguhr. Further purification takes place bypreparative HPLC. The product is dissolved in methanol and mixed with anexcess of 1N hydrochloric acid. The solvent is removed under reducedpressure, and the residue is recrystallized from a little isopropanol.Drying under high vacuum results in 100 mg (62% of theory) of the titlecompound.

¹H-NMR (400 MHz, DMSO-d₆): δ=10.08 (s, 1H), 8.91 (d, 1H), 7.87 (s, 1H),7.84-7.74 (m, 2H), 7.53-7.33 (m, 3H), 7.25-7.00 (m, 2H), 4.35 (m, 1H),3.75 (s, 3H), 3.65 (m, 1H), 3.48-3.30 (m, 2H), 3.25-3.15 (m, 3H), 2.25(m, 1H), 2.18-2.05 (m, 1H), 1.98-1.88 (m, 2H), 1.80-1.63 (m, 1H).

HPLC (method 1): R_(t)=4.16 min.

MS (ESIpos): m/z=377 (M+H)⁺ (free base).

Method b):

2.51 g (13.1 mmol) of EDC, 1.77 g (13.1 mmol) of HOBt and 5.47 ml (39.2mmol) of triethylamine are added to a solution of 2.92 g (10.9 mmol) of7-(2-methoxyphenyl)-1-benzofuran-2-carboxylic acid (Example 21A) and2.17 g (10.9 mmol) of (R)-3-aminoquinuclidine dihydrochloride in 35 mlof DMF at 0° C. After stirring at room temperature for 18 hours, afurther 434 mg (2.2 mmol) of (R)-3-aminoquinuclidine dihydrochloride and418 mg (2.2 mmol) of EDC are added. After 2 h at 55° C., the reactionsolution is concentrated and the residue is partitioned between 200 mleach of ethyl acetate and 2N sodium hydroxide solution. The organicphase is washed. 15 times with 100 ml of 2N sodium hydroxide solutioneach time. The combined aqueous phases are back-extracted with 250 ml ofethyl acetate. The combined organic phases are dried over sodiumsulphate and concentrated and, after addition of a 5:1 mixture ofmethanol and 1N hydrochloric acid to the residue, again concentrated anddried under high vacuum. Recrystallization of the residue from 10 ml ofa 10:1 mixture of isopropanol and ethanol results in 2.73 g (60.5% oftheory) of the title compound.

EXAMPLE 103N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[4-(methoxy)-3-pyridinyl]-1-benzofuran-2-carboxamideHydrochloride

98 mg (0.64 mmol) of 4-methoxy-3-pyridinylboronic acid and 0.86 ml of 1Nsodium hydroxide solution are added to a mixture of 100 mg (0.29 mmol)ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzofuran-2-carboxamide(Example 30A) and 21 mg (0.03 mmol) of PdCl₂(dppf) in 2 ml of DMF. Thereaction mixture is heated at 85° C. overnight. The solvent is removedunder reduced pressure, and the crude product is taken up in methanoland filtered through kieselguhr. Purification takes place by preparativeHPLC. The product fractions are mixed with an excess of 1N hydrochloricacid. The solvent is removed under reduced pressure. Drying under highvacuum results in 58 mg (49% of theory) of the title compound.

¹H-NMR (400 MHz, DMSO-d₆): δ=10.55 (s, 1H), 9.20 (d, 1H), 9.05 (s, 1H),8.95 (d, 1H), 7.96-7.89 (m, 2H), 7.82 (d, 1H), 7.65 (d, 1H), 7.50 (t,1H), 4.35 (m, 1H), 4.10 (s, 3H), 3.65-3.15 (m, 6H), 2.20 (m, 1H),2.18-2.05 (m, 1H), 1.98-1.88 (m, 2H), 1.80-1.63 (m, 1H).

HPLC (method 1): δ=3.35 min.

MS (ESIpos): m/z=378 (M+H)⁺ (free base).

EXAMPLE 104N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[4-(4-morpholinylcarbonyl)phenyl]-1-benzofuran-2-carboxamideHydrochloride

631 mg (1.43 mmol) of 4-(4-morpholinylcarbonyl)phenyltrifluoromethane-sulphonate (Example 18A), 545 mg (2.15 mmol) ofbis(pinacolato)diboron, 456 mg (4.65 mmol) of potassium acetate, 52 mg(0.07 mmol) of PdCl₂(dppf), 500 mg (1.43 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzofuran-2-carboxamide(Example 30A), 3.6 ml of 2 M sodium carbonate solution and a further 52mg (0.07 mmol) of PdCl₂(dppf) in 8 ml of DMF are reacted by generalmethod D. Drying under high vacuum results in 455 mg (61% of theory) ofthe title compound.

¹H-NMR (400 MHz, DMSO-d₆): δ=10.45 (s, 1H), 9.10 (d, 1H), 8.02-7.92 (m,3H), 7.78 (d, 1H), 7.71 (d, 1H), 7.60 (d, 2H), 7.45 (t, 1H), 4.35 (m,1H), 3.75-3.35 (m, 11H), 3.25-3.15 (m, 3H), 2.25 (m, 1H), 2.18-2.05 (m,1H), 1.98-1.88 (m, 2H), 1.80-1.63 (m, 1H).

HPLC (method 1): R_(t)=3.79 min.

MS (ESIpos): m/z=460 (M+H)⁺ (free base).

EXAMPLE 105N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[3-(1-piperidinyl)phenyl]-1-benzofuran-2-carboxamideDihydrochloride

311 mg (1.29 mmol) of 3-(1-piperidinyl)phenylboronic acid and 3.44 ml of1N sodium hydroxide solution are added to a mixture of 300 mg (0.86mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzofuran-2-carboxamide(Example 30A) and 63 mg (0.09 mmol) of PdCl₂(dppf) in 4 ml of DMF. Thereaction mixture is heated at 95° C. overnight. The solvent is removedunder reduced pressure, and the crude product is taken up in methanoland filtered through kieselguhr. Purification takes place by preparativeHPLC. The product is dissolved in methanol, and an excess of 1Nhydrochloric acid is added. The solvent is removed under reducedpressure. Drying under high vacuum results in 164 mg (41% of theory) ofthe title compound.

¹H-NMR (200 MHz, DMSO-d₆): δ=10.55 (s, 1H), 9.10 (d, 1H), 8.75 (s, 1H),7.95-7.63 (m, 7H), 7.45 (t, 1H), 4.35 (m, 1H), 4.13-3.40 (m, 7H),3.35-3.10 (m, 3H), 2.15-1.50 (m, 11H).

HPLC (method 1): R_(t)=3.72 min.

MS (ESIpos): m/z=430 (M+H)⁺ (free base).

EXAMPLE 106N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-(3-pyridinyl)-1-benzofuran-2-carboxamideDihydrochloride

70 mg (0.57 mmol) of 3-pyridineboronic acid and 0.86 ml of 1N sodiumhydroxide solution are added to a mixture of 100 mg (0.86 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzofuran-2-carboxamide(Example 30A) and 63 mg (0.09 mmol) of PdCl₂(dppf) in 4 ml of DMF. Thereaction mixture is heated at 95° C. overnight. The solvent is removedunder reduced pressure, and the crude product is taken up in methanoland filtered through kieselguhr. Purification takes place by preparativeHPLC. The product is dissolved in methanol, and an excess of 1Nhydrochloric acid is added. The solvent is removed under reducedpressure. Drying under high vacuum results in 49 mg (45% of theory) ofthe title compound.

¹H-NMR (300 MHz, DMSO-d₆): δ=10.55 (s, 1H), 9.51 (s, 1H), 9.30 (d, 1H),9.20 (s, 1H), 8.94-8.80 (m, 2H), 8.07-7.80 (m, 4H), 7.55 (t, 1H), 4.35(m, 1H), 3.65-3.15 (m, 6H), 2.20 (m, 1H), 2.18-2.05 (m, 1H), 1.98-1.88(m, 2H), 1.80-1.63 (m, 1H).

HPLC (method 1): R_(t)=3.27 min.

MS (ESIpos): m/z=348 (M+H)⁺ (free base).

EXAMPLE 107N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-(3-{[(methylamino)carbonyl]amino}phenyl)-1-benzofuran-2-carboxamideHydrochloride

63 mg (0.18 mmol) of7-(3-aminophenyl)-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2-carboxamide(Example 114), 40 mg (0.70 mmol) of methyl isocyanate and 0.12 ml (0.88mmol) of triethylamine are heated in 3 ml of THF/DMF (1:1) at 40° C.overnight. A further 40 mg (0.70 mmol) of methyl isocyanate and acatalytic amount of DMAP are added, and the mixture is heated at 50° C.overnight. Cooling is followed by addition of water, filtration andremoval of the solvent under reduced pressure. Purification takes placeby preparative HPLC. The product is dissolved in methanol, and an excessof 1N hydrochloric acid is added. The solvent is removed under reducedpressure. Drying under high vacuum results in 18 mg (23% of theory) ofthe title compound.

¹H-NMR (400 MHz, DMSO-d₆): δ=9.98 (s, 1H), 8.85 (s, 1H), 8.63 (d, 1H),8.15 (s, 1H), 7.80 (m, 2H), 7.65 (d, 1H), 7.45 (t, 1H), 7.38 (s, 2H),6.20 (m, 1H), 4.35 (m, 1H), 3.75-3.63 (m, 1H), 3.60-3.15 (m, 5H), 2.65(s, 3H), 2.30 (m, 1H), 2.18-2.05 (m, 1H), 1.98-1.88 (m, 2H), 1.80-1.63(m, 1H).

HPLC (method 1): R_(t)=3.89 min.

MS (ESIpos): m/z=419 (M+H)⁺ (free base).

EXAMPLE 108N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-(3-{[(ethylamino)carbonyl]amino}phenyl)-1-benzofuran-2-carboxamideHydrochloride

63 mg (0.18 mmol) of7-(3-aminophenyl)-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2-carboxamide(Example 114), 50 mg (0.70 mmol) of ethyl isocyanate and 0.12 ml (0.88mmol) of triethylamine are heated in 3 ml of THF/DMF (1:1) at 40° C.overnight. A further 50 mg (0.70 mmol) of ethyl isocyanate and acatalytic amount of DMAP are added, and the mixture is heated at 50° C.overnight. Cooling is followed by addition of water, filtration andremoval of the solvent under reduced pressure. Purification takes placeby preparative HPLC. The product is dissolved in methanol, and an excessof 1N hydrochloric acid is added. The solvent is removed under reducedpressure. Drying under high vacuum results in 15 mg (18% of theory) ofthe title compound.

¹H-NMR (400 MHz, DMSO-d₆): δ=9.80 (s, 1H), 8.74 (s, 1H), 8.63 (d, 1H),8.10 (s, 1H), 7.80 (m, 2H), 7.60 (d, 1H), 7.45 (t, 1H), 7.38 (s, 2H),6.20 (m, 1H), 4.35 (m, 1H), 3.75-3.63 (m, 1H), 3.60-3.15 (m, 5H), 3.10(m, 2H), 2.65 (s, 3H), 2.30 (m, 1H), 2.18-2.05 (m, 1H), 1.98-1.88 (m,2H), 1.80-1.63 (m, 1H), 1.05 (t, 3H).

HPLC (method 1): R_(t)=4.01 min.

MS (ESIpos): m/z=433 (M+H)⁺ (free base).

EXAMPLE 109N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[3-({[(1-methylethy)amino]carbonyl}-amino)phenyl]-1-benzofuran-2-carboxamideHydrochloride

50 mg (0.14 mmol) of7-(3-aminophenyl)-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2-carboxamide(Example 114), 47 mg (0.55 mmol) of isopropyl isocyanate and 0.12 ml(0.88 mmol) of triethylamine are heated in 3 ml of THF/DMF (1:1) at 40°C. overnight. A further 47 mg (0.55 mmol) of isopropyl isocyanate and acatalytic amount of DMAP are added, and the mixture is heated at 50° C.overnight. Cooling is followed by addition of water, filtration andremoval of the solvent under reduced pressure. Purification takes placeby preparative HPLC. The product is dissolved in methanol, and an excessof 1N hydrochloric acid is added. The solvent is removed under reducedpressure. Drying under high vacuum results in 13 mg (18% of theory) ofthe title compound.

¹H-NMR (400 MHz, DMSO-d₆): δ=9.80 (s, 1H), 8.70 (d, 1H), 8.65 (s, 1H),8.05 (s, 1H), 7.80 (m, 2H), 7.60 (d, 1H), 7.45 (t, 1H), 7.38 (s, 2H),6.20 (m, 1H), 4.35 (m, 1H), 3.80-3.72 (m, 1H), 3.70-3.63 (m, 1H),3.50-3.05 (m, 5H), 2.30 (m, 1H), 2.18-2.05 (m, 1H), 1.98-1.88 (m, 2H),1.80-1.63 (m, 1H), 1.10 (d, 6H).

HPLC (method 1): R_(t)=4.12 min.

MS (ESIpos): m/z=447 (M+H)⁺ (free base).

EXAMPLE 110N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[3-({[(1,1-dimethylethyl)amino]carbonyl}-amino)phenyl]-1-benzofuran-2-carboxamideHydrochloride

63 mg (0.14 mmol) of7-(3-aminophenyl)-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2-carboxamide(Example 114), 69 mg (0.70 mmol) of tert-butyl isocyanate and 0.12 ml(0.88 mmol) of triethylamine are heated in 3 ml of THF/DMF (1:1) at 40°C. overnight. A further 69 mg (0.70 mmol) of tert-butyl isocyanate and acatalytic amount of DMAP are added, and the mixture is heated at 50° C.overnight. Cooling is followed by addition of water, filtration andremoval of the solvent under reduced pressure. Purification takes placeby preparative HPLC. The product is dissolved in methanol, and an excessof 1N hydrochloric acid is added. The solvent is removed under reducedpressure. Drying under high vacuum results in 8 mg (9% of theory) of thetitle compound.

¹H-NMR (400 MHz, DMSO-d₆): δ=9.70 (s, 1H), 8.80 (d, 1H), 8.55 (s, 1H),7.85 (s, 1H), 7.80 (m, 2H), 7.60 (d, 1H), 7.45 (t, 1H), 7.38 (s, 2H),6.10 (m, 1H), 4.35 (m, 1H), 3.70-3.63 (m, 1H), 3.50-105 (m, 5H), 2.30(m, 1H), 2.18-2.05 (m, 1H), 1.98-1.88 (m, 2H), 1.80-1.63 (m, 1H), 1.30(s, 9H).

HPLC (method 1): R_(t)=4.27 min.

MS (ESIpos): m/z=461 (M+H)⁺ (free base).

EXAMPLE 111N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-{3-[(methylsulphonyl)amino]phenyl}-1-benzofuran-2-carboxamideHydrochloride

73 mg (0.20 mmol) of7-(3-aminophenyl)-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2-carboxamide(Example 114), 69 mg (0.61 mmol) of methansulphonyl chloride and 0.14 ml(1.01 mmol) of triethylamine are heated in 3 ml of THF/DMF (1:1) at 50°C. overnight. Cooling is followed by addition of water, filtration andremoval of the solvent under reduced pressure. Purification takes placeby preparative HPLC. The product is dissolved in methanol, and an excessof 1N hydrochloric acid is added. The solvent is removed under reducedpressure. Drying under high vacuum results in 16 mg (14% of theory) ofthe title compound.

¹H-NMR (300 MHz, DMSO-d₆): δ=10.15 (s, 1H), 9.90 (s, 1H), 8.76 (d, 1H),7.90 (s, 1H), 7.85-7.75 (m, 2H), 7.66-7:60 (m, 2H), 7.55-7.53 (m, 2H),7.25 (m, 1H), 4.37 (m, 1H), 3.70-3.63 (m, 1H), 3.45-3.05 (m, 5H), 3.10(s, 3H), 2.30 (m, 1H), 2.18-2.05 (m, 1H), 1.98-1.88 (m, 2H), 1.80-1.63(m, 1H).

HPLC (method 1): R_(t)=3.97 min.

MS (ESIpos): m/z=440 (M+H)⁺ (free base).

EXAMPLE 112N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-{2-[(cyclobutylcarbonyl)amino]phenyl}-1-benzofuran-2-carboxamideHydrochloride

60 mg (0.15 mmol) of7-(2-aminophenyl)-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2-carboxamide(Example 132), 26 mg (0.22 mmol) of cyclobutanecarbonyl chloride and0.06 ml (0.44 mmol) of triethylamine are shaken in 2 ml of THF/DMF (1:1)at RT overnight. The solvent is removed under reduced pressure.Purification takes place by preparative HPLC. The product is dissolvedin methanol, and an excess of 1N hydrochloric acid is added. The solventis removed under reduced pressure. Drying under high vacuum results in39 mg (56% of theory) of the title compound.

¹H-NMR (300 MHz, DMSO-d₆): δ=10.15 (s, 1H), 9.05 (s, 1H), 8.40 (d, 1H),7.95 (s, 1H), 7.80-7.70 (m, 2H), 7.55-7.30 (m, 6H), 4.32 (m, 1H),3.70-3.63 (m, 1H), 3.45-3.05 (m, 5H), 2.98-2.88 (m, 1H), 2.30 (m, 1H),2.18-2.05. (m, 1H), 1.98-1.55 (m, 9H).

HPLC (method 1): R_(t)=3.95 min.

MS (ESIpos): m/z=444 (M+H)⁺ (free base).

EXAMPLE 113N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-5-(5-pyrimidinyl)-1-benzofuran-2-carboxamideHydrochloride

177 mg (0.86 mmol) of5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine and 2.15 ml of1N sodium hydroxide solution are added to a mixture of 250 mg (0.72mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-5-bromo-1-benzofuran-2-carboxamide(Example 3A) and 52 mg (0.07 mmol) of PdCl₂(dppf) in 3 ml of DMF. Thereaction mixture is heated at 90° C. overnight. The solvent is removedunder reduced pressure, and the crude product is taken up in methanoland filtered through kieselguhr. Purification takes place by preparativeHPLC. The product is dissolved in methanol, and an excess of 1Nhydrochloric acid is added. The solvent is removed under reducedpressure. Recrystallization of the residue from isopropanol and dryingunder high vacuum results in 28 mg (10% of theory) of the titlecompound.

¹H-NMR (300 MHz, DMSO-d₆): δ=10.30 (s, 1H), 9.22-9.13 (m, 4H), 8.24 (m,1H), 7.93-7.81 (m, 3H), 4.39 (m, 1H), 3.68-3.48 (m, 1H), 3.45-3.13 (m,5H), 2.28-2.20 (m, 1H), 2.18-2.07 (m, 1H), 1.97-1.88 (m, 2H), 1.80-1.57(m, 1H).

HPLC (method 1): R_(t)=3.26 min.

MS (ESIpos): m/z=349 (M+H)⁺ (free base).

EXAMPLE 1147-(3-Aminophenyl)-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2-carboxamide

Method a):

622 mg (1.68 mmol) of 3-aminophenylboronic acid hemisulphate and 11.2 mlof 1N sodium hydroxide solution are added to a mixture of 978 mg (2.80mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzofuran-2-carboxamide(Example 30A) and 205 mg (0.28 mmol) of PdCl₂(dppf) in 15 ml of DMF. Thereaction mixture is heated at 95° C. overnight. The crude product isfiltered through kieselguhr, washed with DMF and freed of solvent underreduced pressure. The residue is mixed with 200 ml of 1N sodiumhydroxide solution and 200 ml of ethyl acetate. After separation of thephases, the organic phase is washed twice more with 100 ml of 1N sodiumhydroxide solution each time and then once more with 100 ml of asaturated sodium chloride solution. Drying over magnesium sulphate isfollowed by purification of the crude product by preparative HPLC. Afterremoval of the solvent in a rotary evaporator it is possible to obtain875 mg (73% of theory) of the title compound in the form of a white foamby twice adding dichloromethane and concentrating again.

¹H-NMR (300 MHz, DMSO-d₆): δ=8.48 (d, 1H), 8.21 (s, 1H), 7.76-7.69 (m,1H), 7.54 (d, 1H), 7.45-7.37 (m, 1H), 7.20-7.00 (m, 3H); 6.67-6.61 (m,1H), 4.13-4.06 (m, 1H), 3.48-3.26 (m, 1H), 3.10-3.01 (m, 1H), 2.93-2.79(m, 4H), 2.03 (m, 1H), 2.00-1.88 (m, 1H), 1.79-1.67 (m, 2H), 1.58-1.42(m, 1H).

HPLC (method 1): R_(t)=3.46 min.

MS (ESIpos): m/z=362 (M+H)⁺.

Method b):

419 mg (1.13 mmol) of bis[3-(dihydroxyboranyl)anilinium]sulphate and7.56 ml of 1N sodium hydroxide solution are added to a mixture of 660 mg(1.89 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzofuran-2-carboxamide(Example 30A) and 138 mg (0.19 mmol) of PdCl₂(dppf) in 8 ml of DMF. Thereaction mixture is heated at 95° C. overnight. The solvent is removedunder reduced pressure, and the crude product is taken up in methanoland filtered through kieselguhr. Further purification takes place bypreparative HPLC. The solvent is removed from the product fractionsunder reduced pressure. Drying under high vacuum results in 485 mg (71%of theory) of the title compound.

¹H-NMR (300 MHz, DMSO-d₆): δ=8.48 (d, 1H), 8.21 (s, 1H), 7.70 (s, 1H),7.55 (m, 1H), 7.40 (t, 1H), 7.18 (t, 1H), 7.10-7.00 (m, 2H), 6.66 (m,1H), 4.20 (br. s, 2H), 4.05 (m, 1H), 3.25 (m, 1H), 3.05 (m, 1H),2.90-2.70 (m, 4H), 2.05 (m, 1H), 1.70 (m, 1H), 1.65 (m, 2H), 1.45 (m,1H).

HPLC (method 1): R_(t)=3.50 min.

MS (ESIpos): m/z=362 (M+H)⁺.

EXAMPLE 1157-[3-(Acetylamino)phenyl]-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2-carboxamideHydrochloride

75 mg (0.16 mmol) of7-(3-aminophenyl)-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2-carboxamide(Example 114), 18 μl (0.24 mmol) of acetyl chloride and 68 μl (0.49mmol) of triethylamine are stirred in 2 ml of THF at RT overnight. Thesolvent is removed under reduced pressure. Purification takes place bypreparative HPLC. The product is dissolved in methanol, and an excess of1N hydrochloric acid is added. Removal of the solvent under reducedpressure and drying under high vacuum results in 51 mg (72% of theory)of the title compound.

¹H-NMR (300. MHz, DMSO-d₆): δ=10.37 (s, 1H), 10.30 (br. s, 1H),8.67-8.59 (m, 2H), 7.82-7.68 (m, 3H), 7.58-7.41 (m, 4H), 4.40 (m, 1H),3.73-3.60 (m, 1H), 3.48-3.37 (m, 1H), 3.78-3.15 (m, 4H), 2.29 (m, 1H),2.19-2.09 (m, 1H), 2.13 (s, 3H), 1.98-1.90 (m, 2H), 1.81-1.69 (m, 1H).

HPLC (method 1): R_(t)=4.04 min.

MS (ESIpos): m/z=404 (M+H)⁺ (free base).

EXAMPLE 116N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-{3-[(cyclopropylcarbonyl)amino]phenyl}-benzofuran-2-carboxamideHydrochloride

75 mg (0.21 mmol) of7-(3-aminophenyl)-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2-carboxamide(Example 114), 28 μl (0.31 mmol) of cyclopropylcarbonyl chloride and 87μl (0.62 mmol) of triethylamine are stirred in 2 ml of THF at RTovernight. After addition of water, the solvent is removed under reducedpressure. Purification takes place by preparative HPLC. The product isdissolved in methanol, and an excess of 1N hydrochloric acid is added.Removal of the solvent under reduced pressure and drying under highvacuum result in 55 mg (57% of theory) of the title compound.

¹H-NMR (300 MHz, DMSO-d₆): δ=10.53 (s, 1H), 10.08 (br. s, 1H), 8.83 (m,1H), 8.28 (s, 1H), 7.82-7.75 (m, 2H), 7.71 (d, 1H), 7.62 (d, 1H),7.58-7.50 (m, 1H), 7.48-7.41 (m, 2H), 4.38 (m, 1H), 3.71-3.60 (m, 1H),3.50-3.15 (m, 5H), 2.27 (m, 1H), 2.21-2.11 (m, 1H), 1.99-1.82 (m, 3H),1.80-1.71 (m, 1H), 0.88-0.77 (m, 4H).

HPLC (method 1): R_(t)=4.07 min.

MS (ESIpos): m/z=430 (M+H)⁺ (free base).

EXAMPLE 117N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-(3-{[(methoxy)acetyl]amino}phenyl)-1-benzofuran-2-carboxamideHydrochloride

75 mg (0.21 mmol) of7-(3-aminophenyl)-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2-carboxamide(Example 114), 21 μl (0.31 mmol) of methoxyacetyl chloride and 87 μl(0.62 mmol) of triethylamine are stirred in 2 ml of THF at RT overnight.After addition of water, the solvent is removed under reduced pressure.Purification takes place by preparative HPLC. The product is dissolvedin methanol, and an excess of 1N hydrochloric acid is added. Removal ofthe solvent under reduced pressure and drying under high vacuum resultin 56 mg (55% of theory) of the title compound.

¹H-NMR (300 MHz, DMSO-d₆): δ=10.17 (br. s, 1H), 10.10 (s, 1H), 8.63-8.55(m, 2H), 7.82-7.68 (m, 3H), 7.64-7.57 (m, 2H), 7.52-7.41 (m, 2H), 4.39(m, 1H), 4.10 (s, 2H), 3.71-3.61 (m, 1H), 3.49-3.14 (m, 5H), 3.41 (s,3H), 2.29 (m, 1H), 2.19-2.05 (m, 1H), 1.99-1.89 (m, 2H), 1.80-1.69 (m,1H).

HPLC (method 1): R_(t)=0.4.07 min.

MS (ESIpos): m/z=434 (M+H)⁺ (free base).

EXAMPLE 118N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-{3-[(cyclobutylcarbonyl)amino]phenyl}-1-benzofuran-2-carboxamideHydrochloride

75 mg (0.21 mmol) of7-(3-aminophenyl)-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2-carboxamide(Example 114), 37 mg (0.31 mmol) of cyclobutanecarbonyl chloride and 87μl (0.62 mmol) of triethylamine are stirred in 2 ml of THF at RTovernight. After addition of water, the solvent is removed under reducedpressure. Purification takes place by preparative HPLC. The product isdissolved in methanol, and an excess of 1N hydrochloric acid is added.Removal of the solvent under reduced pressure and drying under highvacuum result in 57 mg (57% of theory) of the title compound.

¹H-NMR (300 MHz, DMSO-d₆): δ=10.14 (br. s, 1H), 10.07 (s, 1H), 8.82 (d,1H), 8.35 (s, 1H), 7.80-7.78 (m, 2H), 7.74-7.61 (m, 2H), 7.57-7.41 (m,3H), 4.36 (m, 1H), 3.70-3.61 (m, 1H), 3.45-3.13 (m, 5H), 2.30-1.67 (m,12H).

HPLC (method 1): R_(t)=4.22 min.

MS (ESIpos): m/z=444 (M+H)⁺ (free base).

EXAMPLE 119N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-{2-[(cyclopropylcarbonyl)amino]phenyl}-1-benzofuran-2-carboxamideHydrochloride

60 mg (0.15 mmol) of7-(2-aminophenyl)-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2-carboxamide(Example 132), 20 μl (0.31 mmol) of cyclopropylcarbonyl chloride and 87μl (0.62 mmol) of triethylamine are stirred in 2 ml of THF/DMF (1:1) atRT overnight. After addition of water, the solvent is removed underreduced pressure. Purification takes place by preparative HPLC. Theproduct is dissolved in methanol, and an excess of 1N hydrochloric acidis added. Removal of the solvent under reduced pressure and drying underhigh vacuum result in 27 mg (40% of theory) of the title compound.

¹H-NMR (300 MHz, DMSO-d₆): δ=10.07 (br. s, 1H), 9.48 (s, 1H), 8.84 (d,1H), 7.83-7.77 (m, 1H), 7.72 (m, 1H), 7.54-7.31 (m, 6H), 4.30 (m, 1H),3.70-3.61 (m, 1H), 3.37-3.03 (m, 5H), 2.23 (m, 1H), 2.14-2.03 (m, 1H),1.95-1.83 (m, 2H), 1.79-1.68 (m, 1H), 1.53 (m, 1H), 1.31-1.15 (m, 4H).

HPLC (method 1): R_(t)=3.85 min.

MS (ESIpos): m/z=430 (M+H)⁺ (free base).

EXAMPLE 120N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-(2-{[(methoxy)acetyl]amino}phenyl)-1-benzofuran-2-carboxamideHydrochloride

60 mg (0.15 mmol) of7-(2-aminophenyl)-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2-carboxamide(Example 132), 20 μl (0.22 mmol) of methoxyacetyl chloride and 61 μl(0.44 mmol) of triethylamine are stirred in 2 ml of THF/DMF (1:1) at RTovernight. After addition of water, the solvent is removed under reducedpressure. Purification takes place by preparative HPLC. The product isdissolved in methanol, and an excess of 1N hydrochloric acid is added.Removal of the solvent under reduced pressure and drying under highvacuum result in 29 mg (40% of theory) of the title compound.

¹H-NMR (300 MHz, DMSO-d₆): δ=10.15 (br. s, 1H), 9.05 (s, 1H), 8.53 (d,1H), 7.88-7.73 (m, 3H), 7.52-7.34 (m, 5H), 4.33 (m, 1H), 3.77 (s, 2H),3.69-3.59 (m, 1H), 3.44-3.14 (m, 5H), 3.04 (s, 3H), 2.22 (m, 1H),2.18-2.05 (m, 1H), 1.96-1.84 (m, 2H), 1.80-1.67 (m, 1H).

HPLC (method 1): R_(t)=3.84 min.

MS (ESIpos): m/z=434 (M+H)⁺ (free base).

EXAMPLE 121N-[(3S)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[4-(4-morpholinyl)phenyl]-1-benzofuran-2-carboxamideHydrochloride

107 mg (0.52 mmol) of 4-morpholinophenylboronic acid and 1.72 ml of 1Nsodium hydroxide solution are added to a mixture of 150 mg (0.43 mmol)ofN-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzofuran-2-carboxamide(Example 31A) and 35 mg (0.04 mmol) of PdCl₂(dppf) in 4 ml of DMF. Thereaction mixture is heated at 95° C. overnight. The crude product isfiltered through kieselguhr, and, after washing with DMF, the solvent isremoved under reduced pressure. To remove the last residues of catalyst,a further filtration through silica gel is carried out, washing withdichloromethane and methanol. The crude product is purified bypreparative HPLC. The product is dissolved in methanol, and an excess of1N hydrochloric acid is added. Removal of the solvent under reducedpressure and drying under high vacuum result in 84 mg (42% of theory) ofthe title compound.

¹H-NMR (300 MHz, DMSO-d₆): δ=10.48 (br. s, 1H), 9.05 (d, 1H), 7.90-7.82(m, 3H), 7.70 (d, 1H), 7.63 (d, 1H), 7.42-7.35 (m, 1H), 7.20-7.12 (m,2H), 4.40-4.31 (m, 1H), 3.84-3.77 (m, 4H), 3.69-3.57 (m, 1H), 3.48-3.12(m, 9H), 2.22 (m, 1H), 2.19-2.08 (m, 1H), 1.96-1.85 (m, 2H), 1.80-1.71(m, 1H).

HPLC (method 1): R_(t)=3.82 min.

MS (ESIpos): m/z=432 (M+H)⁺.

EXAMPLE 122N-[(3S)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[2-(hydroxymethyl)phenyl]-1-benzofuran-2-carboxamideHydrochloride

78 mg (0.52 mmol) of 2-(hydroxymethyl)phenylboronic acid and 1.72 ml of1N sodium hydroxide solution are added to a mixture of 150 mg (0.43mmol) ofN-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzofuran-2-carboxamide(Example 31A) and 35 mg (0.04 mmol) of PdCl₂(dppf) in 3 ml of DMF. Thereaction mixture is heated at 95° C. overnight. The crude product isfiltered through kieselguhr, and, after washing with DMF, the solvent isremoved under reduced pressure. To remove the last residues of catalyst,a further filtration through silica gel is carried out, washing withdichloromethane and methanol. The crude product is purified bypreparative HPLC. The product is dissolved in methanol, and an excess of1N hydrochloric acid is added. Removal of the solvent under reducedpressure and drying under high vacuum result in 81 mg (46% of theory) ofthe title compound.

¹H-NMR (300 MHz, DMSO-d₆): δ=10.12 (br. s, 1H), 8.94 (d, 1H), 7.91-7.79(m, 3H), 7.69 (d, 1H), 7.53-7.32 (m, 5H), 4.33-4.22 (m, 3H), 3.68-3.57(m, 1H), 3.48-3.12 (m, 5H), 2.19 (m, 1H), 2.15-2.04 (m, 1H), 1.94-1.83(m, 2H), 1.79-1.67 (m, 1H).

HPLC (method 1): R_(t)=3.87 min.

MS (ESIpos): m/z=377 (M+H)⁺.

EXAMPLE 123N-[(3S)-1-Azabicyclo[2.2.2]oct-3-yl]-7-(3-pyridinyl)-1-benzofuran-2-carboxamideHydrochloride

63 mg (0.57 mmol) of 3-pyridineboronic acid, and 1.72 ml of 1N sodiumhydroxide solution are added to a mixture of 150 mg (0.43 mmol) ofN-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzofuran-2-carboxamide(Example 31A) and 35 mg (0.04 mmol) of PdCl₂(dppf) in 4 ml of DMF. Thereaction mixture is heated at 95° C. overnight. The solvent is removedunder reduced pressure and the crude product is taken up in methanol andfiltered through kieselguhr. To remove the last residues of catalyst, afurther filtration through silica gel is carried out, washing withdichloromethane and methanol. Purification takes place by preparativeHPLC. The product is dissolved in methanol, and an excess of 1Nhydrochloric acid is added. The solvent is removed under reducedpressure. Drying under high vacuum results in 76 mg (42% of theory) ofthe title compound.

¹H-NMR (300 MHz, DMSO-d₆): δ=10.49 (s, 1H), 9.51 (s, 1H), 9.30 (d, 1H),8.94-8.80 (m, 2H), 8.07-7.80 (m, 4H), 7.55 (t, 1H), 4.35 (m, 1H),3.65-3.15 (m, 6H), 2.20 (m, 1H), 2.18-2.05 (m, 1H), 1.98-1.88 (m, 2H),1.80-1.63 (m, 1H).

HPLC (method 1): R_(t)=3.30 min.

MS (ESIpos): m/z=348 (M+H)⁺ (free base).

EXAMPLE 124N-[(3S)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[4-(methoxy)phenyl]-1-benzofuran-2-carboxamideHydrochloride

78 mg (0.52 mmol) of 4-(methoxy)phenylboronic acid and 1.72 ml of 1Nsodium hydroxide solution are added to a mixture of 150 mg (0.43 mmol)ofN-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzofuran-2-carboxamide(Example 31A) and 35 mg (0.04 mmol) of PdCl₂(dppf) in 4 ml of DMF. Thereaction mixture is heated at 95° C. overnight. The solvent is removedunder reduced pressure and the crude product is taken up in methanol andfiltered through kieselguhr. To remove the last residues of catalyst, afurther filtration through silica gel is carried out, washing withdichloromethane and methanol. Purification takes place by preparativeHPLC. An excess of 1N hydrochloric acid is added to the productfractions. The solvent is removed under reduced pressure. Drying underhigh vacuum results in 27 mg (15% of theory) of the title compound.

The analytical data agree with those of the enantiomeric compound(Example 99).

EXAMPLE 125N-[(3S)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[3-(methoxy)phenyl]-1-benzofuran-2-carboxamideHydrochloride

78 mg (0.52 mmol) of 3-(methoxy)phenylboronic acid and 1.72 ml of 1Nsodium hydroxide solution are added to a mixture of 150 mg (0.43 mmol)ofN-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzofuran-2-carboxamide(Example 31A) and 35 mg (0.04 mmol) of PdCl₂(dppf) in 3 ml of DMF. Thereaction mixture is heated at 95° C. overnight. The solvent is removedunder reduced pressure and the crude product is taken up in methanol andfiltered through kieselguhr. To remove the last residues of catalyst, afurther filtration through silica gel is carried out, washing withdichloromethane and methanol. Purification takes place by preparativeHPLC. The product is dissolved in methanol, and an excess of 1Nhydrochloric acid is added. The solvent is removed under reducedpressure. Drying under high vacuum results in 23 mg (13% of theory) ofthe title compound.

The analytical data agree with those of the enantiomeric compound(Example 101).

EXAMPLE 126N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[2-({[(1-methylethyl)amino]carbonyl}-amino)phenyl]-1-benzofuran-2-carboxamideHydrochloride

75 mg (0.16 mmol) of7-(2-aminophenyl)-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2-carboxamide(Example 132), 65 μl (0.66 mmol) of isopropyl isocyanate and 114 μl(0.82 mmol) of triethylamine are heated in 3 ml of THF/DMF (1:1) at 50°C. for 48 h. Cooling is followed by addition of water, filtration andremoval of the solvent under reduced pressure. Purification takes placeby preparative HPLC. The product is dissolved in methanol, and an excessof 1N hydrochloric acid is added. The solvent is removed under reducedpressure. Drying under high vacuum results in 21 mg (26% of theory) ofthe title compound.

¹H-NMR (300 MHz, DMSO-d₆): δ=10.09 (br. s, 1H), 8.60 (d, 1H), 7.88-7.77(m, 3H), 7.46-7.33 (m, 3H), 7.29 (dd, 1H), 7.19-7.10 (m, 1H), 6.22 (br.s, 1H), 4.29 (m, 1H), 3.75-3.54 (m, 2H), 3.39-3.13 (m, 5H), 2.22 (m,1H), 2.15-2.02 (m, 1H), 1.96-1.86 (m, 2H), 1.80-1.69 (m, 1H), 0.96 (d,6H).

HPLC (method 1): R_(t)=3.92 min.

MS (ESIpos): m/z=447 (M+H)⁺ (free base).

EXAMPLE 127N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-(2-{[(ethylamino)carbonyl]amino}phenyl)-1-benzofuran-2-carboxamideHydrochloride

75 mg (0.16 mmol) of7-(2-aminophenyl)-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2-carboxamide(Example 132), 50 μl (0.66 mmol) of ethyl isocyanate and 110 μl (0.82mmol) of triethylamine are heated together with a catalytic amount ofDMAP in 3 ml of THF/DMF (1:1) at 50° C. for 48 h. Cooling is followed byaddition of water, filtration and removal of the solvent under reducedpressure. Purification takes place by preparative HPLC. The product isdissolved in methanol, and an excess of 1N hydrochloric acid is added.The solvent is removed under reduced pressure. Drying under high vacuumresults in 10 mg (12% of theory) of the title compound.

¹H-NMR (300 MHz, DMSO-d₆): δ=10.41 (br. s, 1H), 9.30 (d, 1H), 8.69 (d,1H), 7.96-7.78 (m, 3H), 7.59-7.11 (m, 4H), 4.30 (m, 1H), 3.69-3.54 (m,1H), 3.40-3.13 (m, 5H), 2.99 (q, 2H), 2.24-2.19 (m, 1H), 2.17-2.04 (m,1H), 1.96-1.84 (m, 2H), 1.80-1.64 (m, 1H), 0.92 (t, 3H).

HPLC (method 1): R_(t)=3.86 min.

MS (ESIpos): m/z=433 (M+H)⁺ (free base).

EXAMPLE 128N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-(2-{[(methylamino)carbonyl]amino}phenyl)-1-benzofuran-2-carboxamideHydrochloride

75 mg (0.16 mmol) of7-(2-aminophenyl)-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2-carboxamide(Example 132), 37 mg (0.66 mmol) of methyl isocyanate and 110 μl (0.82mmol) of triethylamine are heated together with a catalytic amount ofDMAP in 3 ml of THF/DMF (1:1) at 50° C. overnight. Cooling is followedby addition of water, filtration and removal of the solvent underreduced pressure. Purification takes place by preparative HPLC. Theproduct is dissolved in methanol, and an excess of 1N hydrochloric acidis added. The solvent is removed under reduced pressure. Drying underhigh vacuum results in 29 mg (35% of theory) of the title compound.

¹H-NMR (300 MHz, DMSO-d₆): δ=10.22 (br. s, 1H), 8.60 (d, 1H), 8.69 (d,1H), 7.86-7.74 (m, 3H), 7.51-7.28 (m, 5H), 7.18-7.11 (m, 1H), 6.21 (br.s, 1H), 4.29 (m, 1H), 3.69-3.58 (m, 1H), 3.38-3.13 (m, 5H), 2.51 (s,3H), 2.28-2.22 (m, 1H), 2.18-2.04 (m, 1H), 1.99-1.87 (m, 2H), 1.82-1.68(m, 1H).

HPLC (method 1): R_(t)=3.72 min.

MS (ESIpos): m/z=419 (M+H)⁺ (free base).

EXAMPLE 129N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[2-({[(1,1-dimethylethyl)amino]carbonyl}-amino)phenyl]-1-benzofuran-2-carboxamideHydrochloride

75 mg (0.16 mmol) of7-(2-aminophenyl)-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2-carboxamide(Example 132), 65 mg (0.66 mmol) of 1,1-dimethylethyl isocyanate and 110μl (0.82 mmol) of triethylamine are heated together with a catalyticamount of DMAP in 3 ml of THF/DMF (1:1) at 50° C. overnight. Cooling isfollowed by addition of water, filtration and removal of the solventunder reduced pressure. Purification takes place by preparative HPLC.The product is dissolved in methanol, and an excess of 1N hydrochloricacid is added. The solvent is removed under reduced pressure. Dryingunder high vacuum results in 10 mg (12% of theory) of the titlecompound.

HPLC (method 1): R_(t)=4.06 min.

MS (ESIpos): m/z=461 (M+H)⁺ (free base).

EXAMPLE 130N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide

600 mg (1.45 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamidehydrochloride (Example 102) are dissolved in 15 ml of ethyl acetate andextracted three times with 1N sodium hydroxide solution. The organicphase is dried over sodium sulphate and then concentrated. Drying underhigh vacuum results in 534 mg (97.6% of theory) of the title compound.

¹H-NMR (200 MHz, DMSO-d₆): δ=8.34 (d, 1H), 7.72 (dd, 1H), 7.70 (s, 1H),7.50-7.30 (m, 4H), 7.20 (m, 1H), 7.08 (m, 1H), 3.93 (m, 1H), 3.76 (s,3H), 3.11 (m, 1H), 2.86 (m, 1H), 2.69 (m, 4H), 1.86 (m, 1H), 1.75 (m,1H), 1.58 (m, 2H), 1.32 (m, 1H).

HPLC (method 1): R_(t)=4.1 min.

MS (ESIpos): m/z=377 (M+H)⁺.

EXAMPLE 131N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[2-(hydroxymethyl)phenyl]-1-benzothiophene-2-carboxamideHydrochloride

200 mg (0.45 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzothiophene-2-carboxamidehydrochloride (Example 8A) and 67.9 mg (0.45 mmol) of2-(hydroxymethyl)phenylboronic acid are introduced into 2 ml of DMF.Addition of 0.67 ml of 2 M sodium carbonate solution and 18.2 mg (0.02mmol) of PdCl₂(dppf) is followed by heating at 80° C. After 18 h, thereaction mixture is filtered through kieselguhr and purified byseparation by preparative HPLC. The product fractions are concentratedand, after addition of a 5:1 mixture of methanol and 4N hydrogenchloride in dioxane, again concentrated. Drying under high vacuumresults in 148 mg (72% of theory) of the title compound.

¹H-NMR (300 MHz, DMSO-d₆): δ=10.30 (br. s, 1H), 9.10 (d, 1H), 8.47 (s,1H), 8.07 (d, 1H), 7.78 (d, 1H), 7.68-7.54 (m, 2H), 7.52-7.39 (m, 3H),4.40 (m, 1H), 4.36 (s, 2H); 3.72 (m, 1H), 3.53-3.20 (m, 5H), 2.29 (m,1H), 2.21 (m, 1H), 2.00 (m, 2H), 1.82 (m, 1H).

HPLC (method 1): R_(t)=3.9 min.

MS (ESIpos): m/z=393 (M+H)⁺ (free base).

EXAMPLE 1327-(2-Aminophenyl)-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2-carboxamide

752 mg (3.44 mmol) of2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenylamine and 11.45 mlof 1N sodium hydroxide solution are added to a mixture of 1.0 g (2.86mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzofuran-2-carboxamide(Example 30A) and 234 mg (0.29 mmol) of PdCl₂(dppf) in 15 ml of DMF. Thereaction mixture is heated at 95° C. overnight and then filtered throughkieselguhr. The solvent is then removed under reduced pressure, and theresidue is taken up in 100 ml of ethyl acetate and 100 ml of 1N sodiumhydroxide solution. The organic phase is washed twice with 1N sodiumhydroxide solution and once with saturated sodium chloride solution. Thecombined organic phases are dried over magnesium sulphate, and thesolvent is removed in a rotary evaporator under reduced pressure. Thecrude product is taken up in methanol and shaken together with acidicion exchanger (Dowex® WX2-200) for about 30 min. The loaded ionexchanger is washed three times with 30 ml of methanol each time andthen with DMF. It is washed successively with methanol, dichloromethane,methanol, water, methanol, dichloromethane, methanol, THF and finallyonce again with methanol. The product is eluted withmethanol/triethylamine 95:5. The solvent is removed in a rotaryevaporator under reduced pressure. Drying under high vacuum results in601 mg (48% of theory) of the title compound in sufficient purity forfurther reactions.

HPLC (method 1): R_(t)=3.51 min.

MS (ESIpos): m/z=362 (M+H)⁺.

EXAMPLE 133N-[(3S)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[4-(4-morpholinylcarbonyl)phenyl]-1-benzothiophene-2-carboxamideHydrochloride

244.0 mg (0.65 mmol) of 4-(4-morpholinylcarbonyl)phenyltrifluoromethane-sulphonate (Example 18A), 189.6 mg (0.75 mmol) ofbis(pinacolato)diboron, 158.8 mg (1.62 mmol) of potassium acetate, 18.2mg (0.02 mmol) of PdCl₂(dppf), 200.0 mg (0.50 mmol) ofN-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzothiophene-2-carboxamidehydrochloride (Example 22A), 1.24 ml of 2 M sodium carbonate solutionand a further 18.2 mg (0.02 mmol) of PdCl₂(dppf) in 2.5 ml of DMF arereacted by general method D. Drying under high vacuum results in 76.8 mg(30.1% of theory) of the title compound.

The spectroscopic data agree with those of the enantiomeric compound(Example 72).

EXAMPLE 134N-[(3S)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[3-(4-morpholinyl)phenyl]-1-benzothiophene-2-carboxamideHydrochloride

143.3 mg (0.49 mmol) of 3-(4-morpholinyl)phenyltrifluoromethanesulphonate (Example 17A), 142.2 mg (0.56 mmol) ofbis(pinacolato)diboron, 119.1 mg (1.21 mmol) of potassium acetate, 13.7mg (0.02 mmol) of PdCl₂(dppf), 150 mg (0.37 mmol) ofN-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzothiophene-2-carboxamidehydrochloride (Example 22A), 0.93 ml of 2 M sodium carbonate solutionand a further 13.7 mg (0.02 mmol) of PdCl₂(dppf) in 2.0 ml of DMF arereacted by general method D. Drying under high vacuum results in 67 mg(37.1% of theory) of the title compound.

The spectroscopic data agree with those of the enantiomeric compound(Example 70).

EXAMPLE 135N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-{(3-[(cyclopropylamino)carbonyl]phenyl}-1-benzothiophene-2-carboxamideHydrochloride

50 mg (0.11 mmol) of3-(2-{[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]carbonyl}-1-benzothien-7-yl)benzoicacid hydrochloride (Example 75) and 12.9 mg (0.23 mmol) ofcyclopropylamine are reacted together by general method E. 17.6 mg(31.1% of theory) of the title compound are obtained.

¹H-NMR (400 MHz, methanol-d₄): δ=8.18 (s, 1H), 8.15 (s, 1H), 7.93 (d,1H), 7.88 (m, 2H), 7.62 (dd, 1H), 7.56 (m, 2H), 4.45 (m, 1H), 3.84 (m,1H), 3.48 (m, 1H), 3.42-3.27 (m, 4H), 2.89 (m, 1H), 2.38 (m, 1H), 2.28(m, 1H), 2.10 (m, 2H), 1.96 (m, 1H), 0.82 (m, 2H), 0.67 (m, 2H).

HPLC (method 1): R_(t)=3.95 min.

-   -   LC-MS (method 6): R_(t)=3.36 min.; m/z=445 (M+H)⁺ (free base).

EXAMPLE 136N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-(3-{[ethyl(methyl)amino]carbonyl}phenyl)-1-benzothiophene-2-carboxamideHydrochloride

50 mg (0.11 mmol) of3-(2-{[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]carbonyl}-1-benzothien-7-yl)benzoicacid hydrochloride (Example 75) and 13.3 mg (0.23 mmol) ofethylmethylamine are reacted together by general method E. 20.1 mg(36.8% of theory) of the title compound are obtained.

¹H-NMR (400 MHz, methanol-d₄): δ=8.19 (s, 1H), 7.95 (d, 1H), 7.82 (d,1H), 7.73 (m, 1H), 7.64 (dd, 1H), 7.60-7.46 (m, 3H), 4.45 (m, 1H), 3.83(m, 1H), 3.61 (m, 1H), 3.51-3.28 (m, 6H), 3.10 (m, 3H), 2.39 (m, 1H),2.28 (m, 1H), 2.10 (m, 2H), 1.96 (m, 1H), 1.23 (m, 3H).

HPLC (method 1): R_(t)=4.00 min.

LC-MS (method 6): R_(t)=3.40 min.; m/z=447 (M+H)⁺ (free base).

EXAMPLE 137N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[3-(2,5-dihydro-1H-pyrrol-1-ylcarbonyl)-phenyl]-1-benzothiophene-2-carboxamideHydrochloride

50 mg (0.11 mmol) of3-(2-{[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]carbonyl}-1-benzothien-7-yl)benzoicacid hydrochloride (Example 75) and 15.6 mg (0:23 mmol) of 3-pyrrolineare reacted together by general method E. 20 mg (35.9% of theory) of thetitle compound are obtained.

HPLC (method 1): R_(t)=4.00 min.

LC-MS (method 6): R_(t)=3.40 min.; m/z=457 (M+H)⁺ (free base).

EXAMPLE 138N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-(3-{[(3-methoxypropyl)amino]carbonyl}-phenyl)-1-benzothiophene-2-carboxamideHydrochloride

50 mg (0.11 mmol) of3-(2-{[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]carbonyl}-1-benzothien-7-yl)benzoicacid hydrochloride (Example 75) and 20.1 mg (0.23 mmol) of3-methoxypropylamine are reacted together by general method E. 29.2 mg(49.8% of theory) of the title compound are obtained.

HPLC (method 1): R_(t)=3.94 min.

LC-MS (method 6): R_(t)=3.37 min.; m/z=477 (M+H)⁺ (free base).

EXAMPLE 139N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-(3-{[(2-methoxyethyl)(methyl)amino]-carbonyl}phenyl)-1-benzothiophene-2-carboxamideHydrochloride

50 mg (0.11 mmol) of3-(2-{[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]carbonyl}-1-benzothien-7-yl)benzoicacid hydrochloride (Example 75) and 20.1 mg (0.23 mmol) of(2-methoxyethyl)methylamine are reacted together by general method E.20.5 mg (31.8% of theory) of the title compound are obtained.

HPLC (method 1): R_(t)=3.93 min.

LC-MS (method 6): R_(t)=3.35 min.; m/z=477 (M+H)⁺ (free base).

EXAMPLE 140N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-(3-{[(3-ethoxypropyl)amino]carbonyl}-phenyl)-1-benzothiophene-2-carboxamideHydrochloride

50 mg (0.11 mmol) of3-(2-{[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]carbonyl}-1-benzothien-7-yl)benzoicacid hydrochloride (Example 75) and 20.1 mg (0.23 mmol) of3-ethoxypropylamine are reacted together by general method E. 23.4 mg(37.1% of theory) of the title compound are obtained.

¹H-NMR (400 MHz, methanol-d₄): δ=8.18 (s, 1H), 8.15 (s, 1H), 7.94 (d,1H), 7.89 (m, 2H), 7.64 (dd, 1H), 7.56 (m, 2H), 4.45 (m, 1H), 3.84 (m,1H), 3.55 (m, 2H), 3.53-3.25 (m, 9H), 2.39 (m, 1H), 2.28 (m, 1H), 2.10(m, 2H), 1.96 (m, 1H), 1.91 (m, 2H), 1.17 (m, 3H).

HPLC (method 1): R_(t)=4.07 min.

LC-MS (method 6): R_(t)=3.46 min.; m/z=491 (M+H)⁺ (free base).

EXAMPLE 141N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-{(3-[(4-methyl-1-piperazinyl)carbonyl]-phenyl}-1-benzothiophene-2-carboxamideDihydrochloride

50 mg (0.11 mmol) of3-(2-{[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]carbonyl}-1-benzothien-7-yl)benzoicacid hydrochloride (Example 75) and 22.6 mg (0.23 mmol) ofN-methylpiperazine are reacted together by general method E. 4.2 mg(6.6% of theory) of the title compound are obtained.

¹H-NMR (400 MHz, methanol-d₄): δ=8.23 (s, 1H), 7.97 (dd, 1H), 7.88 (m,2H), 7.69 (m, 1H), 7.57 (m, 3H), 4.46 (m, 1H), 3.84 (m, 1H), 3.50 (m,1H), 3.46-3.25 (m, 12H), 2.97 (s, 3H), 2.39 (m, 1H), 2.29 (m, 1H), 2.10(m, 2H), 1.96 (m, 1H).

HPLC (method 1): R_(t)=3.62 min.

LC-MS (method 6): R_(t)=2.94 min.; m/z=488 (M+H)⁺ (free base).

EXAMPLE 142N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-{3-[(cyclobutylcarbonyl)amino]phenyl}-1-benzothiophene-2-carboxamideHydrochloride

50 mg (0.12 mmol) of7-(3-aminophenyl)-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzothiophene-2-carboxamidehydrochloride (Example 21) and 28.6 mg (0.24 mmol) ofcyclobutanecarbonyl chloride are reacted together by general method F.38 mg (61.3% of theory) of the title compound are obtained.

HPLC (method 1): R_(t)=4.22 min.

MS (ESIpos): m/z=460 (M+H)⁺ (free base).

EXAMPLE 143N-[3-(2-{[(3R)-1-Azabicyclo[2.2.2]oct-3-ylamino]carbonyl}-1-benzothien-7-yl)-phenyl]-5-isoxazolecarboxamideHydrochloride

50 mg (0.12 mmol) of7-(3-aminophenyl)-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzothiophene-2-carboxamidehydrochloride (Example 21) and 31.8 mg (0.24 mmol) ofisoxazole-5-carbonyl chloride are reacted together by general method F.44.4 mg (72.6% of theory) of the title compound are obtained.

¹H-NMR (400 MHz, methanol-d₄): δ=8.58 (d, 1H), 8.18 (s, 2H), 7.93 (dd,1H), 7.79 (m, 1H), 7.55 (m, 4H), 7.13 (m, 1H), 4.45 (m, 1H), 3.83 (m,1H), 3.48 (m, 1H), 3.42-3.27 (m, 4H), 2.39 (m, 1H), 2.28 (m, 1H), 2.10(m, 2H), 1.96 (m, 1H).

HPLC (method 1): R_(t)=4.12 min.

MS (ESIpos): m/z=473 (M+H)⁺ (free base).

EXAMPLE 144N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-{3-[(cyclopentylcarbonyl)amino]phenyl}-1-benzothiophene-2-carboxamideHydrochloride

50 mg (0.12 mmol) of7-(3-aminophenyl)-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzothiophene-2-carboxamidehydrochloride (Example 21) and 32 mg (0.24 mmol) of cyclopentylcarbonylchloride are reacted together by general method F. 30.5 mg (52.8% oftheory) of the title compound are obtained.

¹H-NMR (400 MHz, methanol-d₄): δ=8.17 (s, 1H), 8.03 (m, 1H), 7.91 (dd,1H), 7.60 (m, 1H), 7.57-7.38 (m, 4H), 4.45 (m, 1H), 3.83 (m, 1H), 3.48(m, 1H), 3.42-3.27 (m, 4H), 2.86 (m, 1H), 2.38 (m, 1H), 2.28 (m, 1H),2.10 (m, 2H), 1.96 (m, 3H), 1.90-1.72 (m, 4H), 1.66 (m, 2H).

HPLC (method 1): R_(t)=4.40 min.

MS (ESIpos): m/z=474 (M+H)⁺ (free base).

EXAMPLE 145N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-{3-[(cyclohexylcarbonyl)amino]phenyl}-1-benzothiophene-2-carboxamideHydrochloride

50 mg (0.12 mmol) of7-(3-aminophenyl)-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzothiophene-2-carboxamidehydrochloride (Example 21) and 35.4 mg (0.24 mmol) of cyclohexylcarbonylchloride are reacted together by general method F. 9.8 mg (16.2% oftheory) of the title compound are obtained.

HPLC (method 1): R_(t)=4.51 min.

MS (ESIpos): m/z=488 (M+H)⁺ (free base).

EXAMPLE 146N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-{3-[(tetrahydro-2-furanylcarbonyl)amino]-phenyl}-1-benzothiophene-2-carboxamideHydrochloride

50 mg (0.12 mmol) of7-(3-aminophenyl)-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzothiophene-2-carboxamidehydrochloride (Example 21) and 32.5 mg (0.24 mmol) oftetrahydrofuran-2-carbonyl chloride are reacted together by generalmethod F. 40.9 mg (68.1% of theory) of the title compound are obtained.

¹H-NMR (400 MHz, methanol-d₁): δ=8.17 (s, 1H), 8.04 (s, 1H), 7.91 (d,1H), 7.61 (m, 1H), 7.58-7.40 (m, 4H), 4.46 (m, 1H), 4.04 (dd, 1H), 3.92(m, 2H), 3.83 (m, 2H), 3.48 (m, 1H), 3.42-3.27 (m, 4H), 3.23 (m, 1H),2.38 (m, 1H), 2.28 (m, 1H), 2.22 (m, 2H), 2.10 (m, 2H), 1.96 (m, 1H).

HPLC (method 1): R_(t)=3.99 min.

MS (ESIpos): m/z=. 476 (M+H)⁺ (free base).

EXAMPLE 147N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[3-(isobutyrylamino)phenyl]-1-benzothiophene-2-carboxamideHydrochloride

50 mg (0.12 mmol) of7-(3-aminophenyl)-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzothiophene-2-carboxamidehydrochloride (Example 21) and 25.7 mg (0.24 mmol) of isobutyrylchloride are reacted together by general method F. 35.1 mg (64.9% oftheory) of the title compound are obtained.

¹H-NMR (400 MHz, methanol-d₄): δ=8.17 (s, 1H), 8.03 (s, 1H), 7.90 (d,1H), 7.61 (m, 1H), 7.57-7.40 (m, 4H), 4.45 (m, 1H), 3.83 (m, 1H), 3.48(m, 1H), 3.42-3.27 (m, 4H), 2.68 (m, 1H), 2.38 (m, 1H), 2.28 (m, 1H),2.10 (m, 2H), 1.96 (m, 1H), 1.21 (d, 6H).

HPLC (method 1): R_(t)=4.19 min.

MS (ESIpos): m/z=448 (M+H)⁺ (free base).

EXAMPLE 148N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[3-(2-furoylamino)phenyl]-1-benzothiophene-2-carboxamideHydrochloride

50 mg (0.12 mmol) of7-(3-aminophenyl)-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzothiophene-2-carboxamidehydrochloride (Example 21) and 31.5 mg (0.24 mmol) of furan-2-carbonylchloride are reacted together by general method F. 29.1 mg (51.1% oftheory) of the title compound are obtained.

¹H-NMR (400 MHz, methanol-d₄): δ=8.17 (s, 2H), 7.91 (d, 1H), 7.74 (m,2H), 7.58-7.47 (m, 4H), 7.29 (d, 1H), 6.65 (m, 1H), 4.44 (m, 1H), 3.83(m, 1H), 3.47 (m, 1H), 3.42-3.27 (m, 4H), 2.38 (m, 1H), 2.28 (m, 1H),2.10 (m, 2H), 1.96 (m, 1H).

HPLC (method 1): R_(t)=4.19 min.

MS (ESIpos): m/z=472 (M+H)⁺ (free base).

EXAMPLE 1493-(2-{[(3R)-1-Azabicyclo[2.2.2]oct-3-ylamino]carbonyl}-1-benzofuran-7-yl)-benzoicAcid Hydrochloride

4.3 ml of 2 M aqueous sodium carbonate solution and 116.9 mg (0.14 mmol)of PdCl₂(dppf) are added to a mixture of 1104 mg (2.86 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzofuran-2-carboxamidehydrochloride (Example 30A) and 475 mg (2.86 mmol) of3-carboxyphenylboronic acid in 10 ml of DMF. The reaction mixture isheated at 90° C. for 18 h and then filtered through kieselguhr andevaporated to dryness. Purification of the crude product by preparativeHPLC, subsequent addition of a 3:1 mixture of acetonitrile and 1Nhydrochloric acid, concentrating and drying under high vacuum result in724 mg (59.2% of theory) of the title compound.

¹H-NMR (400 MHz, methanol-d₄): δ=8.62 (s, 1H), 8.11 (d, 1H), 8.08 (d,1H), 7.76 (d, 1H), 7.73-7.61 (m, 3H), 7.46 (dd, 1H), 4.49 (m, 1H), 3.83(m, 1H), 3.48 (m, 1H), 3.43-3.27 (m, 4H), 2.40 (m, 1H), 2.28 (m, 1H),2.10 (m, 2H), 1.96 (m, 1H).

HPLC (method 1): R_(t)=3.89 min.

MS (ESIpos): m/z=391 (M+H)⁺ (free base).

EXAMPLE 150N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[2-(hydroxymethyl)phenyl]-1-benzofuran-carboxamideHydrochloride

0.64 ml of 2 M aqueous sodium carbonate solution and 17.5 mg (0.02 mmol)of PdCl₂(dppf) are added to a mixture of 150 mg (0.43 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzofuran-2-carboxamidehydrochloride (Example 30A) and 65.3 mg (0.43 mmol) of2-(hydroxymethyl)phenylboronic acid in 1.5 ml of DMF. The reactionmixture is heated at 90° C. for 18 h and then filtered throughkieselguhr and evaporated to dryness. Purification of the crude productby preparative HPLC, subsequent addition of a 3:1 mixture ofacetonitrile and 1N hydrochloric acid, concentration and drying underhigh vacuum result in 13 mg (7.1% of theory) of the title compound.

HPLC (method 1): R_(t)=3.87 min.

MS (ESIpos): m/z=377 (M+H)⁺ (free base).

EXAMPLE 151N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-(2,5-dimethoxyphenyl)-1-benzofuran-2-carboxamideHydrochloride

0.78 ml of 2 M aqueous sodium carbonate solution and 21.2 mg (0.03 mmol)of PdCl₂(dppf) are added to a mixture of 200 mg (0.52 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzofuran-2-carboxamidehydrochloride (Example 30A) and 94.4 mg (0.52 mmol) of2,5-dimethoxyphenylboronic acid in 2 ml of DMF. The reaction mixture isheated at 70° C. for 17 h and then filtered through kieselguhr andevaporated to dryness. Purification of the crude product by preparativeHPLC, subsequent addition of a 3:1 mixture of methanol and 1Nhydrochloric acid, concentration and drying under high vacuum result in75 mg (31.7% of theory) of the title compound.

HPLC (method 1): R_(t)=4.15 min.

MS (ESIpos): m/z=407 (M+H)⁺ (free base).

EXAMPLE 1527-[2-(Aminomethyl)phenyl]-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2-carboxamideDihydrochloride

500 mg (1.75 mmol) of tert-butyl 2-bromobenzylcarbamate, 512 mg (2.02mmol) of bis(pinacolato)diboron, 428.7 mg (4.37 mmol) of potassiumacetate, 49.2 mg (0.07 mmol) of PdCl₂(dppf), 518.4 mg (1.34 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzofuran-2-carboxamidehydrochloride (Example 30A), 3.36 ml of 2 M sodium carbonate solutionand a further 49.2 mg (0.07 mmol) of PdCl₂(dppf) in 5 ml of DMF arereacted by general method D. The crude product which has been driedunder high vacuum is stirred in 8 ml of a 1:1 mixture of methanol and 4M hydrogen chloride in dioxane at room temperature for 2 h. The reactionsolution is concentrated and the resulting crude product is purified bypreparative HPLC. The product fractions are concentrated and, afteraddition of a 3:1 mixture of methanol and 1N hydrochloric acid, againconcentrated and dried under high vacuum. 245.5 mg (44.5% of theory) ofthe title compound are obtained.

¹H-NMR (300 MHz, DMSO-d₆): δ=10.48 (br. s, 1H), 9.26 (d, 1H), 8.47 (br.s, 3H), 8.05 (s, 1H), 7.88 (dd, 1H), 7.80 (d, 1H), 7.62-7.40 (m, 5H),4.31 (m, 1H), 3.86 (m, 2H), 3.48 (m, 1H), 3.51-3.10 (m, 5H), 2.18 (m,1H), 2.11 (m, 1H), 1.90 (m, 2H), 1.71 (m, 1H).

HPLC (method 7): R_(t)=3.55 min.

MS (ESIpos): m/z=376 (M+H)⁺ (free base).

EXAMPLE 1533-(2-{[(3S)-1-Azabicyclo[2.2.2]oct-3-ylamino]carbonyl}-1-benzofuran-7-yl)-benzoicAcid Hydrochloride

3.89 ml of 2 M aqueous sodium carbonate solution and 105.9 mg (0.13mmol) of PdCl₂(dppf) are added to a mixture of 1000 mg (2.59 mmol) ofN-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzofuran-2-carboxamidehydrochloride (free base: Example 31A) and 430.2 mg (2.59 mmol) of3-carboxyphenylboronic acid in. 8 ml of DMF. The reaction mixture isheated at 70° C. for 18 h and then filtered through kieselguhr andevaporated to dryness. Purification of the crude product by preparativeHPLC, subsequent addition of a 3:1 mixture of methanol and 1Nhydrochloric acid, concentration and drying under high vacuum result in142.5 mg 1.5 (12% of theory) and a further 627.9 mg (of 80% purity) ofthe title compound. The spectroscopic data agree with those of theenantiomeric compound (Example 149).

EXAMPLE 154N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-{3-[(cyclopropylamino)carbonyl]phenyl}-1-benzofuran-2-carboxamideHydrochloride

50 mg (0.12 mmol) of3-(2-{[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]carbonyl}-1-benzofuran-7-yl)benzoicacid hydrochloride (Example 149) and 13.4 mg (0.23 mmol) ofcyclopropylamine are reacted together by general method E. 20 mg (32.2%of theory) of the title compound are obtained.

HPLC (method 1): R_(t)=3.93 min.

LC-MS (method 6): R_(t)=3.33 min.; m/z=429 (M+H)⁺ (free base).

EXAMPLE 155N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-(3-{[ethyl(methyl)amino]carbonyl}phenyl)-1-benzofuran-2-carboxamideHydrochloride

50 mg (0.12 mmol) of3-(2-{[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]carbonyl}-1-benzofuran-7-yl)benzoicacid hydrochloride (Example 149) and 13.9 mg (0.23 mmol) ofmethylethylamine are reacted together by general method E. 19.8 mg(29.4% of theory) of the title compound are obtained.

HPLC (method 1): R_(t)=4.03 min.

LC-MS (method 6): R_(t)=3.38 min.; m/z=431 (M+H)⁺ (free base).

EXAMPLE 156N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-{3-[(butylamino)carbonyl]phenyl}-1-benzofuran-2-carboxamideHydrochloride

50 mg (0.12 mmol) of3-(2-{[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]carbonyl}-1-benzofuran-7-yl)benzoicacid hydrochloride (Example 149) and 17.1 mg (0.23 mmol) of n-butylamineare reacted together by general method E. 15.2 mg (26.2% of theory) ofthe title compound are obtained.

HPLC (method 1): R_(t)=4.21 min.

LC-MS (method 6): R_(t)=3.49 min.; m/z=445 (M+H)⁺ (free base).

EXAMPLE 157N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-{3-[(isobutylamino)carbonyl]phenyl}-1-benzofuran-2-carboxamideHydrochloride

50 mg (0.12 mmol) of3-(2-{[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]carbonyl}-1-benzofuran-7-yl)benzoicacid hydrochloride (Example 149) and 17.1 mg (0.23 mmol) ofiso-butylamine are reacted together by general method E. 15.2 mg (26.9%of theory) of the title compound are obtained.

HPLC (method 1): R_(t)=4.18 min.

LC-MS (method 6): R_(t)=3.49 min.; m/z=445 (M+H)⁺ (free base).

EXAMPLE 158N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[3-(1-piperidinylcarbonyl)phenyl]-1-benzofuran-2-carboxamideHydrochloride

50 mg (0.12 mmol) of3-(2-{[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]carbonyl}-1-benzofuran-7-yl)benzoicacid hydrochloride (Example 149) and 20.0 mg (0.23 mmol) of piperidineare reacted together by general method E. 16.4 mg (27.6% of theory) ofthe title compound are obtained.

HPLC (method 1): R_(t)=4.22 min.

LC-MS (method 6): R_(t)=3.51 min.; m/z=457 (M+H)⁺ (free base).

EXAMPLE 159N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[3-({[2-(dimethylamino)ethyl]amino}-carbonyl)phenyl]-1-benzofuran-2-carboxamideHydrochloride

50 mg (0.12 mmol) of3-(2-{[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]carbonyl}-1-benzofuran-7-yl)benzoicacid hydrochloride (Example 149) and 20.7 mg (0.23 mmol) ofN-(2-aminoethyl)-N,N-dimethylamine are reacted together by generalmethod E. 17.4 mg (24.8% of theory) of the title compound are obtained.

HPLC (method 1): R_(t)=3.64 min.

LC-MS (method 6): R_(t)=2.93 min.; m/z=460 (M+H)⁺ (free base).

EXAMPLE 160N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-(3-{[(3-methoxypropyl)amino]carbonyl}-phenyl)-1-benzofuran-2-carboxamideHydrochloride

50 mg (0.12 mmol) of3-(2-{[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]carbonyl}-1-benzofuran-7-yl)benzoicacid hydrochloride (Example 149) and 20.9 mg (0.23 mmol) of3-methoxypropylamine are reacted together by general method E. 22.7 mg(36.4% of theory) of the title compound are obtained.

HPLC (method 1): R_(t)=3.93 min.

LC-MS (method 6): R_(t)=3.36 min.; m/z=461 (M+H)⁺ (free base).

EXAMPLE 161N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-(3-{[(2-methoxyethyl)(methyl)amino]-carbonyl}phenyl)-1-benzofuran-2-carboxamideHydrochloride

50 mg (0.12 mmol) of3-(2-{[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]carbonyl}-1-benzofuran-7-yl)benzoicacid hydrochloride (Example 149) and 20.9 mg (0.23 mmol) ofN-(2-methoxyethyl)-N-methylamine are reacted together by general methodE. 20.4 mg (31.3% of theory) of the title compound are obtained.

HPLC (method 1): R_(t)=3.96 min.

LC-MS (method 6): R_(t)=3.34 min.; m/z=461 (M+H)⁺ (free base).

EXAMPLE 162N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-(3-{[(3-ethoxypropyl)amino]carbonyl}phenyl)-1-benzofuran-2-carboxamideHydrochloride

50 mg (0.12 mmol) of3-(2-{[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]carbonyl}-1-benzofuran-7-yl)benzoicacid hydrochloride (Example 149) and 24.2 mg (0.23 mmol) of3-ethoxypropylamine are reacted together by general method E. 17.8 mg(28.9% of theory) of the title compound are obtained.

HPLC (method 1): R_(t)=4.06 min.

LC-MS (method 6): R_(t)=3.43 min.; m/z=475 (M+H)⁺ (free base).

EXAMPLE 163N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-{3-[(4-methyl-1-piperazinyl)carbonyl]-phenyl}-1-benzofuran-2-carboxamideDihydrochloride

50 mg (0.12 mmol) of3-(2-{[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]carbonyl}-1-benzofuran-7-yl)benzoicacid hydrochloride (Example 149) and 23.5 mg (0.23 mmol) ofN-methylpiperazine are reacted together by general method E. 29.6 mg(41.9% of theory) of the title compound are obtained.

HPLC (method 1): R_(t)=3.60 min.

LC-MS (method 6): R_(t)=2.91 min.; m/z=472 (M+H)⁺ (free base).

EXAMPLE 164N-[(3S)-1-Azabicyclo[2.2.2]oct-3-yl]-7-(3-{[ethyl(methyl)amino]carbonyl}phenyl)-1-benzofuran-2-carboxamideHydrochloride

50 mg (0.12 mmol) of3-(2-{[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino]carbonyl}-1-benzofuran-7-yl)benzoicacid hydrochloride (Example 153) and 13.9 mg (0.23 mmol) ofmethylethylamine are reacted together by general method E. 50A mg (91.4%of theory) of the title compound are obtained.

The spectroscopic data agree with those of the enantiomeric compound(Example 155).

EXAMPLE 165N-[(3S)-1-Azabicyclo[2.2.2]oct-3-yl]-7-{3-[(butylamino)carbonyl]phenyl}-1-benzofuran-2-carboxamideHydrochloride

50 mg (0.12 mmol) of3-(2-{[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino]carbonyl}-1-benzofuran-7-yl)benzoicacid hydrochloride (Example 153) and 17.1 mg (0.23 mmol) of n-butylamineare reacted together by general method E. 49.4 mg (87.5% of theory) ofthe title compound are obtained.

The spectroscopic data agree with those of the enantiomeric compound(Example 156).

EXAMPLE 166N-[(3S)-1-Azabicyclo[2.2.2]oct-3-yl]-7-{3-[(isobutylamino)carbonyl]phenyl}-1-benzofuran-2-carboxamideHydrochloride

50 mg (0.12 mmol) of3-(2-{[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino]carbonyl}-1-benzofuran-7-yl)benzoicacid hydrochloride (Example 153) and 17.1 mg (0.23 mmol) ofiso-butylamine are reacted together by general method E. 40.3 mg (71.4%of theory) of the title compound are obtained.

The spectroscopic data agree with those of the enantiomeric compound(Example 157).

EXAMPLE 167N-[(3S)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[3-(1-piperidinylcarbonyl)phenyl]-1-benzofuran-2-carboxamideHydrochloride

50 mg (0.12 mmol) of3-(2-{[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino]carbonyl}-1-benzofuran-7-yl)benzoicacid hydrochloride (Example 153) and 20.0 mg (0.23 mmol) of piperidineare reacted together by general method E. 29.7 mg (49.9% of theory) ofthe title compound are obtained.

The spectroscopic data agree with those of the enantiomeric compound(Example 158).

EXAMPLE 168N-[(3S)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[3-({[2-(dimethylamino)ethyl]amino}-carbonyl)phenyl]-1-benzofuran-2-carboxamideHydrochloride

50 mg (0.12 mmol) of3-(2-{[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino]carbonyl}-1-benzofuran-7-yl)benzoicacid hydrochloride (Example 153) and 20.7 mg (0.23 mmol) ofN-(2-aminoethyl)-N,N-dimethylamine are reacted together by generalmethod E. 42.5 mg (64.5% of theory) of the title compound are obtained.

The spectroscopic data agree with those of the enantiomeric compound(Example 159).

EXAMPLE 169N-[(3S)-1-Azabicyclo[2.2.2]oct-3-yl]-7-(3-{[(3-methoxypropyl)amino]carbonyl}-phenyl)-1-benzofuran-2-carboxamideHydrochloride

50 mg (0.12 mmol) of3-(2-{[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino]carbonyl}-1-benzofuran-7-yl)benzoicacid hydrochloride (Example 153) and 20.9 mg (0.23 mmol) of3-methoxypropylamine are reacted together by general method E. 29.8 mg(44.5% of theory) of the title compound are obtained.

The spectroscopic data agree with those of the enantiomeric compound(Example 160).

EXAMPLE 170N-[(3S)-1-Azabicyclo[2.2.2]oct-3-yl]-7-(3-{[(2-methoxyethyl)(methyl)amino]-carbonyl}phenyl)-1-benzofuran-2-carboxamideHydrochloride

50 mg (0.12 mmol) of3-(2-{[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino]carbonyl}-1-benzofuran-7-yl)benzoicacid hydrochloride (Example 153) and 20.9 mg (0.23 mmol) ofN-(2-methoxyethyl)-N-methylamine are reacted together by general methodE. 22.1 mg (35.1% of theory) of the title compound are obtained. Thespectroscopic data agree with those of the enantiomeric compound(Example 161).

EXAMPLE 171N-[(3S)-1-Azabicyclo[2.2.2]oct-3-yl]-7-(3-{[(3-ethoxypropyl)amino]carbonyl}-phenyl)-1-benzofuran-2-carboxamideHydrochloride

50 mg (0.12 mmol) of3-(2-{[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino]carbonyl}-1-benzofuran-7-yl)benzoicacid hydrochloride (Example 153) and 24.2 mg (0.23 mmol) of3-ethoxypropylamine are reacted together by general method E. 23.6 mg(36.9% of theory) of the title compound are obtained.

The spectroscopic data agree with those of the enantiomeric compound(Example 162).

EXAMPLE 172N-[(3S)-1-Azabicyclo[2.2.2]oct-3-yl]-7-{3-[(4-methyl-1-piperazinyl)carbonyl]-phenyl}-1-benzofuran-2-carboxamideDihydrochloride

50 mg (0.12 mmol) of3-(2-{[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino]carbonyl}-1-benzofuran-7-yl)benzoicacid hydrochloride (Example 153) and 23.5 mg (0.23 mmol) ofN-methylpiperazine are reacted together by general method E. 9.2 mg(15.4% of theory) of the title compound are obtained.

The spectroscopic data agree with those of the enantiomeric compound(Example 163).

EXAMPLE 173N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[3-(1-pyrrolidinyl)phenyl]-1-benzofuran-2-carboxamideHydrochloride

114.3 mg (0.51 mmol) of 1-(3-bromophenyl)pyrrolidine, 148.1 mg (0.58mmol) of bis(pinacolato)diboron, 124.1 mg (1.26 mmol) of potassiumacetate, 14.2 mg (0.02 mmol) of PdCl₂(dppf), 150 mg (0.39 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzofuran-2-carboxamidehydrochloride (Example 30A), 0.97 ml of 2 M sodium carbonate solutionand a further 14.2 mg (0.02 mmol) of PdCl₂(dppf) in 2.0 ml of DMF arereacted by general method D. Drying under high vacuum results in 95.6 mg(54.4% of theory) of the title compound.

HPLC (method 1): R_(t)=3.85 min.

MS (ESIpos): m/z=416 (M+H)⁺ (free base).

EXAMPLE 1747-[2-(Aminomethyl)phenyl]-N-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2-carboxamideDihydrochloride

500 mg (1.75 mmol) of tert-butyl 2-bromobenzylcarbamate, 512 mg (2.02mmol) of bis(pinacolato)diboron, 428.7 mg (4.37 mmol) of potassiumacetate, 49.2 mg (0.07 mmol) of PdCl₂(dppf), 518.4 mg (1.34 mmol) ofN-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzofuran-2-carboxamidehydrochloride (free base: Example 31A), 3.36 ml of 2 M sodium carbonatesolution and a further 49.2 mg (0.07 mmol) of PdCl₂(dppf) in 5 ml of DMFare reacted by general method D. The crude product which has been driedunder high vacuum is stirred in 4 ml of a 1:1 mixture of methanol and 4M hydrogen chloride in dioxane at room temperature for 2 h. The reactionsolution is concentrated, and the resulting crude product is purified bypreparative HPLC. The product fractions are concentrated and, afteraddition of a 3:1 mixture of methanol and 1N hydrochloric acid, againconcentrated and dried under high vacuum. 121.6 mg (22.4% of theory) ofthe title compound are obtained.

The spectroscopic data agree with those of the enantiomeric compound(Example 152).

EXAMPLE 175N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[2-({[(methylamino)carbonyl]amino}-methyl)phenyl]-1-benzofuran-2-carboxamideHydrochloride

62.2 μl (0.45 mmol) of triethylamine and 53 μl (0.89 mmol) of methylisocyanate are added to a solution of 100 mg (0.22 mmol) of7-[2-(aminomethyl)phenyl]-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2-carboxamidedihydrochloride (Example 152) in 1 ml of a 5:1 mixture of THF and DMF.After 18 h at room temperature, the reaction mixture is concentrated andpurified by preparative HPLC. The product fractions are concentratedand, after addition of a 3:1 mixture of methanol and 1N hydrochloricacid, again concentrated and dried under high vacuum. 75 mg (66% oftheory) of the title compound are obtained.

¹H-NMR (400 MHz, methanol-d₄): δ=7.78 (m, 1H), 7.68 (s, 1H), 7.52-7.30(m, 6H), 4.47 (m, 1H), 4.23 (m, 2H), 3.77 (m, 1H), 3.53-3.25 (m, 5H),2.69 (s, 3H), 2.37 (m, 1H), 2.20 (m, 1H), 2.08 (m, 2H), 1.88 (m, 1H).

HPLC (method 1): R_(t)=3.78 min.

MS (ESIpos): m/z=433 (M+H)⁺ (free base).

EXAMPLE 176N-[(3S)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[2-({[(methylamino)carbonyl]amino}-methyl)phenyl]-1-benzofuran-2-carboxamideHydrochloride

36 μl (0.26 mmol) of triethylamine and 29.5 μl (0.52 mmol) of methylisocyanate are added to a solution of 57.9 mg (0.13 mmol) of7-[2-(aminomethyl)phenyl]-N-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2-carboxamidedihydrochloride (Example 174) in 0.7 ml of a 5:1 mixture of THF and DMF.After. 18 h at room temperature, the reaction mixture is concentratedand purified by preparative HPLC. The product fractions are concentratedand, after addition of a 3:1 mixture of methanol and 1N hydrochloricacid, again concentrated and dried under high vacuum. 49.2 mg (81.2% oftheory) of the title compound are obtained. The spectroscopic data agreewith those of the enantiomeric compound (Example 175).

EXAMPLE 177N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-{3-[(2,2-dimethylpropanoyl)amino]phenyl}-1-benzofuran-2-carboxamideHydrochloride

50 mg (0.14 mmol) of7-(3-aminophenyl)-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2-carboxamide(Example 114) and 33.4 mg (0.28 mmol) of pivaloyl chloride are reactedtogether by general method F. 15.2 mg (20.7% of theory) of the titlecompound are obtained.

HPLC (method 1): R_(t)=4.30 min.

MS (ESIpos): m/z=446 (M+H)⁺ (free base).

EXAMPLE 178N-[3-(2-{[(3R)-1-Azabicyclo[2.2.2]oct-3-ylamino]carbonyl}-1-benzofuran-7-yl)-phenyl]-5-isoxazolecarboxamideHydrochloride

50 mg (0.14 mmol) of7-(3-aminophenyl)-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2-carboxamide(Example 114) and 36.4 mg (0.28 mmol) of 5-isoxazolecarbonyl chlorideare reacted together by general method F. 39.6 mg (53.3% of theory) ofthe title compound are obtained.

HPLC (method 1): R_(t)=4.18 min.

MS (ESIpos): m/z=457 (M+H)⁺ (free base).

EXAMPLE 179N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-{3-[(cyclopentylcarbonyl)amino]phenyl}-1-benzofuran-2-carboxamideHydrochloride

50 mg (0.14 mmol) of7-(3-aminophenyl)-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2-carboxamide(Example 114) and 36.7 mg (0.28 mmol) of cyclopentanecarbonyl chlorideare reacted together by general method F. 33.2 mg (45.1% of theory) ofthe title compound are obtained.

HPLC (method 1): R_(t)=4.38 min.

MS (ESIpos): m/z=458 (M+H)⁺ (free base).

EXAMPLE 180N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[3-(isobutyrylamino)phenyl]-1-benzofuran-2-carboxamideHydrochloride

50 mg (0.14 mmol) of7-(3-aminophenyl)-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2-carboxamide(Example 114) and 29.5 mg (0.28 mmol) of isobutyryl chloride are reactedtogether by general method F. 12.8 mg (19.5% of theory) of the titlecompound are obtained.

HPLC (method 1): R_(t)=4.19 min.

MS (ESIpos): m/z=432 (M+H)⁺ (free base).

EXAMPLE 181N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[3-(2-furoylamino)phenyl]-1-benzofuran-carboxamideHydrochloride

50 mg (0.14 mmol) of7-(3-aminophenyl)-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2-carboxamide(Example 114) and 36.1 mg (0.28 mmol) of furan-2-carbonyl chloride arereacted together by general method. F. 7.4 mg (10.6% of theory) of thetitle compound are obtained.

HPLC (method 1): R_(t)=4.27 min.

MS (ESIpos): m/z=456 (M+H)⁺ (free base).

EXAMPLE 182N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-(2-methoxyphenyl)-1-benzofuran-2-carboxamideAcetate

95.9 mg (0.25 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-(2-methoxyphenyl)-1-benzofuran-2-carboxamide(Example 130) are dissolved in 2 ml of methanol. After addition of 15.3mg (0.25 mmol) of acetic acid, the mixture is concentrated and theresidue is dried under high vacuum. 114.9 mg (99.7% of theory) of thetitle compound are obtained.

¹H-NMR (200 MHz, DMSO-d₆): δ=8.37 (d, 1H), 7.74 (dd, 1H), 7.71 (s, 1H),7.50-7.33 (m, 4H), 7.20 (d, 1H), 7.08 (m, 1H), 3.93 (m, 1H), 3.76 (s,3H), 3.10 (m, 1H), 2.87 (m, 1H), 2.78-2.60 (m, 4H), 1.90 (s, 3H), 1.87(m, 1H), 1.75 (m, 1H), 1.58 (m, 2H), 1.33 (m, 1H).

EXAMPLE 183N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-(2-methoxyphenyl)-1-benzofuran-2-carboxamideTosylate

95.9 mg (0.25 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-(2-methoxyphenyl)-1-benzofuran-2-carboxamide(Example 130) are dissolved in 2 ml of methanol. After addition of 49.2mg (0.25 mmol) of p-toluenesulphonic acid, the mixture is concentratedand the residue is dried under high vacuum. 143 mg (99.4% of theory) ofthe title compound are obtained.

¹H-NMR (200 MHz, DMSO-d₆): δ=9.34 (br. s, 1H), 8.70 (d, 1H), 737 (dd,1H), 7.72 (s, 1H), 7.52-7.35 (m, 6H), 7.21 (d, 1H), 7.15-7.04 (m, 3H),4.30 (m, 1H), 3.76 (s, 3H), 3.68 (m, 1H), 3.33-3.11 (m, 5H), 2.29 (s,3H), 2.19 (m, 1H), 2.07 (m, 1H), 1.91 (m, 2H), 1.74 (m, 1H).

EXAMPLE 184N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-(2-methoxyphenyl)-1-benzofuran-2-carboxamideFumarate

95.9 mg (0.25 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-(2-methoxyphenyl)-1-benzofuran-2-carboxamide(Example 130) are dissolved in 1.5 ml of acetone. After addition of 29.6mg (0.25 mmol) of fumaric acid in 1 ml of hot isopropanol, the mixtureis stirred at 50° C. for 30 min and then concentrated, and the residueis dried under high vacuum. 124.2 mg (99% of theory) of the titlecompound are obtained.

¹H-NMR (200 MHz, DMSO-d₆): δ=8.62 (d, 1H), 7.76 (dd, 1H), 7.72 (s, 1H),7.49-7.33 (m, 4H), 7.21 (d, 1H), 7.09 (m, 1H), 6.50 (s, 2H), 4.16 (m,1H), 3.76 (s, 3H), 3.38 (m, 1H), 3.11 (m, 1H), 3.06-2.85 (m, 4H), 2.03(m, 1H), 1.92 (m, 1H), 1.76 (m, 2H), 1.56 (m, 1H).

EXAMPLE 185N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-(2-methoxyphenyl)-1-benzofuran-2-carboxamideOxalate

95.9 mg (0.25 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-(2-methoxyphenyl)-1-benzofuran-2-carboxamide(Example 130) are dissolved in 1.5 ml of acetone. After addition of 22.9mg (0.25 mmol) of oxalic acid in 1 ml of hot isopropanol, the mixture isstirred at 50° C. for 30 min and then concentrated, and the residue isdried under high vacuum. 117.6 mg (99% of theory) of the title compoundare obtained.

¹H-NMR (200 MHz, DMSO-d₆): δ=8.75 (d, 1H), 7.77 (dd, 1H), 7.72 (s, 1H),7.50-7.33 (m, 4H), 7.20 (d, 1H), 7.09 (m, 1H), 4.28 (m, 1H), 3.75 (s,3H), 3.62 (m, 1H), 3.32-3.08 (m, 5H), 2.17 (m, 1H), 2.04 (m, 1H), 1.89(m, 2H), 1.71 (m, 1H).

EXAMPLE 186N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-(2-hydroxyphenyl)-1-benzofuran-2-carboxamide

2.42 ml of a 1 M boron tribromide solution in dichloromethane are addeddropwise to a suspension, cooled to −20° C., of 200 mg (0.48 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-(2-methoxyphenyl)-1-benzofuran-2-carboxamidehydrochloride (Example 102) in 8 ml of dichloromethane. After 2 h, thereaction is stopped by adding diethyl ether. The mixture is stirred atroom temperature for 30 min and, after addition of water, neutralizedwith 1N sodium hydroxide solution. After extraction with ethyl acetate,the organic phases are combined and dried over sodium sulphate.Concentration and drying under high vacuum result in 125.9 mg (71.7% oftheory) of the title compound.

HPLC (method 1): R_(t)=3.84 min.

MS (ESIpos): m/z=363 (M+H)⁺.

EXAMPLE 187(3R)-3-({[7-(2-Methoxyphenyl)-1-benzofuran-2-yl]carbonyl}amino)-1-methyl-1-azoniabicyclo[2.2.2]octaneChloride

60.5 mg (1.51 mmol) of sodium hydride (60% suspension in mineral oil)are added to a solution, cooled to −20° C., of 250 mg (0.61 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-(2-methoxyphenyl)-1-benzofuran-2-carboxamidehydrochloride (Example 102) in 2.5 ml of DMF. After 30 min at roomtemperature and renewed cooling to −20° C., 33.9 μl (0.54 mmol) ofiodomethane are added. After 18 h at room temperature, the reaction isstopped by adding water. The reaction mixture is purified by preparativeHPLC. The product fractions are concentrated, codistilled with 1Nhydrochloric acid, again concentrated and dried under high vacuum. 206mg (79.7% of theory) of the title compound are obtained.

¹H-NMR (200 MHz, DMSO-d₆): δ=9.23 (d, 1H), 8.02 (s, 1H), 7.77 (d, 1H),7.46 (dd, 1H), 7.39 (m, 3H), 7.20 (d, 1H), 7.09 (dd, 1H), 4.32 (m, 1H),3.83 (m, 1H), 3.75 (s, 3H), 3.63 (m, 1H), 3.49-3.33 (m, 4H), 2.96 (s,3H), 2.27 (m, 1H), 2.20 (m, 1H), 1.97 (m, 2H), 1.83 (m, 1H).

HPLC (method 1): R_(t)=4.19 min.

MS (ESIpos): m/z=391 (M+H)⁺.

EXAMPLE 188(3R)-1-Benzyl-3-({[7-(2-methoxyphenyl)-1-benzofuran-2-yl]carbonyl}amino)-1-azoniabicyclo[2.2.2]octaneBromide

288 μl (2.42 mmol) of benzyl bromide and 502 mg (3.63 mmol) of potassiumcarbonate are added to a solution of 500 mg (1.21 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-(2-methoxyphenyl)-1-benzofuran-2-carboxamidehydrochloride (Example 102) in 12.5 ml of DMF. After 20 h at 50° C., thereaction mixture is purified by preparative HPLC. The product fractionsare concentrated and, after addition of 50% strength hydrobromic acid,again concentrated and dried under high vacuum. Recrystallization fromcyclohexane/acetone affords 537 mg (77% of theory) of the titlecompound.

HPLC (method 1): R_(t)=4.44 min.

MS (ESIpos): m/z=467 (M+H)⁺.

EXAMPLE 189(3R)-3-[{[7-(2-Methoxyphenyl)-1-benzofuran-2-yl]carbonyl}(methyl)amino]-1-methyl-1-azoniabicyclo[2.2.2]octaneChloride

84.8 mg (2.12 mmol) of sodium hydride (60% suspension in mineral oil)are added to a solution, cooled to −20° C., of 250 mg (0.61 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-(2-methoxyphenyl)-1-benzofuran-2-carboxamidehydro chloride (Example 102) in 2.5 ml of DMF. After 30 min at roomtemperature and renewed cooling to −20° C., 94.2 μl (1.51 mmol) ofiodomethane are added. After 18 h at room temperature, the reaction isstopped by adding water. The reaction mixture is purified by preparativeHPLC. The product fractions are concentrated, codistilled with a 1:1mixture of methanol and 4 M hydrogen chloride in dioxane, againconcentrated and dried under high vacuum. 58 mg (21.7% of theory) of thetitle compound are obtained.

HPLC (method 1): R_(t)=4.17 min.

MS (ESIpos): m/z=405 (M+H)⁺.

EXAMPLE 1907-(2-Methoxyphenyl)-N-[(3R)-1-oxido-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2-carboxamide

35.8 μl (0.35 mmol) of 30% strength hydrogen peroxide are added to asolution, cooled to 0° C., of 110 mg (0.29 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-(2-methoxyphenyl)-1-benzofuran-2-carboxamide(Example 130) in 2 ml of methanol. After 18 h at room temperature, afurther 35.8 μl (0.35 mmol) of 30% strength hydrogen peroxide are added.After a further 18 h at room temperature, the reaction solution isconcentrated, and the residue is dried under high vacuum. 111.5 mg(97.2% of theory) of the title compound are obtained.

¹H-NMR (400 MHz, methanol-d₄): δ=7.69 (d, 1H), 7.59 (s, 1H), 7.41 (m,3H), 7.37 (dd, 1H), 7.16 (d, 1H), 7.08 (dd, 1H), 4.57 (m, 1H), 3.78 (s,3H), 3.75 (m, 1H), 3.43-3.30 (m, 5H), 2.22 (m, 2H), 2.13 (m, 2H), 1.99(m, 1H).

HPLC (method 1): R_(t)=4.18 min.

MS (ESIpos): m/z=393 (M+H)⁺.

EXAMPLE 191N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-6-[3-(4-morpholinylmethyl)phenyl]-1-benzothiophene-2-carboxamideDihydrochloride

290 mg (3.32 mmol) of morpholine and 31 mg (0.50 mmol) of sodiumcyanoborohydride are successively added to a solution of 80 mg (0.17mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-(3-formylphenyl)-1-benzothiophene-2-carboxamidehydrochloride (Example 33A) in 1.0 ml of a 6:1 mixture of methanol andacetic acid. After 18 h at 80° C., purification is carried out bypreparative HPLC. The product fractions are concentrated and, afteraddition of a 5:1 mixture of methanol and 1N hydrochloric acid, againconcentrated: Drying under high vacuum results in 47 mg (49.8% oftheory) of the title compound.

HPLC (method 1): R_(t)=3.64 min.

MS (ESIpos): m/z=462 (M+H)⁺ (free base).

EXAMPLE 1927-(5-Acetyl-2-thienyl)-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2-carboxamideHydrochloride

0.58 ml of 2 M aqueous sodium carbonate solution and 15.9 mg (0.02 mmol)of PdCl₂(dppf) are added to a mixture of 150 mg (0.39 mmol) ofN-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-bromo-1-benzofuran-2-carboxamidehydrochloride (Example 30A) and 66.1 mg (0.39 mmol) of5-acetyl-2-thienylboronic acid in 2 ml of DMF. The reaction mixture isheated at 70° C. for 18 h and then filtered through kieselguhr andevaporated to dryness. Purification of the crude product by preparativeHPLC, subsequent addition of a 1:1 mixture of methanol and 1Nhydrochloric acid, concentration and drying under high vacuum result in83.6 mg (49.9% of theory) of the title compound.

¹H-NMR (400 MHz, DMSO-d₆): δ=10.29 (br. s, 1H), 9.10 (d, 1H), 8.07 (m,2H), 7.95 (m, 1H), 7.93 (d, 1H), 7.87 (d, 1H), 7.46 (dd, 1H), 4.38 (m,1H), 3.63 (m, 1H), 3.40 (m, 2H), 3.23 (m, 3H), 2.60 (s, 3H), 2.27 (m,1H), 2.16 (m, 1H), 1.94 (m, 2H), 1.77 (m, 1H).

HPLC (method 1): R_(t)=3.99 min.

MS (ESIpos): m/z=495 (M+H)⁺ (free base).

The invention claimed is:
 1. A compound of the formula

for the treatment of Alzheimer's disease or schizophrenia, wherein R¹ is1-azabicyclo[2.2.2]oct-3-yl, which is optionally substituted via thenitrogen atom by a radical selected from the group of C₁-C₄-alkyl,benzyl and oxy, R² is hydrogen or C₁-C₆-alkyl, R³ is hydrogen, halogenor C₁-C₆-alkyl, R⁴ is hydrogen, halogen, cyano, amino, trifluoromethyl,trifluoromethoxy, C₁-C₆-alkyl, C₁-C₆-alkylcarbonyl, C₁-C₆-alkylamino,formyl, hydroxycarbonyl, C₁-C₆-alkoxy, C₁-C₆-alkoxycarbonyl,C₁-C₆-alkylthio, C₁-C₆-alkylcarbonylamino, C₁-C₆-alkylaminocarbonyl,C₁-C₄-alkylsulphonylamino, C₃-C₈-cycloalkylcarbonylamino,C₃-C₆-cycloalkylaminocarbonyl, pyrrolyl, C₁-C₆-alkylaminocarbonylamino,heterocyclylcarbonyl, heterocyclylcarbonylamino,heteroarylcarbonylamino, hydroxyl, phenyl or heterocyclyl, whereinC₁-C₆-alkyl is optionally substituted by hydroxyl, cyano, amino,C₁-C₆-alkylaminocarbonylamino, C₁-C₆-alkylaminocarboxyl, heterocyclyl oraryl, C₁-C₆-alkylaminocarbonyl is optionally substituted by C₁-C₆-alkoxyor C₁-C₆-alkylamino, C₁-C₆-alkylcarbonylamino is optionally substitutedby C₁-C₆-alkoxy, and heterocyclyl is optionally substituted by oxo, A isoxygen or sulphur, the ring B is benzo, optionally substituted byradicals from the series halogen, cyano, formyl, trifluoromethyl,trifluoromethoxy, nitro, amino, C₁-C₆-alkyl and C₁-C₆-alkoxy, and E isC≡C, arylene and heteroarylene, wherein arylene and heteroarylene areoptionally substituted by radicals from the series halogen, cyano,trifluoromethyl, trifluoromethoxy, nitro, amino, C₁-C₆-alkoxy andC₁-C₆-alkyl, or a solvate, a salt or a solvate of a salt thereof.
 2. Thecompound according to claim 1, of the formula (I), wherein R¹ is1-azabicyclo[2.2.2]oct-3-yl, R² is hydrogen or C₁-C₄-alkyl, R³ ishydrogen, fluorine, chlorine, bromine or C₁-C₄-alkyl, R⁴ is hydrogen,fluorine, chlorine, bromine, cyano, amino, trifluoromethyl,trifluoromethoxy, C₁-C₄-alkyl, C₁-C₄-alkylcarbonyl, C₁-C₄-alkylamino,formyl, hydroxycarbonyl, C₁-C₄-alkoxy, C₁-C₄-alkoxycarbonyl,C₁-C₄-alkylthio, C₁-C₄-alkylcarbonylamino, C₁-C₄-alkylaminocarbonyl,C₁-C₄-alkylsulphonylamino, C₃-C₆-cycloalkylcarbonylamino,C₃-C₆-cycloalkylaminocarbonyl, pyrrolyl, C₁-C₄-alkylaminocarbonylamino,heterocyclylcarbonyl, heterocyclylcarbonylamino,heteroarylcarbonylamino, hydroxyl, phenyl or heterocyclyl, whereinC₁-C₄-alkyl is optionally substituted by hydroxyl, cyano, amino,C₁-C₄-alkylaminocarbonylamino, C₁-C₄-alkylaminocarboxyl, heterocyclyl oraryl, C₁-C₄-alkylaminocarbonyl is optionally substituted by C₁-C₄-alkoxyor C₁-C₄-alkylamino, C₁-C₄-alkylcarbonylamino is optionally substitutedby C₁-C₄-alkoxy, and heterocyclyl is optionally substituted by oxo, A isoxygen or sulphur, the ring B is benzo, optionally substituted byradicals from the series halogen, cyano, trifluoromethyl,trifluoromethoxy and C₁-C₄-alkyl, and E is C≡C, arylene andheteroarylene, where arylene and heteroarylene are optionallysubstituted by radicals from the series halogen, cyano, trifluoromethyl,trifluoromethoxy, nitro, amino, C₁-C₄-alkoxy and C₁-C₄-alkyl, or asolvate, a salt or solvate of a salt thereof.
 3. The compound accordingto claim 1, of the formula (I), wherein R¹ is1-azabicyclo[2.2.2]oct-3-yl, R² and R³ are hydrogen, R⁴ is hydrogen,fluorine, chlorine, bromine, cyano, amino, trifluoromethyl,trifluoromethoxy, C₁-C₄-alkyl, C₁-C₄-alkylcarbonyl, C₁-C₄-alkylamino,formyl, hydroxycarbonyl, C₁-C₄-alkoxy, C₁-C₄-alkoxycarbonyl,C₁-C₆-alkylthio, C₁-C₄-alkylcarbonylamino, C₁-C₄-alkylaminocarbonyl,C₁-C₄-alkylsulphonylamino, C₃-C₆-cycloalkylcarbonylamino,C₃-C₆-cycloalkylaminocarbonyl, pyrrolyl, C₁-C₄-alkylaminocarbonylamino,heterocyclylcarbonyl, heterocyclylcarbonylamino,heteroarylcarbonylamino, hydroxyl, phenyl or heterocyclyl, whereinC₁-C₄-alkyl is optionally substituted by hydroxyl, cyano, amino,C₁-C₄-alkylaminocarbonylamino, C₁-C₄-alkylaminocarboxyl, heterocyclyl oraryl, C₁-C₄-alkylaminocarbonyl is optionally substituted by C₁-C₄-alkoxyor C₁-C₄-alkylamino, C₁-C₄-alkylcarbonylamino is optionally substitutedby C₁-C₄-alkoxy, and heterocyclyl is optionally substituted by oxo, A isoxygen, the ring B is benzo, optionally substituted by radicals from theseries halogen, cyano, trifluoromethyl, trifluoromethoxy andC₁-C₄-alkyl, and E is C≡C, arylene and heteroarylene, where arylene andheteroarylene are optionally substituted by radicals from the serieshalogen, cyano, trifluoromethyl, trifluoromethoxy, nitro, amino,C₁-C₄-alkoxy and C₁-C₄-alkyl, or a solvate, a salt, or a solvate of asalt thereof.
 4. The compound according to claim 1, of the formula (I),wherein R¹ is 1-azabicyclo[2.2.2]oct-3-yl, R² is hydrogen orC₁-C₆-alkyl, R³ is hydrogen, halogen or C₁-C₆-alkyl, R⁴ is hydrogen,halogen, cyano, amino, trifluoromethyl, trifluoromethoxy, C₁-C₆-alkyl,C₁-C₆-alkylcarbonyl, C₁-C₆-alkylamino, formyl, hydroxycarbonyl,C₁-C₆-alkoxy, C₁-C₆-alkoxycarbonyl, C₁-C₆-alkylthio,C₁-C₆-alkylcarbonylamino, C₁-C₄-alkylsulphonylamino,C₃-C₈-cycloalkylcarbonylamino, pyrrolyl, C₁-C₆-alkylaminocarbonylamino,heterocyclylcarbonyl, phenyl or heterocyclyl, wherein C₁-C₆-alkyl isoptionally substituted by hydroxyl, amino,C₁-C₆-alkylaminocarbonylamino, C₁-C₆-alkylaminocarboxyl, heterocyclyl oraryl, C₁-C₆-alkylcarbonylamino is optionally substituted byC₁-C₆-alkoxy, and heterocyclyl is optionally substituted by oxo, A isoxygen or sulphur, the ring B is benzo, optionally substituted byradicals from the series halogen, cyano, formyl, trifluoromethyl,trifluoromethoxy, nitro, amino, C₁-C₆-alkyl and C₁-C₆-alkoxy, and E isC≡C, arylene and heteroarylene, where arylene and heteroarylene areoptionally substituted by radicals from the series halogen, cyano,trifluoromethyl, trifluoromethoxy, nitro, amino, C₁-C₆-alkoxy andC₁-C₆-alkyl, or a solvate, a salt, or a solvate of a salt thereof. 5.The compound of the formula (I) according claim 1, wherein R¹ is1-azabicyclo[2.2.2]oct-3-yl, R² is hydrogen or C₁-C₆-alkyl, R³ ishydrogen, halogen or C₁-C₆-alkyl, R⁴ is hydrogen, halogen, cyano,trifluoromethyl, trifluoromethoxy, C₁-C₆-alkyl, C₁-C₆-alkoxy orheterocyclyl, where alkyl is optionally substituted by a hydroxylradical, A is oxygen or sulphur, the ring B is benzo, optionallysubstituted by radicals from the series halogen, cyano, trifluoromethyl,trifluoromethoxy, nitro, amino, C₁-C₆-alkyl and C₁-C₆-alkoxy, and E isC≡C, arylene or heteroarylene, where arylene and heteroarylene areoptionally substituted by radicals from the series halogen, cyano,trifluoromethyl, trifluoromethoxy, nitro, amino, C₁-C₆-alkyl andC₁-C₆-alkoxy, or a solvate, a salt, or a solvate of a salt thereof. 6.The compound according to claim 1, of the formula

wherein R¹ is (3R)-1-azabicyclo[2.2.2]oct-3-yl, R² and R³ are,independently of one another, hydrogen or methyl, R⁴ is hydrogen,halogen, cyano, trifluoromethyl, trifluoromethoxy, C₁-C₆-alkyl,C₁-C₆-alkoxy or heterocyclyl, where alkyl is optionally substituted by ahydroxyl radical, and R^(B) is hydrogen, halogen, cyano,trifluoromethyl, trifluoromethoxy, nitro, amino, C₁-C₆-alkyl orC₁-C₆-alkoxy, or a solvate, a salt, or a solvate of a salt thereof. 7.The compound according to claim 1, of the formula

wherein R¹ is (3R)-1-azabicyclo[2.2.2]oct-3-yl, R² and R³ are,independently of one another, hydrogen or methyl, R⁴ is hydrogen,halogen, cyano, trifluoromethyl, trifluoromethoxy, C₁-C₆-alkyl,C₁-C₆-alkoxy or heterocyclyl, where alkyl is optionally substituted by ahydroxyl radical, R^(B) is hydrogen, halogen, cyano, trifluoromethyl,trifluoromethoxy, nitro, amino, C₁-C₆-alkyl and C₁-C₆-alkoxy, or asolvate, a salt, or a solvate of a salt thereof.
 8. The compoundaccording to claim 6, wherein R¹ is (3R)-1-azabicyclo[2.2.2]oct-3-yl, R²and R³ are hydrogen, R⁴ is hydrogen, fluorine, chlorine, bromine,trifluoromethoxy, hydroxymethyl, methoxy or 6-membered heterocyclyl, andR^(B) is hydrogen, halogen, cyano, trifluoromethyl, trifluoromethoxy orC₁-C₄-alkyl, or a solvate, a salt, or a solvate of a salt thereof. 9.The compound according to claim 1, of the formula

wherein E is phenylene, R⁴ is C₁-C₆-alkoxy, aminomethyl,hydroxycarbonyl, C₃-C₈-cycloalkylcarbonylamino, a group of the formula

wherein R⁵ is C₁-C₆-alkyl, n is zero, 1, 2, 3 or 4, or 5- to 6-memberedheterocyclyl which is optionally substituted by oxo, and A is sulphur oroxygen, or a solvate, a salt, or a solvate of a salt thereof.
 10. Thecompound according to claim 9, of the formula (Ic) wherein E isphenylene, R⁴ is C₁-C₄-alkoxy, aminomethyl, hydroxycarbonyl,C₃-C₆-cycloalkylcarbonylamino, a group of the formula

wherein R⁵ is C₁-C₄-alkyl, n is zero, 1 or 2, or 5- to 6-memberedheterocyclyl which is optionally substituted by oxo, and A is sulphur oroxygen, or a solvate, a salt, or a solvate of a salt thereof.
 11. Thecompound according to claim 1, wherein the compound is selected from thegroup consisting of:

or a solvate, a salt, or a solvate of a salt thereof.
 12. Medicamentcomprising at least one compound according to claim 1 and at least onepharmaceutically acceptable, essentially nontoxic carrier or excipient.13. The compound according to claim 1, wherein the compound is selectedfrom the group consisting of:

or a solvate, a salt, or a solvate of a salt thereof.